2025/04/30 更新

写真a

カトウ シンゴ
加藤 真吾
Shingo Kato
所属
附属病院 がんゲノム診断科 准教授
職名
准教授
ホームページ
プロフィール
米国National Cancer InstituteのVaccine Branchで腫瘍免疫制御に関わる免疫細胞の一種であるNatural Killer T細胞に関して研究を行ってきました。臨床の専門は膵癌なので、米国で学んだことを膵癌研究に活かし、主に動物モデルでの解析を行っています。また、がんクリニカルシークエンス検査を横浜市立大学附属病院に導入し、附属病院が神奈川県におけるがんクリニカルシークエンスの拠点病院となるよう、活動を行っています。
外部リンク

学位

  • 博士(医学) ( 横浜市立大学 )

研究キーワード

  • 腫瘍免疫

  • がんクリニカルシークエンス

研究分野

  • ライフサイエンス / 腫瘍診断、治療学

  • ライフサイエンス / 免疫学  / 腫瘍免疫

学歴

  • 横浜市立大学   医学部   大学院博士課程

    2009年4月 - 2012年3月

      詳細を見る

  • 横浜市立大学   医学部

    2000年4月 - 2006年3月

      詳細を見る

経歴

  • 横浜市市立大学附属病院   がんゲノム診断科   准教授

    2024年4月 - 現在

      詳細を見る

  • 横浜市立大学附属病院   がんゲノム診断科   講師

    2018年4月 - 2024年3月

      詳細を見る

  • 横浜市立大学附属病院   救急部   助教

    2015年4月 - 2018年3月

      詳細を見る

  • National Cancer Institute / NIH, USA   Vaccine Branch   Visiting Fellow

    2012年6月 - 2015年3月

      詳細を見る

  • 横浜市立大学附属病院   消化器内科   指導診療医

    2008年4月 - 2012年5月

      詳細を見る

  • 横浜市立大学附属病院   初期研修医

    2006年4月 - 2008年3月

      詳細を見る

▼全件表示

論文

  • Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer 査読

    Kumiko Nishio, Lise Pasquet, Kaddy Camara, Julia DiSapio, Kevin S. Hsu, Shingo Kato, Anja Bloom, Stewart K. Richardson, Joshua A. Welsh, Tianbo Jiang, Jennifer C. Jones, Susanna Cardell, Hiroshi Watarai, Masaki Terabe, Purevdorj B. Olkhanud, Amy R. Howell, Jay A. Berzofsky

    Journal of Clinical Investigation   134 ( 4 )   2024年2月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:American Society for Clinical Investigation  

    DOI: 10.1172/jci165281

    researchmap

  • Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice

    Masashi Izumiya, Shingo Kato, Yoshitaka Hippo

    Cancers   13 ( 10 )   2292 - 2292   2021年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:MDPI AG  

    Epithelial cells in the biliary system can develop refractory types of cancers, which are often associated with inflammation caused by viruses, parasites, stones, and chemicals. Genomic studies have revealed recurrent genetic changes and deregulated signaling pathways in biliary tract cancer (BTC). The causal roles have been at least partly clarified using various genetically engineered mice. Technical advances in Cre-LoxP technology, together with hydrodynamic tail injection, CRISPR/Cas9 technology, in vivo electroporation, and organoid culture have enabled more precise modeling of BTC. Organoid-based genetic modeling, combined with implantation in mice, has recently drawn attention as a means to accelerate the development of BTC models. Although each model may not perfectly mimic the disease, they can complement one another, or two different approaches can be integrated to establish a novel model. In addition, a comparison of the outcomes among these models with the same genotype provides mechanistic insights into the interplay between genetic alterations and the microenvironment in the pathogenesis of BTCs. Here, we review the current status of genetic models of BTCs in mice to provide information that facilitates the wise selection of models and to inform the future development of ideal disease models.

    DOI: 10.3390/cancers13102292

    researchmap

  • Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds

    Shingo Kato, Kentaro Fushimi, Yuichiro Yabuki, Yoshiaki Maru, Sho Hasegawa, Tetsuya Matsuura, Daisuke Kurotaki, Akihiro Suzuki, Noritoshi Kobayashi, Masato Yoneda, Takuma Higurashi, Makiko Enaka, Tomohiko Tamura, Yoshitaka Hippo, Atsushi Nakajima

    Oncogenesis   10 ( 4 )   2021年4月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title>Genetically engineered mice (GEM) are the gold standard for cancer modeling. However, strict recapitulation of stepwise carcinogenesis from a single tumor-initiating epithelial cell among genetically intact cells in adults is not feasible with the currently available techniques using GEM. In previous studies, we partially overcame this challenge by physically isolating organs from adult animals, followed by genetic engineering in organoids and subcutaneous inoculation in nude mice. Despite the establishment of suitable ex vivo carcinogenesis models for diverse tissues, tumor development remained ectopic and occurred under immunodeficient conditions. Further refinement was, therefore, necessary to establish ideal models. Given the poor prognosis and few models owing to the lack of gall bladder (GB)-specific <italic>Cre</italic> strain, we assumed that the development of authentic models would considerably benefit GB cancer research. Here, we established a novel model using GB organoids with mutant <italic>Kras</italic> and <italic>Trp53</italic> loss generated in vitro by lentiviral <italic>Cre</italic> transduction and CRISPR/Cas9 gene editing, respectively. Organoid-derived subcutaneous tumor fragments were sutured to the outer surface of the GB in syngeneic mice, which developed orthotopic tumors that resembled human GB cancer in histological and transcriptional features. This model revealed the infiltration of similar subsets of immune cells in both subcutaneous and orthotopic tumors, confirming the appropriate immune environment during carcinogenesis. In addition, we accurately validated the in vivo efficacy of gemcitabine, a common therapeutic agent for GB cancer, in large cohorts. Taken together, this model may serve as a promising avatar of patients with GB cancer in drug discovery and precision medicine.

    DOI: 10.1038/s41389-021-00322-1

    researchmap

    その他リンク: http://www.nature.com/articles/s41389-021-00322-1

  • Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.

    Hidenori Ohkubo, Takaomi Kessoku, Kosuke Tanaka, Kota Takahashi, Tomohiro Takatsu, Tsutomu Yoshihara, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Toshihiro Misumi, Satoru Shinoda, Vincenzo Stanghellini, Atsushi Nakajima

    Bioscience of microbiota, food and health   43 ( 2 )   135 - 144   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Chronic intestinal pseudo-obstruction (CIPO) is a rare intractable disease with limited treatment options. Small intestinal bacterial overgrowth (SIBO) often co-occurs with several diseases, including CIPO. While rifaximin (RFX) is effective in treating SIBO, its efficacy for CIPO remains unclear. Here, we aimed to investigate the efficacy and safety of RFX in adult patients with CIPO. Twelve patients were randomly assigned to receive RFX (400 mg three times daily, n=8) or a placebo (PBO, n=4) for 4 weeks. The global symptom score for abdominal bloating (GSS-bloating) and an original whole gastrointestinal symptoms score (O-WGSS) were collected, and a glucose hydrogen breath test (GHBT) and abdominal computed tomography (CT) were performed. No significant differences were observed in the primary endpoint. GSS-bloating improved by 75% and 25% in the PBO and RFX groups, respectively, and O-WGSS improved by 25% in both groups. No significant differences were observed in secondary and other endpoints, including the SIBO eradication rate in the GHBT and small intestinal volume on CT. In a post hoc analysis of SIBO-positive patients with CIPO (4/4 and 4/8 in the PBO and RFX groups), SIBO was eradicated in 25% and 75% of the patients (PBO and RFX groups, respectively) at the end of treatment, indicating a high eradication rate in the RFX group. Furthermore, the small intestinal gas volume decreased in the RFX group, and no severe adverse events occurred. Although no significant improvements were observed in subjective indicators, RFX may be beneficial in alleviating SIBO and reducing the small intestinal gas volume in SIBO-positive patients with CIPO.

    DOI: 10.12938/bmfh.2023-080

    PubMed

    researchmap

  • 肝細胞癌の肝移植後再発に対して,がん遺伝子パネル検査にて有効薬剤の推奨を受けた一例

    室井 健太, 岩城 慶大, 小林 貴, 大谷 知宏, 野上 麻子, 加藤 真吾, 米田 正人, 中島 淳

    日本消化器病学会関東支部例会プログラム・抄録集   377回   36 - 36   2023年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-関東支部  

    researchmap

  • The Prevalence and Characteristics of Symptomatic Uncomplicated Diverticular Disease Among Asian Patients With Unexplained Abdominal Symptoms

    Tsumugi Jono, Yuki Kasai, Takaomi Kessoku, Tomoki Ogata, Kosuke Tanaka, Tsutomu Yoshihara, Noboru Misawa, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Kosuke Seita, Takayuki Kato, Eiji Sakai, Takeo Kurihashi, Machiko Nakatogawa, Shunsuke Oyamada, Seiji Futagami, Kok-Ann Gwee, Atsushi Nakajima

    Journal of Neurogastroenterology and Motility   2023年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:The Korean Society of Neurogastroenterology and Motility  

    DOI: 10.5056/jnm22162

    researchmap

  • Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors 査読

    Takahiro Hayashi, Kensuke Tateishi, Shinichiro Matsuyama, Hiromichi Iwashita, Yohei Miyake, Akito Oshima, Hirokuni Honma, Jo Sasame, Katsuhiro Takabayashi, Kyoka Sugino, Emi Hirata, Naoko Udaka, Yuko Matsushita, Ikuma Kato, Hiroaki Hayashi, Taishi Nakamura, Naoki Ikegaya, Yutaro Takayama, Masaki Sonoda, Chihiro Oka, Mitsuru Sato, Masataka Isoda, Miyui Kato, Kaho Uchiyama, Tamon Tanaka, Toshiki Muramatsu, Shigeta Miyake, Ryosuke Suzuki, Mutsumi Takadera, Junya Tatezuki, Junichi Ayabe, Jun Suenaga, Shigeo Matsunaga, Kosuke Miyahara, Hiroshi Manaka, Hidetoshi Murata, Takaakira Yokoyama, Yoshihide Tanaka, Takashi Shuto, Koichi Ichimura, Shingo Kato, Shoji Yamanaka, Daniel P. Cahill, Satoshi Fujii, Ganesh M. Shankar, Tetsuya Yamamoto

    Clinical Cancer Research   30 ( 1 )   116 - 126   2023年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:American Association for Cancer Research (AACR)  

    Abstract

    Purpose:

    The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses an integrated approach involving histopathology and molecular profiling. Because majority of adult malignant brain tumors are gliomas and primary CNS lymphomas (PCNSL), rapid differentiation of these diseases is required for therapeutic decisions. In addition, diffuse gliomas require molecular information on single-nucleotide variants (SNV), such as IDH1/2. Here, we report an intraoperative integrated diagnostic (i-ID) system to classify CNS malignant tumors, which updates legacy frozen-section (FS) diagnosis through incorporation of a qPCR-based genotyping assay.

    Experimental Design:

    FS evaluation, including GFAP and CD20 rapid IHC, was performed on adult malignant CNS tumors. PCNSL was diagnosed through positive CD20 and negative GFAP immunostaining. For suspected glioma, genotyping for IDH1/2, TERT SNV, and CDKN2A copy-number alteration was routinely performed, whereas H3F3A and BRAF SNV were assessed for selected cases. i-ID was determined on the basis of the 2021 WHO classification and compared with the permanent integrated diagnosis (p-ID) to assess its reliability.

    Results:

    After retrospectively analyzing 153 cases, 101 cases were prospectively examined using the i-ID system. Assessment of IDH1/2, TERT, H3F3AK27M, BRAFV600E, and CDKN2A alterations with i-ID and permanent genomic analysis was concordant in 100%, 100%, 100%, 100%, and 96.4%, respectively. Combination with FS and intraoperative genotyping assay improved diagnostic accuracy in gliomas. Overall, i-ID matched with p-ID in 80/82 (97.6%) patients with glioma and 18/19 (94.7%) with PCNSL.

    Conclusions:

    The i-ID system provides reliable integrated diagnosis of adult malignant CNS tumors.

    DOI: 10.1158/1078-0432.ccr-23-1660

    researchmap

    その他リンク: https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1660/3383719/ccr-23-1660.pdf

  • Changes in the Number of Gastrointestinal Cancers and Stage at Diagnosis with COVID-19 Pandemic in Japan: A Multicenter Cohort Study. 国際誌

    Kento Kuzuu, Noboru Misawa, Keiichi Ashikari, Shigeki Tamura, Shingo Kato, Kunihiro Hosono, Masato Yoneda, Takashi Nonaka, Shozo Matsushima, Tatsuji Komatsu, Atsushi Nakajima, Takuma Higurashi

    Cancers   15 ( 17 )   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This retrospective cohort study compared the number of newly diagnosed patients, stage at diagnosis, and detection process of gastrointestinal cancers based on hospital-based cancer registry data at two tertiary Japanese hospitals. The pre-COVID-19 period was from January 2017 to February 2020, with phase 1 (midst of COVID-19 pandemic) from March to December 2020 and phase 2 (the transition period to the "new normal") from January to December 2021. Each month, the number of patients diagnosed with esophageal, gastric, colorectal, pancreatic, liver, and biliary tract cancers were aggregated, classified by stage and detection process, and compared, including a total of 6453 patients. The number of colorectal Stage 0-II patients decreased significantly in phase 1 and increased in phase 2. The total number of colorectal cancer patients returned to pre-COVID-19 levels (mean monthly patients [SD]: 41.61 [6.81] vs. 36.00 [6.72] vs. 46.00 [11.32]). The number of patients with gastric cancer Stage I significantly decreased in phase 2 following phase 1. The number of gastric cancer patients decreased significantly from pre-COVID-19 levels (30.63 [6.62] vs. 22.40 [5.85] vs. 24.50 [4.15]). During phase 2, the number of patients diagnosed after screening with colorectal cancer increased significantly, whereas that with gastric cancer remained considerably lower. The number of Stage III colorectal and gastric cancer patients increased significantly from the pre-COVID-19 levels. Thus, gastric cancer may not be optimally screened during phases 1 and 2. There was a significant increase in patients with Stage III colorectal and gastric cancers from the pre-COVID-19 period; hence, the stage at diagnosis may have progressed.

    DOI: 10.3390/cancers15174410

    PubMed

    researchmap

  • AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines 査読

    Nami Masumoto, Shingo Kato, Masahiro Aichi, Sho Hasegawa, Kota Sahara, Kumiko Suyama, Akane Sano, Tomoyuki Miyazaki, Koji Okudela, Takeshi Kaneko, Takuya Takahashi

    Thoracic Cancer   14 ( 29 )   2897 - 2908   2023年8月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Background

    Small cell lung cancer (SCLC) is a neuroendocrine tumor with poor prognosis. Neuroendocrine tumors possess characteristics of both nerve cells and hormone‐secreting cells; therefore, targeting the neuronal properties of these tumors may lead to the development of new therapeutic options. Among the endogenous signaling pathways in the nervous system, targeting the glutamate pathway may be a useful strategy for glioblastoma treatment. Perampanel, an antagonist of the synaptic glutamate α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid receptor (AMPAR), has been reported to be effective in patients with glioblastoma. In this study, we aimed to investigate the antitumor effects of AMPAR antagonists in human SCLC cell lines.

    Methods

    We performed to examine the expression of AMPAR using Western blot and immunohistochemical analysis. The antitumor effects of AMPAR antagonists on human SCLC cell lines were investigated in vitro and in vivo. We also analyzed the signaling pathway of AMPAR antagonists in SCLC cell lines. Statistical analysis was performed by the GraphPad Prism 6 software.

    Results

    We first examined the expression of endogenous AMPAR in six human SCLC cell lines, detecting AMPAR proteins in all of them. Next, we tested the anti−proliferative effect of two AMPAR antagonists, talampanel and cyanquixaline, using SCLC cells in vitro and in vivo. Both AMPAR antagonists inhibited cell proliferation and mitogen‐activated protein kinase (MAPK) phosphorylation in SCLC cells in vitro. Further, we observed reduced proliferation of implanted cell lines in an in vivo setting, assessed by Ki‐67 immunohistochemistry. Additionally, using immunohistochemical analysis we confirmed AMPAR protein expression in human SCLC samples.

    Conclusion

    AMPAR may be a potential therapeutic target for SCLC.

    DOI: 10.1111/1759-7714.15075

    researchmap

  • Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care. 国際誌

    Kosuke Tanaka, Hidenori Ohkubo, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Noboru Misawa, Akiko Fuyuki, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Takeo Kurihashi, Masataka Taguri, Atsushi Nakajima, Kok-Ann Gwee, Takaomi Kessoku

    Journal of neurogastroenterology and motility   29 ( 3 )   378 - 387   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIMS: Natural history of chronic intestinal pseudo-obstruction (CIPO), a rare disease characterized by episodes of non-mechanical obstruction, is unclear in adults. This study evaluates the clinical course of CIPO and palliative care needs of patients. METHODS: From October 2010 to September 2021, 74 patients who underwent cine MRI and had a definitive diagnosis of CIPO were prospectively included. We investigated disease etiology and outcomes, age at onset, nutritional status at consultation (body mass index and serum albumin), hydrogen breath test results, and total parenteral nutrition (TPN) during the disease course. RESULTS: Forty-seven patients (64%) were women, with a mean age of 44 years at onset and 49 years at diagnosis. Primary CIPO was observed in 48 patients (65%). Secondary CIPO was observed in 26 cases (35%), of whom 18 (69%) had scleroderma. The mean body mass index, serum albumin level, and hydrogen breath test positivity rate were 17 kg/m2, 3.8 mg/dL, and 60%, respectively. TPN and invasive decompression therapy were required by 23 (31%) and 18 (24%) patients, respectively. Intestinal sterilization was performed in 51 (69%) patients and was effective in 33 (65%); of these, 28 (85%) were taking metronidazole. Seven (9%) patients used opioids. There were 9 deaths (12%), including 5 (56%) from infection and 2 (22%) from suicide. Of the deaths, 6 (67%) and 4 (44%) underwent TPN management and decompression therapy, respectively. Fifty-one patients (69%) wanted palliative care. CONCLUSION: CIPO is a rare, severe, and under-recognized disease. Standardization of treatment strategies, including palliative care and psychiatric interventions, is desired.

    DOI: 10.5056/jnm22152

    PubMed

    researchmap

  • Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy

    Masahiro Aichi, Sho Hasegawa, Yusuke Kurita, Satoru Shinoda, Shingo Kato, Taichi Mizushima, Naho Ruiz Yokota, Etsuko Miyagi

    Nutrition   109   111966 - 111966   2023年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.nut.2022.111966

    researchmap

  • Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan

    Hidenori Kage, Aya Shinozaki‐Ushiku, Kazunaga Ishigaki, Yusuke Sato, Masahiko Tanabe, Shota Tanaka, Michihiro Tanikawa, Kousuke Watanabe, Shingo Kato, Kiwamu Akagi, Keita Uchino, Kinuko Mitani, Shunji Takahashi, Yuji Miura, Sadakatsu Ikeda, Yasushi Kojima, Kiyotaka Watanabe, Hitoshi Mochizuki, Hironori Yamaguchi, Yoshimasa Kawazoe, Kosuke Kashiwabara, Shinji Kohsaka, Kenji Tatsuno, Tetsuo Ushiku, Kazuhiko Ohe, Yutaka Yatomi, Yasuyuki Seto, Hiroyuki Aburatani, Hiroyuki Mano, Kiyoshi Miyagawa, Katsutoshi Oda

    Cancer Science   2023年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    DOI: 10.1111/cas.15717

    researchmap

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.15717

  • EUS-BDの早期偶発症に関する因子

    佐藤 高光, 細野 邦広, 長谷川 翔, 栗田 裕介, 八木 伸, 鈴木 洸, 加藤 真吾, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   64 ( Suppl.2 )   2118 - 2118   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Franseen Needles May Be Promising for Improving the Sampling Adequacy of EUS-FNA for Subepithelial Lesions. 国際誌

    Noriki Kasuga, Yusuke Kurita, Emiko Tanida, Shin Yagi, Ko Suzuki, Sho Hasegawa, Takamitsu Sato, Kunihiro Hosono, Shingo Kato, Yusuke Sekino, Noritoshi Kobayashi, Itaru Endo, Kensuke Kubota, Atsushi Nakajima

    Diagnostics (Basel, Switzerland)   12 ( 7 )   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is useful in diagnosing subepithelial lesions (SELs), and adequate tissue sampling is necessary to differentiate between benign and malignant diseases to determine therapeutic strategies. This study aimed to evaluate sampling adequacy and diagnostic performance of EUS-FNA for SELs with Franseen needles. This retrospective study enrolled 130 patients who underwent EUS-FNA with a 22-gauge needle for SELs from January 2010 to March 2021. We compared sampling adequacy and predictive factors influencing the sampling adequacy of EUS-FNA for SELs between Franseen and conventional needles. The sampling adequacy rates were 95.0% (38/40) with Franseen needles and 76.7% (69/90) with conventional needles (p = 0.011). The mean number of punctures with Franseen needles (2.80) was significantly less than that with conventional needles (3.42) (p &lt; 0.001). In the multivariate analysis, the use of Franseen needles (p = 0.029; odds ratio [OR], 5.37; 95% confidence interval [CI], 1.18-23.36) was an independent factor influencing the sampling adequacy. Compared to conventional needles, the Franseen needle could play a vital role in accurately diagnosing SELs by yielding better sampling adequacy and reducing the number of passes.

    DOI: 10.3390/diagnostics12071667

    PubMed

    researchmap

  • Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study. 国際誌

    Yuki Kasai, Takaomi Kessoku, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Takashi Kobayashi, Michihiro Iwaki, Anna Ozaki, Asako Nogami, Yasushi Honda, Yuji Ogawa, Shingo Kato, Kento Imajo, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Haruki Usuda, Koichiro Wada, Miwa Kawanaka, Takumi Kawaguchi, Takuji Torimura, Masayoshi Kage, Hideyuki Hyogo, Hirokazu Takahashi, Yuichiro Eguchi, Shinichi Aishima, Noritoshi Kobayashi, Yoshio Sumida, Akira Honda, Shunsuke Oyamada, Satoru Shinoda, Satoru Saito, Atsushi Nakajima

    Clinical and translational gastroenterology   13 ( 7 )   e00503   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: No reports on both blood and fecal bile acids (BAs) in patients with nonalcoholic fatty liver disease (NAFLD) exist. We simultaneously assessed the serum and fecal BA patterns in healthy participants and those with NAFLD. METHODS: We collected stool samples from 287 participants from 5 hospitals in Japan (healthy control [HC]: n = 88; mild fibrosis: n = 104; and advanced fibrosis group: n = 95). Blood samples were collected and analyzed for serum BAs and 7α-hydroxy-4-cholesten-3-one (C4)-a surrogate marker for BA synthesis ability-from 141 patients. Concentrations of BAs, including cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid, ursodeoxycholic acid, and lithocholic acid (LCA), were measured using liquid chromatography-mass spectrometry. RESULTS: The total fecal BA concentration was significantly higher in the NAFLD group with worsening of fibrosis than in the HC group. Most of the fecal BAs were secondary and unconjugated. In the fecal BA fraction, CA, DCA, chenodeoxycholic acid, ursodeoxycholic acid, and LCA were significantly higher in the NAFLD than in the HC group. The total serum BA concentration was higher in the NAFLD group with worsening of fibrosis than in the HC group. In the serum BA fraction, CA, LCA, and C4 concentrations were significantly higher in the NAFLD than in the HC group. DISCUSSION: Fecal and serum BA and C4 concentrations were high in patients with NAFLD with worsening of fibrosis, suggesting involvement of abnormal BA metabolism in NAFLD with fibrosis progression. Abnormalities in BA metabolism may be a therapeutic target in NAFLD with fibrosis.

    DOI: 10.14309/ctg.0000000000000503

    PubMed

    researchmap

  • Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.

    Yusuke Kurita, Noritoshi Kobayashi, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Shin Haba, Motohiko Tokuhisa, Sho Hasegawa, Takamitsu Sato, Kunihiro Hosono, Shingo Kato, Takaomi Kessoku, Itaru Endo, Yasuhiro Shimizu, Kensuke Kubota, Atsushi Nakajima, Yasushi Ichikawa, Yasumasa Niwa

    Internal medicine (Tokyo, Japan)   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objective The effectiveness of everolimus for the management of pancreatic neuroendocrine neoplasms (PNENs), including the G3/NEC types, remains unclear. We therefore investigated the effectiveness of the drug for the management of PNENs. Methods We analyzed the progression-free survival (PFS) and overall survival (OS) associated with everolimus and factors influencing the PFS and OS. Results One hundred patients were evaluated. The PFS associated with the G1/G2 types tended to be significantly longer than that associated with the G3/NEC types (hazard ratio [HR], 0.45; p =0.005). A multivariate analysis showed that the significant factors influencing the PFS were age (<65 years old; HR, 0.44; p =0.002), grade (G1/G2; HR, 0.42; p =0.006), everolimus treatment line (≤2nd; HR, 0.55; p =0.031), and presence of treatment with metformin (yes; HR, 0.29; p =0.044). The median OS was 63.8 months. In the multivariate analysis, the significant factors influencing the OS were grade (G1/G2; HR, 0.21; p <0.001), volume of liver metastasis (≤25%; HR, 0.27; p <0.001), everolimus treatment line (≤2nd; HR, 0.27; p <0.001), and presence of primary tumor resection (yes; HR, 0.33; p =0.005). Conclusions The effectiveness of everolimus in the management of G3/NEC types and prognoses tended to be poorer than those associated with the G1/G2 types. Everolimus combined with metformin and early-line treatment with everolimus may be effective for managing advanced PNENs.

    DOI: 10.2169/internalmedicine.9416-22

    PubMed

    researchmap

  • 悪性肝門部狭窄に対するステント予定交換により安定した治療を目指す

    佐藤 高光, 細野 邦広, 窪田 賢輔, 長谷川 翔, 栗田 裕介, 八木 伸, 鈴木 洸, 加藤 真吾, 佐藤 元一, 中島 淳

    Gastroenterological Endoscopy   64 ( Suppl.1 )   770 - 770   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Learning Curve of Endoscopic Retrograde Cholangiopancreatography Using Single-Balloon Enteroscopy. 国際誌

    Kunihiro Hosono, Takamitsu Sato, Sho Hasegawa, Yusuke Kurita, Shin Yagi, Akito Iwasaki, Yuji Fujita, Yusuke Sekino, Emiko Tanida, Takaomi Kessoku, Shingo Kato, Takuma Higurashi, Masato Yoneda, Kensuke Kubota, Atsushi Nakajima

    Digestive diseases and sciences   67 ( 7 )   2882 - 2890   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) in patients with surgically altered anatomy is technically difficult. Extensive training is required to develop the ability to perform this procedure. AIMS: To investigate the learning curve of single-balloon-assisted enteroscopy ERCP (SBE-ERCP). METHODS: We conducted a retrospective, observational case series at a single center. We evaluated the SBE-ERCP procedures between April 2011 and February 2021. The main outcomes were the rate of reaching the target site and the success rate of the entire procedure. These parameters were additionally expressed as a learning curve. RESULTS: A total of 687 SBE-ERCP procedures were analyzed. The learning curve was analyzed in blocks of 10 cases. In this study, seven endoscopists, experts in conventional ERCP, were included. The overall SBE-ERCP procedural success rate was 92.2% (634/687 cases). Combining all data from individual endoscopists' evaluation periods, the insertion and success rates of the SBE-ERCP procedures gradually increased with increased experience performing SBE-ERCP. The insertion success rates for the number of SBE-ERCP cases (< 20, 21-30, > 30) were 82.9%, 92.9%, and 94.3%, respectively; the procedure success rates were 74.3%, 81.4%, and 92.9%, respectively. The endoscopists who had performed > 30 SBE-ERCP cases had a success rate of ≥ 90%. CONCLUSIONS: Our results suggest that performing > 30 cases is one of the targets for conventional ERCP experts to become competent in performing SBE-ERCP in patients with a surgically altered anatomy.

    DOI: 10.1007/s10620-021-07342-2

    PubMed

    researchmap

  • Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.

    Masato Yoneda, Takuma Yamamoto, Yasushi Honda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Asako Nogami, Takuma Higurashi, Shingo Kato, Kunihiro Hosono, Satoru Saito, Atsushi Nakajima

    Journal of gastroenterology   56 ( 11 )   1022 - 1032   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction associated fatty liver disease (MAFLD) have important associations with cardiovascular disease (CVD). The main objective of this study was to compare the frequency of incidence rate of CVD in the NAFLD or MAFLD patients utilizing a large claims database. METHODS: Using the JMDC database from April 2013 to March 2019, we retrospectively analyzed data for 1,542,688 and 2,452,949 people to estimate the relationship between CVD and NAFLD, MAFLD, respectively. RESULTS: The incidence rates of CVD were 0.97 (95% CI 0.94-1.01) and 2.82 (95% CI 2.64-3.01) per 1000 person-years in the non-NAFLD and NAFLD groups, respectively, and 1.01 (95% CI 0.98-1.03) and 2.69 (95% CI 2.55-2.83) per 1000 person-years in the non-MAFLD and MAFLD groups, respectively. The overall prevalence of hypertriglyceridemia and diabetes mellitus (DM) was 13.1, and 4.2%, respectively, in the non-NAFLD group and 63.6, and 20.2%, respectively, in the NAFLD group. The overall prevalenceof hypertriglyceridemia and DM was 13.6 and 4.3%, respectively, in the non-MAFLD group and 64.1, and 20.6%, respectively, in the MAFLD group. HRs for CVD increased with hypertriglyceridemia and DM. CONCLUSIONS: Results indicated that incident rate of CVD increased with NAFLD/MAFLD; the complication rate of DM and hypertriglyceridemia among NAFLD/MAFLD patients is high and may affect the development of CVD.

    DOI: 10.1007/s00535-021-01828-6

    PubMed

    researchmap

  • 肝移植後胆管狭窄の現状と治療についての検討

    鈴木 洸, 栗田 裕介, 長谷川 翔, 佐藤 高光, 加藤 真吾, 細野 邦広, 窪田 賢輔, 中島 淳

    日本消化器病学会雑誌   118 ( 臨増大会 )   A782 - A782   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 胆管空腸吻合術後の肝内結石症に対する完全切石Strategy

    佐藤 高光, 細野 邦広, 長谷川 翔, 栗田 裕介, 八木 伸, 加藤 真吾, 窪田 賢輔, 中島 淳

    Gastroenterological Endoscopy   63 ( Suppl.2 )   2078 - 2078   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan

    Kento Kuzuu, Noboru Misawa, Keiichi Ashikari, Takaomi Kessoku, Shingo Kato, Kunihiro Hosono, Masato Yoneda, Takashi Nonaka, Shozo Matsushima, Tatsuji Komatsu, Atsushi Nakajima, Takuma Higurashi

    JAMA Network Open   4 ( 9 )   e2126334 - e2126334   2021年9月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:American Medical Association (AMA)  

    DOI: 10.1001/jamanetworkopen.2021.26334

    researchmap

  • Evaluation of a combination protocol of CT-first triage and active telemedicine methods by a selected team tackling COVID-19: An experimental research study

    Shigeta Miyake, Takuma Higurashi, Hideaki Kato, Yutaro Yamaoka, Takaomi Kessoku, Shingo Kato, Fumihiro Ogawa, Yasufumi Oi, Atsushi Nakajima, Tetsuya Yamamoto, Ichiro Takeuchi, Akihide Ryo, Shin Maeda

    Journal of Infection and Public Health   14 ( 9 )   1212 - 1217   2021年9月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.jiph.2021.08.016

    researchmap

  • ロング型シングルバルーンを基盤とした胆管空腸吻合術後の内視鏡Management

    佐藤 高光, 細野 邦広, 窪田 賢輔, 長谷川 翔, 栗田 裕介, 八木 伸, 加藤 真吾, 中島 淳

    胆道   35 ( 3 )   466 - 466   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胆道学会  

    researchmap

  • 膵癌治療(ステント) 膵管空腸吻合術後狭窄に対する内視鏡治療の長期成績

    佐藤 高光, 細野 邦広, 長谷川 翔, 栗田 裕介, 八木 伸, 加藤 真吾, 窪田 賢輔, 中島 淳

    膵臓   36 ( 3 )   A295 - A295   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target

    Takaomi Kessoku, Takashi Kobayashi, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Michihiro Iwaki, Anna Ozaki, Yuki Kasai, Asako Nogami, Yasushi Honda, Yuji Ogawa, Shingo Kato, Kento Imajo, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

    International Journal of Molecular Sciences   22 ( 15 )   8161 - 8161   2021年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:MDPI AG  

    The liver directly accepts blood from the gut and is, therefore, exposed to intestinal bacteria. Recent studies have demonstrated a relationship between gut bacteria and nonalcoholic fatty liver disease (NAFLD). Approximately 10–20% of NAFLD patients develop nonalcoholic steatohepatitis (NASH), and endotoxins produced by Gram-negative bacilli may be involved in NAFLD pathogenesis. NAFLD hyperendotoxicemia has intestinal and hepatic factors. The intestinal factors include impaired intestinal barrier function (leaky gut syndrome) and dysbiosis due to increased abundance of ethanol-producing bacteria, which can change endogenous alcohol concentrations. The hepatic factors include hyperleptinemia, which is associated with an excessive response to endotoxins, leading to intrahepatic inflammation and fibrosis. Clinically, the relationship between gut bacteria and NAFLD has been targeted in some randomized controlled trials of probiotics and other agents, but the results have been inconsistent. A recent randomized, placebo-controlled study explored the utility of lubiprostone, a treatment for constipation, in restoring intestinal barrier function and improving the outcomes of NAFLD patients, marking a new phase in the development of novel therapies targeting the intestinal barrier. This review summarizes recent data from studies in animal models and randomized clinical trials on the role of the gut–liver axis in NAFLD pathogenesis and progression.

    DOI: 10.3390/ijms22158161

    researchmap

  • 高齢者消化器がん化学療法〜高齢者のがん治療を安全・効果的に遂行するための取り組み 切除不能進行膵癌において、サルコペニアの有無はFOLFILINOX導入の判断指標になりえる

    鈴木 洸, 栗田 裕介, 長谷川 翔, 佐藤 高光, 加藤 真吾, 細野 邦広, 小林 規俊, 窪田 賢輔, 中島 淳

    日本高齢消化器病学会誌   24 ( 1 )   119 - 119   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本高齢消化器病学会  

    researchmap

  • IgG4‐related sclerosing cholangitis may be a risk factor for cancer

    Yusuke Kurita, Yuji Fujita, Yusuke Sekino, Seitaro Watanabe, Akito Iwasaki, Koichi Kagawa, Emiko Tanida, Shin Yagi, Sho Hasegawa, Takamitsu Sato, Kunihiro Hosono, Shingo Kato, Noritoshi Kobayashi, Yasushi Ichikawa, Itaru Endo, Atsushi Nakajima, Kensuke Kubota

    Journal of Hepato-Biliary-Pancreatic Sciences   28 ( 6 )   524 - 532   2021年6月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    DOI: 10.1002/jhbp.957

    researchmap

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jhbp.957

  • EUS-BD関連偶発症の包括的検討 より安全な手技を目指して

    佐藤 高光, 細野 邦広, 八木 伸, 栗田 裕介, 長谷川 翔, 加藤 真吾, 窪田 賢輔, 中島 淳

    Gastroenterological Endoscopy   63 ( Suppl.1 )   931 - 931   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 術後再建腸管に合併した胆管結石に対する包括的治療戦略

    長谷川 翔, 細野 邦広, 中島 淳, 八木 伸, 栗田 裕介, 佐藤 高光, 加藤 真吾, 窪田 賢輔

    日本消化器病学会雑誌   118 ( 臨増総会 )   A326 - A326   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Severe acute respiratory syndrome coronavirus 2 prevalence in saliva and gastric and intestinal fluid in patients undergoing gastrointestinal endoscopy in coronavirus disease 2019 endemic areas: Prospective cross-sectional study in Japan. 国際誌

    Shigeta Miyake, Keiichi Ashikari, Shingo Kato, Tomohiro Takatsu, Hirofumi Kuwashima, Hiroaki Kaneko, Koki Nagai, Ikue Watari, Takamitsu Sato, Yutaro Yamaoka, Tetsuya Yamamoto, Akihide Ryo, Shin Maeda, Atsushi Nakajima, Takuma Higurashi

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   34 ( 1 )   96 - 104   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Gastrointestinal endoscopy (GIE) is useful for the early detection and treatment of many diseases; however, GIE is considered a high-risk procedure in the coronavirus disease 2019 (COVID-19) pandemic era. This study aimed to explore the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity in saliva and gastrointestinal fluids to which endoscopy medical staff are exposed. METHODS: The study was a single-center cross-sectional study. From June 1 to July 31, 2020, all patients who underwent GIE at Yokohama City University Hospital were registered. All patients provided 3 mL of saliva. For upper GIE, 10 mL of gastric fluid was collected through the endoscope. For lower GIE, 10 mL of intestinal fluid was collected through the endoscope. The primary outcome was the positive rate of SARS-CoV-2 in saliva and gastrointestinal fluids. We also analyzed serum-specific antibodies for SARS-CoV-2 and patients' background information. RESULTS: A total of 783 samples (560 upper GIE and 223 lower GIE samples) were analyzed. Polymerase chain reaction (PCR) on saliva samples did not show any positive results in either upper or lower GIE samples. However, 2.0% (16/783) of gastrointestinal fluid samples tested positive for SARS-CoV-2. No significant differences in age, sex, purpose of endoscopy, medication, or rate of antibody test positivity were found between PCR positive and PCR negative cases. CONCLUSIONS: Asymptomatic patients, even those with no detectable virus in their saliva, had SARS-CoV-2 in their gastrointestinal tract. Endoscopy medical staff should be aware of infection when performing procedures. The study was registered as UMIN000040587.

    DOI: 10.1111/den.13945

    PubMed

    researchmap

  • Endotoxins and Non-Alcoholic Fatty Liver Disease. 国際誌

    Takaomi Kessoku, Takashi Kobayashi, Kento Imajo, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Asako Nogami, Yasushi Honda, Yuji Ogawa, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Takayuki Okamoto, Haruki Usuda, Koichiro Wada, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima

    Frontiers in endocrinology   12   770986 - 770986   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It occurs with a prevalence of up to 25%, of which 10-20% cases progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. The histopathology of NASH is characterized by neutrophilic infiltration, and endotoxins from gram-negative rods have been postulated as a contributing factor. Elevations in endotoxin levels in the blood can be classified as intestinal and hepatic factors. In recent years, leaky gut syndrome, which is characterized by impaired intestinal barrier function, has become a significant issue. A leaky gut may prompt intestinal bacteria dysbiosis and increase the amount of endotoxin that enters the liver from the portal vein. These contribute to persistent chronic inflammation and progressive liver damage. In addition, hepatic factors suggest that liver damage can be induced by low-dose endotoxins, which does not occur in healthy individuals. In particular, increased expression of CD14, an endotoxin co-receptor in the liver, may result in leptin-induced endotoxin hyper-responsiveness in obese individuals. Thus, elevated blood endotoxin levels contribute to the progression of NASH. The current therapeutic targets for NASH treat steatosis and liver inflammation and fibrosis. While many clinical trials are underway, no studies have been performed on therapeutic agents that target the intestinal barrier. Recently, a randomized placebo-controlled trial examined the role of the intestinal barrier in patients with NAFLD. To our knowledge, this study was the first of its kind and study suggested that the intestinal barrier may be a novel target in the future treatment of NAFLD.

    DOI: 10.3389/fendo.2021.770986

    PubMed

    researchmap

  • Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

    Takaomi Kessoku, Kento Imajo, Takashi Kobayashi, Anna Ozaki, Michihiro Iwaki, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazumi Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima

    The Lancet Gastroenterology & Hepatology   5 ( 11 )   996 - 1007   2020年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/s2468-1253(20)30216-8

    PubMed

    researchmap

  • The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma

    Akito Iwasaki, Kensuke Kubota, Yusuke Kurita, Sho Hasegawa, Yuji Fujita, Koji Kagawa, Shingo Kato, Yusuke Sekino, Kunihiro Hosono, Atsushi Nakajima

    Journal of Hepato-Biliary-Pancreatic Sciences   27 ( 10 )   700 - 711   2020年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    DOI: 10.1002/jhbp.804

    researchmap

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jhbp.804

  • EUS-BDの手技完遂における環境とは

    佐藤 高光, 栗田 裕介, 長谷川 翔, 加藤 真吾, 細野 邦広, 窪田 賢輔, 中島 淳

    Gastroenterological Endoscopy   62 ( Suppl.2 )   2168 - 2168   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 術前放射線化学療法中の膵癌に対する内視鏡的胆道ドレナージの治療成績

    長谷川 翔, 栗田 裕介, 佐藤 高光, 細野 邦広, 加藤 真吾, 遠藤 格, 窪田 賢輔, 中島 淳

    Gastroenterological Endoscopy   62 ( Suppl.2 )   2165 - 2165   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin. 査読 国際誌

    Tsutomu Yoshihara, Yosuke Oikawa, Takayuki Kato, Takaomi Kessoku, Takashi Kobayashi, Shingo Kato, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Hidenori Ohkubo, Takuma Higurashi, Yoko Tateishi, Yoshiki Tanaka, Shunji Nakajima, Hiroshi Ohno, Koichiro Wada, Atsushi Nakajima

    Gut microbes   11 ( 5 )   1385 - 1404   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Proton pump inhibitors (PPIs) can alleviate upper gastrointestinal injury but paradoxically exacerbate aspirin (ASA)-induced small intestine injury. In this study, our goal was to simulate this exacerbation by developing an appropriate animal model, which may help in establishing treatments. Methods: Male mice were fed a 60% fructose diet for 9 weeks, then administered 200 mg/kg ASA 3 h before sacrifice. The PPI omeprazole was administered intraperitoneally once daily for 9 weeks. Bifidobacterium bifidum G9-1 was administered orally for the last week. In addition, Akkermansia muciniphila was administered orally for 9 weeks instead of omeprazole. Results: ASA-induced small-intestine injury was observed in high-fructose fed mice. Omeprazole exacerbated ASA-induced intestinal damage, significantly decreased Bifidobacteria levels, and significantly increased A. muciniphila counts in the jejunum. The direct administration of A. muciniphila caused thinning of the jejunum mucus layer, which was also observed in mice that received ASA and omeprazole. On the other hand, the administration of Bifidobacterium bifidum G9-1 inhibited A. muciniphila growth and reduced thinning of the mucus layer. The number of goblet cells in the jejunum was reduced by the administration of ASA and omeprazole, while Bifidobacterium bifidum G9-1 prevented the reduction. Conclusions: These results suggest that omeprazole-induced gut dysbiosis promotes Akkermansia growth and inhibits Bifidobacterium growth, leading to a thinning of the mucus layer through a reduction in goblet cells in the small intestine. Probiotics are, therefore, a promising approach for the treatment of small intestine injury.

    DOI: 10.1080/19490976.2020.1758290

    PubMed

    researchmap

  • 難渋する胆道ドレナージの工夫 悪性肝門部胆管狭窄に対するEBDとEUS-HGSによるHybrid drainageの工夫

    佐藤 高光, 細野 邦広, 窪田 賢輔, 栗田 裕介, 長谷川 翔, 加藤 真吾, 中島 淳

    胆道   34 ( 3 )   431 - 431   2020年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胆道学会  

    researchmap

  • Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. 査読 国際誌

    Shingo Kato, Kazufumi Honda

    Cancers   12 ( 7 )   1965 - 1965   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MDPI AG  

    Pancreatic cancer remains one of the deadliest cancers worldwide, and it is typically diagnosed late, with a poor prognosis. Early detection is the most important underlying factor for improving the prognosis of pancreatic cancer patients. One of the most effective strategies for detecting cancers at an early stage is screening of the general population. However, because of the low incidence of pancreatic cancer in the general population, the stratification of subjects who need to undergo further examinations by invasive and expensive modalities is important. Therefore, minimally invasive modalities involving biomarkers and imaging techniques that would facilitate the early detection of pancreatic cancer are highly needed. Multiple types of new blood biomarkers have recently been developed, including unique post-translational modifications of circulating proteins, circulating exosomes, microRNAs, and circulating tumor DNA. We previously reported that circulating apolipoprotein A2 undergoes unique processing in the bloodstream of patients with pancreatic cancer and its precancerous lesions. Additionally, we recently demonstrated a new method for measuring pancreatic proton density in the fat fraction using a fat-water magnetic resonance imaging technique that reflects pancreatic steatosis. In this review, we describe recent developments in potential biomarkers and imaging modalities for the early detection and risk stratification of pancreatic cancer, and we discuss current strategies for implementing screening programs for pancreatic cancer.

    DOI: 10.3390/cancers12071965

    PubMed

    researchmap

  • The influence of HLA-B51 on clinical manifestations among Japanese patients with Behçet’s disease: A nationwide survey

    Yuki Mizuki, Nobuyuki Horita, Yukihiro Horie, Masaki Takeuchi, Takehito Ishido, Ryuta Mizuki, Tatsukata Kawagoe, Etsuko Shibuya, Kentaro Yuda, Mizuho Ishido, Kaoru Minegishi, Ryusuke Yoshimi, Yohei Kirino, Shingo Kato, Jun Arimoto, Takeshi Fukumoto, Michiko Kurosawa, Nobuyoshi Kitaichi, Mitsuhiro Takeno, Takeshi Kaneko, Nobuhisa Mizuki

    Modern Rheumatology   30 ( 4 )   708 - 714   2020年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Informa UK Limited  

    DOI: 10.1080/14397595.2019.1649103

    PubMed

    researchmap

  • Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis

    Tetsuya Matsuura, Yoshiaki Maru, Masashi Izumiya, Daisuke Hoshi, Shingo Kato, Masako Ochiai, Mika Hori, Shogo Yamamoto, Kenji Tatsuno, Toshio Imai, Hiroyuki Aburatani, Atsushi Nakajima, Yoshitaka Hippo

    Carcinogenesis   41 ( 4 )   490 - 501   2020年6月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    <title>Abstract</title>
    The organoid culture technique has been recently applied to modeling carcinogenesis in several organs. To further explore its potential and gain novel insights into tumorigenesis, we here investigated whether pancreatic ductal adenocarcinoma (PDA) could be generated as subcutaneous tumors in immunocompromised nude mice, by genetic engineering of normal organoids. As expected, acute induction of KrasG12Din vitro occasionally led to development of tiny nodules compatible with early lesions known as pancreatic intraepithelial neoplasia (PanIN). KrasG12D-expressing cells were enriched after inoculation in the subcutis, yet proved rather declined during culture, suggesting that its advantage might depend on surrounding environments. Depletion of growth factors or concurrent Trp53 deletion resulted in its robust enrichment, invariably leading to development of PanIN or large high-grade adenocarcinoma, respectively, consistent with in vivo mouse studies for the same genotype. Progression from PanIN was also recapitulated by subsequent knockdown of common tumor suppressors, whereas the impact of Tgfbr2 deletion was only partially recapitulated, illustrating genotype-dependent requirement of the pancreatic niche for tumorigenesis. Intriguingly, analysis of tumor-derived organoids revealed that KrasG12D-expressing cells with spontaneous deletion of wild-type Kras were positively selected and exhibited an aging-related mutation signature in nude mice, mirroring the pathogenesis of human PDA, and that the sphere-forming potential and orthotopic tumorigenicity in syngenic mice were significantly augmented. These observations highlighted the relevance of the subcutis of nude mice in promoting PDA development despite its ectopic nature. Taken together, pancreatic carcinogenesis could be considerably recapitulated with organoids, which would probably serve as a novel disease model.

    DOI: 10.1093/carcin/bgz122

    PubMed

    researchmap

    その他リンク: http://academic.oup.com/carcin/article-pdf/41/4/490/33396192/bgz122.pdf

  • AKKERMANSIA MUCINIPHILA AND BIFIDOBACTERIUM BIFIDUM G9-1: KEY PLAYERS IN SMALL INTESTINAL INJURY CAUSED BY THE COMBINATION OF ASPIRIN AND PROTON PUMP INHIBITORS

    Tsutomu Yoshihara, Yosuke Oikawa, Takayuki Kato, Takaomi Kessoku, Takashi Kobayashi, Shingo Kato, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Hidenori Ohkubo, Takuma Higurashi, Yoko Tateishi, Yoshiki Tanaka, Shunji Nakajima, Hiroshi Ohno, Koichiro Wada, Atsushi Nakajima

    GASTROENTEROLOGY   158 ( 6 )   S1158 - S1158   2020年5月

     詳細を見る

    記述言語:英語   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

  • Effect of preventive closure of the frenulum after endoscopic papillectomy: A prospective pilot study. 査読 国際誌

    Koichi Kagawa, Kensuke Kubota, Yusuke Kurita, Yuri Takagi, Ken Ishii, Sho Hasegawa, Akito Iwasaki, Takamitsu Sato, Yuji Fujita, Shingo Kato, Seitaro Watanabe, Yusuke Sekino, Kunihiro Hosono, Atsushi Nakajima

    Journal of gastroenterology and hepatology   35 ( 3 )   374 - 379   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: The usefulness of preventive closure of the frenulum after endoscopic papillectomy (EP) could reduce bleeding. The feasibility and safety of clipping were evaluated in this prospective pilot study. METHODS: This study involved 40 consecutive patients who underwent preventive closure of the frenulum by clipping just after EP. The outcome data were compared with those of the previous 40 patients in whom no preemptive closure had been performed (no-closure group) (UMIN000014783). Additionally, the bleeding sites were examined. RESULTS: The clipping procedure was successful in all patients. As compared to the no-closure group, the rate of bleeding (P = 0.026) and period of hospital stay (P < 0.001) were significantly reduced in the closure group. There was no difference in the procedure time between the two groups. Furthermore, the incidence rates of pancreatitis and perforation were comparable in the two groups. The bleeding was noted in the frenulum area rather than at any other site in 90.9% of cases. CONCLUSION: Preventive closure of the frenulum after EP is an effective, safe, rational, and economical method to reduce the incidence of delayed bleeding, without prolonging the procedure time or increasing the risk of post-procedure pancreatitis perforation.

    DOI: 10.1111/jgh.14922

    PubMed

    researchmap

  • ERCP困難な膵管狭窄に対するEUSガイド下膵管ドレナージの治療成績

    長谷川 翔, 窪田 賢輔, 栗田 裕介, 佐藤 高光, 加藤 真吾, 細野 邦広, 中島 淳

    日本消化器病学会関東支部例会プログラム・抄録集   358回   36 - 36   2020年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-関東支部  

    researchmap

  • Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. 査読 国際誌

    Shingo Kato, Akito Iwasaki, Yusuke Kurita, Jun Arimoto, Toh Yamamoto, Sho Hasegawa, Takamitsu Sato, Kento Imajo, Kunihiro Hosono, Noritoshi Kobayashi, Masato Yoneda, Takuma Higurashi, Kensuke Kubota, Daisuke Utsunomiya, Atsushi Nakajima

    PloS one   14 ( 12 )   e0224921   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Since pancreatic steatosis is reported as a possible risk factor for pancreatic cancer, the development of a non-invasive method to quantify pancreatic steatosis is needed. Proton density fat fraction (PDFF) measurement is a magnetic resonance imaging (MRI) based method for quantitatively assessing the steatosis of a region of interest (ROI). Although it is commonly used for quantification of hepatic steatosis, pancreatic PDFF can greatly vary depending on the ROI's location because of the patchy nature of pancreatic fat accumulation. In this study, we attempted to quantify pancreatic steatosis by fat-water MRI with improved reproducibility. METHODS: Using the MRI images of 159 patients with nonalcoholic fatty liver disease, we attempted to calculate the average PDFF of whole pancreas. We set ROIs covering the entire area of the pancreas appearing in every slice and calculated the average PDFF from all the voxels included in the pancreas. We named this average value as whole-pancreatic PDFF and evaluated the reproducibility of the measured values. In addition to whole-pancreatic PDFF, we measured the average PDFF of the pancreatic head (head-PDFF) and that of the pancreatic body plus tail separately and analyzed their correlation with the clinical characteristics of the patients. RESULTS: The mean inter-examiner coefficient of variation of the whole-pancreatic PDFF was 11.39%. The whole-pancreatic PDFF was correlated with age (p = 0.039), body mass index (p = 0.0093) and presence/absence of diabetes (p = 0.0055). The serum level of low-density lipoprotein cholesterol was inversely correlated with the head-PDFF. CONCLUSION: We developed a new measurement method of the pancreatic PDFF with greater reproducibility. Using this method, we characterized pancreatic steatosis in detail. This novel measurement method allows accurate estimation of the severity of pancreatic steatosis and is therefore useful for the detailed characterization of pancreatic steatosis.

    DOI: 10.1371/journal.pone.0224921

    PubMed

    researchmap

  • CA19-9 as a therapeutic target in pancreatitis. 査読 国際誌

    Shingo Kato, Kazufumi Honda

    Annals of translational medicine   7 ( Suppl 8 )   S318   2019年12月

     詳細を見る

  • Safety of Cold Snare Polypectomy in Patients Receiving Treatment with Antithrombotic Agents. 査読 国際誌

    Jun Arimoto, Hideyuki Chiba, Keiichi Ashikari, Ryo Fukui, Hideyuki Anan, Jun Tachikawa, Takuma Suto, Naoya Kawano, Toshihiro Niikura, Hiroki Kuwabara, Michiko Nakaoka, Shingo Kato, Tomonori Ida, Taiki Morohashi, Tohru Goto, Atsushi Nakajima

    Digestive diseases and sciences   64 ( 11 )   3247 - 3255   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: With the aging of the population and rising incidence of thromboembolic events, the clinical use of antithrombotic agents is also increasing. There are few reports yet on the management of antithrombotic agent use in patients undergoing cold snare polypectomy (CSP). AIMS: The aim of this study was to evaluate whether continued administration of antithrombotic agents in patients undergoing CSP would be associated with an increased rate of delayed post-polypectomy bleeding (DPPB). METHODS: A total of 1177 colorectal polyps in 501 patients were resected at Omori Red Cross Hospital between October 2017 and March 2018. The polyps were divided into two groups depending on whether the patients received antithrombotic agent treatment or not: the antithrombotic group (911 polyps) and the no-antithrombotic group (266 polyps). RESULTS: Among the 1177 polyp resections, there was no case of DPPB, including in the antithrombotic group. Immediate bleeding occurred in a total of 63 (5.4%) cases. Polyp location in the rectum (OR (95% CI) 2.64 (1.223-5.679); p = 0.013), polyp size ≥ 6 mm (OR (95% CI) 4.64 (2.719-7.933); p < 0.001), polypoid growth pattern (OR (95% CI) 2.78 (1.607-4.793); p < 0.001), and antithrombotic agent use (OR (95% CI) 2.98 (1.715-5.183); p < 0.001) were identified as significant risk factors of immediate bleeding. CONCLUSIONS: Continued use of antithrombotic agents does not increase the risk of DPPB, even in those receiving multiple antithrombotic agents. Thus, it is safe to perform CSP even in multiple agent users. Prospective, randomized studies are necessary to confirm our results.

    DOI: 10.1007/s10620-019-5469-1

    PubMed

    researchmap

  • Clinical features of early-stage possible Behçet’s disease patients with a variant-type major organ involvement in Japan

    Takeharu Suzuki, Nobuyuki Horita, Masaki Takeuchi, Takehito Ishido, Yuki Mizuki, Ryuta Mizuki, Tatsukata Kawagoe, Etsuko Shibuya, Kentaro Yuta, Takahiro Yamane, Takahiko Hayashi, Akira Meguro, Mizuho Ishido, Kaoru Minegishi, Ryusuke Yoshimi, Yohei Kirino, Shingo Kato, Jun Arimoto, Takeshi Fukumoto, Yoshiaki Ishigatsubo, Michiko Kurosawa, Mitsuhiro Takeno, Takeshi Kaneko, Nobuhisa Mizuki

    Modern Rheumatology   29 ( 4 )   640 - 646   2019年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Informa UK Limited  

    DOI: 10.1080/14397595.2018.1494501

    PubMed

    researchmap

  • Clinical features of isolated proximal-type immunoglobulin G4-related sclerosing cholangitis. 査読 国際誌

    Yuri Takagi, Kensuke Kubota, Takuya Takayanagi, Yusuke Kurita, Ken Ishii, Sho Hasegawa, Akito Iwasaki, Takamitsu Sato, Yuji Fujita, Shingo Kato, Koichi Kagawa, Seitaro Watanabe, Yusuke Sekino, Kunihiro Hosono, Nobuyuki Matsuhashi, Shoji Yamanaka, Toshiyasu Iwao, Koji Yoshida, Atsushi Nakajima

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   31 ( 4 )   422 - 430   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) presents as isolated proximal-type sclerosing cholangitis (i-SC). The present study sought to clarify the imaging differences between i-SC and Klatskin tumor. Differences between i-SC and IgG4-SC associated with autoimmune pancreatitis (AIP-SC) were also studied. METHODS: Differentiating factors between i-SC and Klatskin tumor were studied. Serum IgG4 level, CA19-9 level, computed tomography (CT) findings, cholangiography findings (symmetrical smooth long stricture extending into the upper bile duct [SSLS]), endosonographic features (continuous symmetrical mucosal lesion to the hilar part [CSML]), endoscopic biopsy results, treatment, relapse, and survival were also compared between patients with i-SC and those with AIP-SC. RESULTS: For a differential diagnosis between i-SC (N = 9) and Klatskin tumor (N = 47), the cut-off value of serum IgG4 level was 150 mg/dL (sensitivity, 0.857, specificity, 0.966). Logistic regression analysis indicated that serum IgG4 level, presence of SSLS, presence of CSML, and presence of swollen ampulla are independent factor for identifying i-SC. Relapse rate was significantly higher in the IgG4-SC with AIP group than in the i-SC group (log rank, P = 0.046). CONCLUSION: Isolated proximal-type sclerosing cholangitis presents as a nodular lesion with SSLS and/or CSML mimicking a Klatskin tumor. Those endoscopic features might provide a diagnostic clue for i-SC. i-SC is likely to have a more favorable prognosis than IgG4-SC with AIP.

    DOI: 10.1111/den.13320

    PubMed

    researchmap

  • 胆膵領域におけるelasticity imagingの役割 超音波内視鏡下エラストグラフィーを用いた膵実質硬度評価の試み

    佐藤 高光, 細野 邦広, 加藤 真吾, 長谷川 翔, 栗田 裕介, 窪田 賢輔, 中島 淳

    超音波医学   46 ( Suppl. )   S336 - S336   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • The ocular involvement did not accompany with the genital ulcer or the gastrointestinal symptoms at the early stage of Behçet’s disease

    Akiko Suwa, Nobuyuki Horita, Takehito Ishido, Masaki Takeuchi, Tatsukata Kawagoe, Etsuko Shibuya, Takahiro Yamane, Takahiko Hayashi, Akira Meguro, Mizuho Ishido, Kaoru Minegishi, Ryusuke Yoshimi, Yohei Kirino, Shingo Kato, Jun Arimoto, Takeshi Fukumoto, Yoshiaki Ishigatsubo, Michiko Kurosawa, Takeshi Kaneko, Mitsuhiro Takeno, Nobuhisa Mizuki

    Modern Rheumatology   29 ( 2 )   357 - 362   2019年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Informa UK Limited  

    DOI: 10.1080/14397595.2018.1457424

    PubMed

    researchmap

  • Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. 査読 国際誌

    Shingo Kato, Takuo Hayashi, Yoshiyuki Suehara, Haruka Hamanoue, Shoji Yamanaka, Yasushi Ichikawa, Takuma Higurashi, Kenichi Ohashi, Shigeo Yamaguchi, Yumi Nozaki, Yasuhisa Terao, Tsuyoshi Saito

    Japanese journal of clinical oncology   49 ( 2 )   174 - 182   2019年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Application of next-generation DNA sequencing (NGS) has recently become increasingly common in the field of clinical oncology in several countries around the world. In Japan also, a system for applying NGS to routine clinical practice is gradually being established. During this process, we introduced in Japan the tumor-profiling MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) assay. Methods: We present here our initial experience with the use of MSK-IMPACT in 68 patients selected from two institutions in Japan between June 2016 and October 2017. Results: MSK-IMPACT sequencing was successful and yielded results in specimens obtained from 64 of the 68 patients, representing an overall assay success rate of 94.1%. The top three cancer types tested were endometrial cancer (17.2%), pancreatic cancer (15.6%) and colorectal cancer (12.5%). Evaluation of the clinical actionability of the genetic alterations revealed that 25.0% of patients (n = 16) harbored at least one actionable alteration. However, enrolling the patients in a genomically matched clinical trial was difficult, mainly because most clinical trials are limited to tumors arising from a specific organ/site. One patient with microsatellite instability-high status, as determined by MSK-IMPACT, was treated with pembrolizumab and showed partial response. Conclusions: Although tumor profiling by NGS and administration of genomically matched therapy is a promising strategy, because of its high cost, we need to consider how we can fit it into the Japanese medical system. Towards this end, we believe that it is important to share our initial experience for furthering precision medicine in Japan.

    DOI: 10.1093/jjco/hyy173

    PubMed

    researchmap

  • Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. 査読 国際誌

    Yuji Ogawa, Kento Imajo, Yasushi Honda, Takaomi Kessoku, Wataru Tomeno, Shingo Kato, Koji Fujita, Masato Yoneda, Satoru Saito, Yusuke Saigusa, Hideyuki Hyogo, Yoshio Sumida, Yoshito Itoh, Kosei Eguchi, Takeharu Yamanaka, Koichiro Wada, Atsushi Nakajima

    Scientific reports   8 ( 1 )   11365 - 11365   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although previous studies have indicated important roles of palmitate, a saturated fatty acid, in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), it remains unclear how palmitate contributes to inflammation and fibrosis in the liver. Administration of palmitate in high fat diet (HFD)-fed but not basal diet (BD)-fed mice resulted in an increase in serum alanine aminotransferase (ALT) levels. Surprisingly, combined administration of very low dose lipopolysaccharide in palmitate-treated mice led to a marked increase in serum ALT levels despite BD-fed conditions. Administration of palmitate alone in BD-fed mice caused inflammatory cell infiltration and liver fibrosis mediated by the toll-like receptor 4 pathway without ALT elevation. In addition, a significant correlation between serum free fatty acid levels and liver fibrosis stage was observed in patients with NAFLD. These results indicate that palmitate may play crucial roles in the pathogenesis of NAFLD in the presence of gut-derived endotoxin.

    DOI: 10.1038/s41598-018-29735-6

    PubMed

    researchmap

  • Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. 査読 国際誌

    Takaomi Kessoku, Kento Imajo, Takashi Kobayashi, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazumi Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

    Contemporary clinical trials   69   40 - 47   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: This paper reports the protocol of a randomised, double-blind, placebo-controlled study to test the efficacy, safety, and tolerability of lubiprostone (LUB) vs. placebo on suppressing gut permeability in non-alcoholic fatty liver disease (NAFLD) patients with constipation. NAFLD, including non-alcoholic steatohepatitis (NASH), is a common chronic liver disorder. Progression is associated with increased gut permeability and gut-derived endotoxins. Most NAFLD/NASH clinical trial drugs aim to improve liver function or systemic metabolism. LUB is a type 2 chloride channel activator used as a laxative for the treatment of patients with constipation. LUB suppresses gut permeability induced by non-steroidal anti-inflammatory drugs in healthy volunteers and lowers blood endotoxin levels. There have been no clinical studies of LUB for NAFLD/NASH patients. METHODS: The study plans to enrol adult patients (20-85 years, planned enrolment, n = 150; planned sample size, n = 120) with NAFLD and constipation, alanine aminotransferase ≥40 IU/L, equivalent steatosis grade ≥1, and equivalent fibrosis stage <4 measured using non-invasive vibration-controlled transient elastography and magnetic resonance imaging. Participants will be randomly allocated into three groups: LUB 12 μg, LUB 24 μg, and a placebo group. RESULTS: The primary endpoint will be changes in alanine aminotransferase from baseline at 12 weeks. The main secondary endpoint will be changes in intestinal permeability from baseline at 12 weeks using the lactulose mannitol ratio. CONCLUSIONS: This study will determine whether LUB improves gut permeability in NAFLD patients with constipation. TRIAL REGISTRATION: This trial is registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000026635).

    DOI: 10.1016/j.cct.2018.04.002

    PubMed

    researchmap

  • Risk factors for post-colorectal endoscopic submucosal dissection (ESD) coagulation syndrome: a multicenter, prospective, observational study. 査読 国際誌

    Jun Arimoto, Takuma Higurashi, Shingo Kato, Akiko Fuyuki, Hidenori Ohkubo, Takashi Nonaka, Yoshikazu Yamaguchi, Keiichi Ashikari, Hideyuki Chiba, Shungo Goto, Masataka Taguri, Takashi Sakaguchi, Kazuhiro Atsukawa, Atsushi Nakajima

    Endoscopy international open   6 ( 3 )   E342-E349 - E349   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and study aims:  Colorectal cancer (CRC) is one of the most common neoplasms and endoscopic submucosal dissection (ESD) is an effective treatment for early-stage CRC. However, it has been observed that patients undergoing ESD often complain of pain, even if ESD has been successfully performed. Risk factors for such pain still remain unknown. The aim of this study was to explore the risk factors for post-colorectal ESD coagulation syndrome (PECS). Patients and methods : This was a prospective multicenter observational trial (UMIN000016781) conducted in 106 of 223 patients who underwent ESD between March 2015 and April 2016. We investigated age, sex, tumor location, ESD operation time, lesion size, duration of hospitalization, and frequency of PECS. We defined PECS as local abdominal pain (evaluated on a visual analogue scale) in the region corresponding to the site of the ESD that occurred within 4 days of the procedure. Results : PECS occurred in 15/106 (14.2 %), and 10 were women ( P  = 0.01, OR: 7.74 [1.6 - 36.4]), 7 had lesions in the cecum ( P  < 0.001, OR: 20.6 [3.7 - 115.2]), and 9 in whom ESD operation time was > 90 min ( P  = 0.002, OR: 10.3 [2.4 - 44.6]). Frequency of deviation from the prescribed clinical path was significantly higher (47 % [7/15] vs. 2 % [2/91], P  < 0.001, OR: 38.9 [6.9 - 219.6]), and hospital stay was significantly longer in the PECS group. . Conclusions : Female gender, location of lesion in the cecum, and ESD operation time > 90 minutes were significant risk factors independent of PECS. These findings are important to management of PECS. .

    DOI: 10.1055/s-0044-101451

    PubMed

    researchmap

  • Possible therapeutic application of targeting type II natural killer T cell-mediated suppression of tumor immunity 査読

    Shingo Kato, Jay A. Berzofsky, Masaki Terabe

    Frontiers in Immunology   9   314   2018年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Frontiers Media S.A.  

    Natural killer T (NKT) cells are a unique T cell subset that exhibits characteristics from both the innate immune cells and T cells. There are at least two subsets of NKT cells, type I and type II. These two subsets of NKT cells have opposite functions in antitumor immunity. Type I NKT cells usually enhance and type II NKT cells suppress antitumor immunity. In addition, these two subsets of NKT cells cross-regulate each other. In this review, we mainly focus on immunosuppressive NKT cells, type II NKT cells. After summarizing their definition, experimental tools to study them, and subsets of them, we will discuss possible therapeutic applications of type II NKT cell pathway targeted therapies.

    DOI: 10.3389/fimmu.2018.00314

    Scopus

    PubMed

    researchmap

  • Clinical manifestations of Behçet's disease depending on sex and age: results from Japanese nationwide registration. 査読

    Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, Hayashi T, Meguro A, Ishido M, Minegishi K, Yoshimi R, Kirino Y, Kato S, Arimoto J, Ishigatsubo Y, Takeno M, Kurosawa M, Kaneko T, Mizuki N

    Rheumatology (Oxford, England)   56 ( 11 )   1918 - 1927   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/rheumatology/kex285

    Web of Science

    PubMed

    researchmap

  • Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. 査読 国際誌

    Izumi Tsuchiya, Yuri Kato, Emiko Tanida, Yoshifumi Masui, Shingo Kato, Atsushi Nakajima, Motoyoshi Izumi

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   29 ( 5 )   576 - 583   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY  

    BACKGROUND AND AIM: Proton pump inhibitors are effective for the treatment of gastric ulcers after endoscopic submucosal dissection (ESD). However, the most excellent therapy is controversial. Vonoprazan, an active potassium-competitive acid blocker, has a strong gastric acid secretion inhibitory effect, but its efficacy for the treatment of post-ESD gastric ulcers is unclear. Herein, we aimed to determine the healing effect of vonoprazan on post-ESD gastric ulcers. METHODS: We carried out a prospective randomized controlled trial examining 92 patients who had undergone ESD for the treatment of gastric neoplasms between April 2015 and June 2016 at Machida Municipal Hospital. Patients were treated with 20 mg/day vonoprazan (V group) or 20 mg/day esomeprazole (E group) for 8 weeks. We evaluated the 8-week cure rate for artificial ulcers and any complications after ESD. RESULTS: A total of 80 patients (median age, 73.5 years; 71.3% male) were analyzed. Cure rate for the V group was significantly higher than that for the E group (94.9% [37/39] vs 78.0% [32/41], respectively; P = 0.049). In a multivariate analysis, only vonoprazan was correlated with ulcer healing (odds ratio = 6.33; 95% CI = 1.21-33.20; P = 0.029). Delayed bleeding was experienced only in the E group (7.3% [3/41]), but no significant difference compared with the V group was observed (P = 0.241). CONCLUSION: Vonoprazan was significantly superior to esomeprazole for the healing of post-ESD gastric ulcers and should be considered as a treatment of first choice.

    DOI: 10.1111/den.12857

    Web of Science

    PubMed

    researchmap

  • Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. 査読

    Terabe M, Robertson FC, Clark K, De Ravin E, Bloom A, Venzon DJ, Kato S, Mirza A, Berzofsky JA

    Oncoimmunology   6 ( 5 )   e1308616   2017年

  • 【Interventional EUSのすべて】EUSガイド下腹腔神経叢・神経節ブロック術 EUS-CPN/CGN

    窪田 賢輔, 栗田 裕介, 岩崎 暁人, 佐藤 高光, 加藤 真吾, 香川 幸一, 細野 邦広, 渡辺 誠太郎, 関野 雄典, 藤田 祐司, 石井 研, 長谷川 翔

    消化器内視鏡   28 ( 10 )   1685 - 1690   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)東京医学社  

    これまで、癌性疼痛や腰部椎間板ヘルニアに伴う腰痛に対して、麻酔科、整形外科専門医によりX線透視下に、患者背側からawakeのまま神経ブロックがブラインドで行われてきた。一方、超音波内視鏡ガイド下腹腔神経ブロック術は鎮静下で、超音波内視鏡ガイド下穿刺吸引法(EUS-FNA)と同様、苦痛なく安全に施行可能で、有効性の高い手技として注目されている。癌性疼痛については、WHOラダーに沿って鎮痛薬はできる限り内服で少量から始め、疼痛が消える量に漸増し、なるべく定時処方で、必要に応じて鎮痛補助薬の併用も考慮すべきとされている。ほとんどの疼痛はWHOラダーに沿った治療でコントロール可能であるが、麻薬を希望しない、または麻薬不耐性などの場合に本法は有効である。超音波内視鏡ガイド下腹腔神経ブロック術には、腹腔神経叢ブロック(EUS-CPB)と神経節ブロック(EUS-CGN)がある。現状では、EUS-CPNはWHOの疼痛コントロールのstep3の選択肢の一つとして施行されている。(著者抄録)

    researchmap

  • 術後再建腸管の狭窄に対するシングルバルーン内視鏡による金属ステントの有用性

    岩崎 暁人, 栗田 裕介, 長谷川 翔, 佐藤 高光, 藤田 祐司, 細野 邦広, 加藤 真吾, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   58 ( Suppl.2 )   1940 - 1940   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 良性胆道狭窄・術前胆道ドレナージに対する超音波内視鏡下胆道ドレナージ術の適応

    佐藤 高光, 栗田 裕介, 長谷川 翔, 岩崎 暁人, 藤田 裕司, 加藤 真吾, 細野 邦広, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   58 ( Suppl.2 )   1939 - 1939   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: Systematic review and meta-analysis. 査読 国際誌

    Jun Arimoto, Nobuyuki Horita, Shingo Kato, Akiko Fuyuki, Takuma Higurashi, Hidenori Ohkubo, Hiroki Endo, Nonaka Takashi, Takeshi Kaneko, Atsushi Nakajima

    Scientific reports   6   29754 - 29754   2016年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    We performed this systematic review and meta-analysis to assess the diagnostic accuracy of detecting glutamate dehydrogenase (GDH) for Clostridium difficile infection (CDI) based on the hierarchical model. Two investigators electrically searched four databases. Reference tests were stool cell cytotoxicity neutralization assay (CCNA) and stool toxigenic culture (TC). To assess the overall accuracy, we calculated the diagnostic odds ratio (DOR) using a DerSimonian-Laird random-model and area the under hierarchical summary receiver operating characteristics (AUC) using Holling's proportional hazard models. The summary estimate of the sensitivity and the specificity were obtained using the bivariate model. According to 42 reports consisting of 3055 reference positive comparisons, and 26188 reference negative comparisons, the DOR was 115 (95%CI: 77-172, I(2) = 12.0%) and the AUC was 0.970 (95%CI: 0.958-0.982). The summary estimate of sensitivity and specificity were 0.911 (95%CI: 0.871-0.940) and 0.912 (95%CI: 0.892-0.928). The positive and negative likelihood ratios were 10.4 (95%CI 8.4-12.7) and 0.098 (95%CI 0.066-0.142), respectively. Detecting GDH for the diagnosis of CDI had both high sensitivity and specificity. Considering its low cost and prevalence, it is appropriate for a screening test for CDI.

    DOI: 10.1038/srep29754

    Web of Science

    PubMed

    researchmap

  • Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. 査読 国際誌

    Takaomi Kessoku, Kento Imajo, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Hironori Mawatari, Koji Fujita, Masato Yoneda, Yoji Nagashima, Satoru Saito, Koichiro Wada, Atsushi Nakajima

    Scientific reports   6   22251 - 22251   2016年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    The natural polyphenol compound resveratrol (RSV) is considered to have a broad spectrum of beneficial biological activities upon human health. However, the exact effect of RSV on steatosis (a phenotype of non-alcoholic fatty liver [NAFL]) or fibrosis and inflammation (major phenotypes of non-alcoholic steatohepatitis [NASH]) is not known. Our data showed that administration of RSV (2 or 20 mg/kg/day) did not suppress steatosis in a high-fat diet-induced model of NAFL in mice. In contrast, identical concentrations of RSV dramatically inhibited inflammation and fibrosis in a low-dose lipopolysaccharide-induced model of NASH. These data suggested that RSV administration-mediated improvement of inflammation and fibrosis was due to the inhibition of LPS reactivity controlled by CD14 expression in Kupffer cells. These findings suggest that RSV could be a candidate agent for the treatment of NASH.

    DOI: 10.1038/srep22251

    Web of Science

    PubMed

    researchmap

  • The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. 査読 国際誌

    Yasushi Honda, Kento Imajo, Takayuki Kato, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Hironori Mawatari, Koji Fujita, Masato Yoneda, Satoru Saito, Atsushi Nakajima

    PloS one   11 ( 1 )   e0146337   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    BACKGROUND & AIMS: In recent years, nonalcoholic steatohepatitis (NASH) has become a considerable healthcare burden worldwide. Pathogenesis of NASH is associated with type 2 diabetes mellitus (T2DM) and insulin resistance. However, a specific drug to treat NASH is lacking. We investigated the effect of the selective sodium glucose cotransporter 2 inhibitor (SGLT2I) ipragliflozin on NASH in mice. METHODS: We used the Amylin liver NASH model (AMLN), which is a diet-induced model of NASH that results in obesity and T2DM. AMLN mice were fed an AMLN diet for 20 weeks. SGLT2I mice were fed an AMLN diet for 12 weeks and an AMLN diet with 40 mg ipragliflozin/kg for 8 weeks. RESULTS: AMLN mice showed steatosis, inflammation, and fibrosis in the liver as well as obesity and insulin resistance, features that are recognized in human NASH. Ipragliflozin improved insulin resistance and liver injury. Ipragliflozin decreased serum levels of free fatty acids, hepatic lipid content, the number of apoptotic cells, and areas of fibrosis; it also increased lipid outflow from the liver. CONCLUSIONS: Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxicity in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on NASH with T2DM.

    DOI: 10.1371/journal.pone.0146337

    Web of Science

    PubMed

    researchmap

  • Vaginal type-II mucosa is an inductive site for primary CD8(+) T-cell mucosal immunity 査読

    Yichuan Wang, Yongjun Sui, Shingo Kato, Alison E. Hogg, Jason C. Steel, John C. Morris, Jay A. Berzofsky

    Nature Communications   6   6100   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    The structured lymphoid tissues are considered the only inductive sites where primary T-cell immune responses occur. The naive T cells in structured lymphoid tissues, once being primed by antigen-bearing dendritic cells, differentiate into memory T cells and traffic back to the mucosal sites through the bloodstream. Contrary to this belief, here we show that the vaginal type-II mucosa itself, despite the lack of structured lymphoid tissues, can act as an inductive site during primary CD8(+) T-cell immune responses. We provide evidence that the vaginal mucosa supports both the local immune priming of naive CD8(+) T cells and the local expansion of antigen-specific CD8(+) T cells, thereby demonstrating a different paradigm for primary mucosal T-cell immune induction.

    DOI: 10.1038/ncomms7100

    Web of Science

    researchmap

  • Endoscopic treatment of postoperative benign bile duct stricture compared with malignant bile duct stricture. 査読 国際誌

    Noritoshi Kobayashi, Takamitsu Sato, Shingo Kato, Seitaro Watanabe, Kunihiro Hosono, Kensuke Kubota, Kazuhisa Takedaz, Itaru Endo, Atsushi Nakajima, Shin Maeda, Yasushi Ichikawa

    Hepato-gastroenterology   61 ( 134 )   1507 - 18   2014年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIMS: Endoscopic treatment for postoperative benign bile duct stricture (BBS) is a therapeutic challenge. No previous studies have compared endoscopic treatments for BBS and malignant bile duct stricture (MBS). The aim of this study was to compare endoscopic treatments for postoperative BBS and MBS. METHODOLOGY: This study enrolled 22 consecutive patients with a diagnosis of postoperative BBS and 110 patients diagnosed with MBS. Cases involving digestive tract reconstruction were excluded. We compared the length of the bile duct strictures, the success rate of endoscopic treatment, and the incidence of complications. RESULTS: The following results were obtained for the postoperative BBS and MBS groups, respectively: length of bile duct stricture, 6.50 mm vs. 24.3 mm (P<0.0001); success rate of endoscopic treatment, 90.9% vs. 93.6% (P=0.6551). Post-ERCP pancreatitis occurred after 11 sessions (10.7%) vs. 7 sessions (1.83%) (P=0.0002), and post-ERCP cholangitis occurred after 7 sessions (6.80%) vs. 4 sessions (1.04%) (P=0.0021). BBS was a significant risk factor for post-ERCP pancreatitis and cholangitis based on a multivariate analysis (OR, 10.732; P=0.0022; OR, 6.443; P=0.0260). CONCLUSIONS: Post-ERCP-related complications were more frequent after postoperative BBS than after MBS. The need for careful endoscopic treatment may be greater for postoperative BBS cases than for MBS cases.

    DOI: 10.5754/hge13136

    Web of Science

    PubMed

    researchmap

  • Positioning of nasobiliary tube using magnet-loaded catheters. 査読 国際誌

    Seitaro Watanabe, Takamitsu Sato, Shingo Kato, Kunihiro Hosono, Noritoshi Kobayashi, Atsushi Nakajima, Kensuke Kubota

    Endoscopy   45 ( 10 )   835 - 7   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:GEORG THIEME VERLAG KG  

    BACKGROUND AND STUDY AIMS: In endoscopic nasobiliary drainage (ENBD), repositioning the catheter from the mouth to the nose is complicated. We devised a method using catheters with magnets and verified its utility and safety. PATIENTS AND METHODS: We prospectively enrolled 20 patients undergoing ENBD at Yokohama City University Hospital. RESULTS: The procedures were successful in all 20 cases and no case required a change of operators to a senior doctor. The mean time for the procedure was 36.6 seconds. The emetic reflex was induced 0.5 times on average using the magnet method. The mean X-ray exposure time was 29.6 seconds. No complications occurred. CONCLUSIONS: The magnet-loaded catheter method for positioning the ENBD catheter before finally leading it through the nose took little time and was performed successfully and safely. Therefore, the magnet method could become the first choice among techniques for ENBD catheter placement.

    DOI: 10.1055/s-0033-1344330

    Web of Science

    PubMed

    researchmap

  • β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy. 査読

    O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA

    Clin Cancer Res.   19 ( 16 )   4404 - 4411   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1078-0432.CCR-12-2169

    Web of Science

    researchmap

  • aPKCλ/ι is a beneficial prognostic marker for pancreatic neoplasms. 査読

    Kato S, Akimoto K, Nagashima Y, Ishiguro H, Kubota K, Kobayashi N, Hosono K, Watanabe S, Sekino Y, Sato T, Sasaki K, Nakaigawa N, Kubota Y, Inayama Y, Endo I, Ohno S, Maeda S, Nakajima A

    Pancreatology.   13 ( 4 )   360 - 368   2013年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.pan.2013.05.006

    researchmap

  • 嚢腫状に拡張した下部胆管に認められた十二指腸乳頭部癌の1例

    藤田 祐司, 渡邉 誠太郎, 佐藤 高光, 加藤 真吾, 細野 邦広, 小林 規俊, 遠藤 格, 山中 正二, 窪田 賢輔

    胆道   27 ( 2 )   240 - 246   2013年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胆道学会  

    症例は70歳女性。USで肝内胆管、総胆管の拡張を認めた。CTで下部胆管に造影効果を有する腫瘍を認めた。内視鏡で十二指腸乳頭部の口側隆起は球状に腫大し、開口部粘膜の潰瘍性病変と十二指腸粘膜の襞集中を認めた。胆管深部挿管は困難でありsuprapapillary incisionを施行した。ERCで胆管末端の嚢腫状拡張を認めた。EUS、IDUSでは胆管末端は12mm径の嚢腫状の拡張を認め、十二指腸乳頭部に腫瘍の筋層浸潤を認めた。乳頭部生検は腺癌であった。術前画像診断でAbから発生した浸潤癌と診断した。非共通管拡張型のCholedochoceleの合併も示唆された。手術施行されたが開腹時、肝臓に微小結節が多発していたため試験開腹のみとなった。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/default/link?pub_year=2013&ichushi_jid=J02149&link_issn=&doc_id=20130607100012&doc_link_id=%2Fdw1tando%2F2013%2F002702%2F012%2F0240-0246%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdw1tando%2F2013%2F002702%2F012%2F0240-0246%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Needle-knife precut papillotomy with a small incision over a pancreatic stent improves the success rate and reduces the complication rate in difficult biliary cannulations. 査読

    Kensuke Kubota, Takamitsu Sato, Shingo Kato, Seitaro Watanabe, Kunihiro Hosono, Noritoshi Kobayashi, Kantaro Hisatomi, Nobuyuki Matsuhashi, Atsushi Nakajima

    Journal of hepato-biliary-pancreatic sciences   20 ( 3 )   382 - 8   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER JAPAN KK  

    BACKGROUND: Successful precut sphincterotomy (PS) in difficult biliary cannulation (DBC) requires a large incision for deroofing the papilla. However, the high complication rate poses a substantial problem, in addition to the need for expert skills. Pancreatic stent placement could facilitate this procedure. Needle-knife precut papillotomy with a small incision using a layer-by-layer method over a pancreatic stent (NKPP-SIPS) could potentially improve the success rate and reduce the complication rate of PS. AIMS: To validate the efficacy, feasibility and safety of NKPP-SIPS in DBC. METHODS: Therapeutic endoscopic retrograde cholangiopancreatography with a naïve papilla was performed in 1619 cases between May 2004 and July 2011. We prospectively divided the patients chronologically, in terms of the period during which the procedure was performed, into two groups: group A; needle-knife precut papillotomy (NKPP) performed between April 2004 and October 2006; group B; NKPP-SIPS performed between November 2006 and July 2011. The success rates and complication rates were evaluated. NKPP was performed without pancreatic stent placement and the cut was made starting at the papillary orifice, extended upward over a length of more than 5-10 mm for deroofing the papilla. On the other hand, in NKPP-SIPS, a pancreatic stent was placed initially as a guide, and to prevent post-ERCP pancreatitis, the incision was begun at the papillary orifice in a layer-by-layer fashion and extended upward in 1-2 mm increments, not going beyond the oral protrusion, finally measuring less than 5 mm in length. RESULTS: PS was performed in 8.3 % of the patients (134/1619). The cannulation success rate of PS in the entire group was 94.0 % (126/134). NKPP and NKPP-SIPS were performed in 36 and 98 of the patients, respectively. There was one case of major bleeding in group A, and no severe complications in group B. The success rates of bile duct cannulation increased from 86.1 % (31/36) in group A to 96.9 % (95/98) in group B (p = 0.0189). The overall complication rate of PS was YC 33 % (12/36) in group A (major bleeding 8.3 %; mild to moderate pancreatitis 19.4 %; perforation requiring surgery 2.8 %), and 7.1 % (7/98) in group B (mild to moderate pancreatitis 6.1 %; minor perforation 1 %) (p < 0.001). CONCLUSIONS: NKPP-SIPS has significantly improved the success rate and reduced the complication rate of DBC, proving that a small incision starting at the orifice of the PS is sufficient, feasible and safe in DBC, when a pancreatic stent is inserted at the outset.

    DOI: 10.1007/s00534-012-0552-4

    Web of Science

    PubMed

    researchmap

  • Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity 査読

    Liat Izhak, Elena Ambrosino, Shingo Kato, Stanley T. Parish, Jessica J. O'Konek, Hannah Weber, Zheng Xia, David Venzon, Jay A. Berzofsky, Masaki Terabe

    CANCER RESEARCH   73 ( 5 )   1514 - 1523   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    The nature of the regulatory cell types that dominate in any given tumor is not understood at present. Here, we addressed this question for regulatory T cells (Treg) and type II natural killer T (NKT) cells in syngeneic models of colorectal and renal cancer. In mice with both type I and II NKT cells, or in mice with neither type of NKT cell, Treg depletion was sufficient to protect against tumor outgrowth. Surprisingly, in mice lacking only type I NKT cells, Treg blockade was insufficient for protection. Thus, we hypothesized that type II NKT cells may be neutralized by type I NKT cells, leaving Tregs as the primary suppressor, whereas in mice lacking type I NKT cells, unopposed type II NKT cells could suppress tumor immunity even when Tregs were blocked. We confirmed this hypothesis in 3 ways by reconstituting type I NKT cells as well as selectively blocking or activating type II NKT cells with antibody or the agonist sulfatide, respectively. In this manner, we showed that blockade of both type II NKT cells and Tregs is necessary to abrogate suppression of tumor immunity, but a third cell, the type I NKT cell, determines the balance between these regulatory mechanisms. As patients with cancer often have deficient type I NKT cell function, managing this delicate balance among 3 T-cell subsets may be critical for the success of immunotherapy for human cancer. Cancer Res; 73(5); 1514-23. (C) 2012 AACR.

    DOI: 10.1158/0008-5472.CAN-12-2567

    Web of Science

    researchmap

  • Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. 査読 国際誌

    Yuji Ogawa, Kento Imajo, Masato Yoneda, Takaomi Kessoku, Wataru Tomeno, Yoshiyasu Shinohara, Shingo Kato, Hironori Mawatari, Yuichi Nozaki, Koji Fujita, Hiroyuki Kirikoshi, Shin Maeda, Satoru Saito, Koichiro Wada, Atsushi Nakajima

    PloS one   8 ( 6 )   e65211   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AIMS: Liver inflammation is a risk factor for the progression of nonalcoholic fatty liver disease (NAFLD). However, the diagnosis of liver inflammation is very difficult and invasive liver biopsy is still the only method to reliably detect liver inflammation. We previously reported that overexpression of CD14 in Kupffer cells may trigger the progression to nonalcoholic steatohepatitis (NASH) via liver inflammation following hyper-reactivity to low-dose lipopolysaccharide. Therefore, the aim of this study was to investigate the relationship between soluble type of CD14 (sCD14) and histological features in patients with NAFLD. METHODS: Our cohort consisted of 113 patients with liver biopsy-confirmed NAFLD and 21 age-matched healthy controls. Serum sCD14 levels were measured by an enzyme-linked immunosorbent assay. RESULTS: Serum sCD14 levels were significantly associated with diagnosis of NASH and the area under the receiver operator characteristic curve (AUROC) to distinguish between not NASH and NASH was 0.802. Moreover, serum sCD14 levels were significantly associated with the disease activity based on NAFLD activity score and hepatic CD14 mRNA expression, which is correlated with membrane CD14 (mCD14) expression, in patients with NAFLD. In multiple regression analysis, the serum sCD14 levels were independently associated with liver inflammation. The AUROC to distinguish between mild and severe liver inflammation in patients with NAFLD was 0.752. CONCLUSIONS: We found that serum sCD14 levels increased significantly with increasing liver inflammation grade in patients with NAFLD, reflecting increased hepatic CD14 expression. Serum sCD14 is a promising tool to predict the worsening of liver inflammation, and may offer a potential biomarker for evaluation of therapeutic effects in NAFLD.

    DOI: 10.1371/journal.pone.0065211

    PubMed

    researchmap

  • A novel scoring system for arterial invasion of pancreatic body and tail cancer based on multidetector row computed tomography and biomarkers 査読

    Seitaro Watanabe, Noritoshi Kobayashi, Kensuke Kubota, Takamitsu Sato, Shingo Kato, Kunihiro Hosono, Takeshi Shimamura, Yoshiaki Inayama, Atsushi Nakajima, Itaru Endo

    Pancreatology   13 ( 2 )   161 - 169   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:Elsevier B.V.  

    Background/objectives: The absence of major-vessel involvement is a crucial factor in the resectability and prognosis of pancreatic cancer. However, arterial invasion cannot be evaluated adequately using imaging findings alone. We therefore developed a scoring system to assess arterial invasion by pancreatic adenocarcinoma using multidetector row computed tomography (MDCT) and serum tumor markers. Methods: Twenty patients who underwent distal pancreatectomy and splenectomy for pancreatic adenocarcinoma were examined retrospectively using 4-, 16- or 64-row MDCT and serum tumor markers. Splenic arterial invasion was evaluated in terms of length of tumor contact, circumferential involvement (&lt
    180° or ≥180°) and deformity of vascular diameter. Preoperative expression of carbohydrate antigen 19-9 (CA19-9), DUPAN-2 and S-Pancreas-1 antigen (SPan-1) were also evaluated. The presence or absence of arterial invasion was confirmed histopathologically in all 20 cases. Results: In 11 of 20 cases invasion into splenic arteries was observed histopathologically, mostly involving the external elastic lamina and periarterial nerves. Sensitivity, specificity and accuracy were 100%, 88.9% and 95%, respectively, for length of tumor contact (&lt
    16 mm or ≥16 mm), 90.9%, 77.8% and 85% for circumferential involvement (&lt
    180° or ≥180°), and 100%, 66.7% and 85% for deformity of vascular diameter. Furthermore, the sensitivity, specificity and accuracy were all increased to 100% when tumor markers were included in the score. Conclusions: MDCT is a useful technique for diagnosing arterial invasion of pancreatic body and tail cancer, even in comparison with pathological examination
    however, this new scoring system can be further complemented and made more reliable by measurements of serous tumor markers. Copyright © 2012, IAP and EPC.

    DOI: 10.1016/j.pan.2012.12.364

    Scopus

    PubMed

    researchmap

  • Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer 査読

    Yukihiko Hiroshima, Fumio Nakamura, Hiroshi Miyamoto, Ryutaro Mori, Koichi Taniguchi, Ryusei Matsuyama, Hirotoshi Akiyama, Kuniya Tanaka, Yasushi Ichikawa, Shingo Kato, Noritoshi Kobayashi, Kensuke Kubota, Yoji Nagashima, Yoshio Goshima, Itaru Endo

    Annals of Surgical Oncology   20 ( 3 )   S369 - S378   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background. Pancreatic cancer is an aggressive malignancy with one of the worst mortality rates of all cancers. Recently, collapsin response mediator proteins (CRMPs) were reported to be associated with proliferation, apoptosis, differentiation, and invasion in several cancers. However, CRMP expression and their role in pancreatic cancer have not been investigated. This study aimed to clarify the clinical significance of CRMPs in pancreatic cancer. Methods. Expression of crmp genes in 11 pairs of pancreatic cancer and corresponding noncancerous pancreas tissues were examined by real-time RT-PCR. Knockdown of CRMP4 expression using siRNA was examined in pancreatic cancer cell lines to determine whether CRMP4 regulates cell proliferation and invasion in vitro. Furthermore, CRMP4 protein levels in primary tumors of pancreatic cancer (n = 53) were examined by immunohistochemistry and compared with the clinicopathological features of the tumors. Results. Of all the CRMPs, only CRMP4 was differentially expressed in pancreatic cancer tissues (p = 0.008). CRMP4 knockdown using siRNA reduced cellular invasion, but did not affect proliferation. The expression of CRMP4 was detected immunohistochemically in 34 (64.2 %) of the 53 pancreatic cancer samples, and CRMP4 expression was correlated with severe venous invasion (p = 0.044), stage (p = 0.019), and liver metastasis (p = 0.021). Multivariate analyses suggested that venous invasion and CRMP4 overexpression were prognostic factors for survival. Conclusions. Our results suggested that CRMP4 is significantly associated with poor prognosis by promoting liver metastasis and can serve as a novel therapeutic target for pancreatic cancer. © Society of Surgical Oncology 2012.

    DOI: 10.1245/s10434-012-2491-3

    Web of Science

    Scopus

    PubMed

    researchmap

  • Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence 査読

    Takashi Uchiyama, Hirokazu Takahashi, Hiroki Endo, Shingo Kato, Eiji Sakai, Kunihiro Hosono, Masato Yoneda, Masahiko Inamori, Yoshitaka Hippo, Hitoshi Nakagama, Atsushi Nakajima

    DIGESTIVE ENDOSCOPY   24 ( 5 )   353 - 357   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Aim: Endoscopic screening and removal of colorectal adenomas can reduce the incidence of colorectal cancer. However, given the possibility of adenoma recurrence, surveillance colonoscopy is currently recommended after the initial screening and removal of colorectal adenomas. Aberrant crypt foci (ACF) have been shown to serve as a reliable surrogate marker of colorectal carcinogenesis. In this study, the relationship between the number of ACF at the initial endoscopic polypectomy and the likelihood of colorectal adenoma recurrence after polypectomy were investigated. Methods: High-magnification chromoscopic colonoscopy was performed in 82 subjects who underwent endoscopic polypectomy to identify ACF in the lower rectum. Surveillance colonoscopy was then performed 3 years after the baseline polypectomy at Yokohama City University Hospital. Results: The number of ACF was greater in patients who showed adenoma recurrence (7.88 +/- 6.35) than in those who did not (2.19 +/- 2.95) (P &lt; 0.001). Receiveroperating curve analysis showed that the number of ACF was a highly specific predictor of the risk of adenoma recurrence. Conclusions: This is the first study conducted to investigate the relationship between the number of ACF after endoscopic polypectomy and the likelihood of recurrence of colorectal adenomas. These results suggest that the number of ACF is a useful predictor of the likelihood of colorectal adenoma recurrence.

    DOI: 10.1111/j.1443-1661.2012.01289.x

    Web of Science

    PubMed

    researchmap

  • Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling 査読

    Kento Imajo, Koji Fujita, Masato Yoneda, Yuichi Nozaki, Yuji Ogawa, Yoshiyasu Shinohara, Shingo Kato, Hironori Mawatari, Wataru Shibata, Hiroshi Kitani, Kenichi Ikejima, Hiroyuki Kirikoshi, Noriko Nakajima, Satoru Saito, Shiro Maeyama, Sumio Watanabe, Koichiro Wada, Atsushi Nakajima

    CELL METABOLISM   16 ( 1 )   44 - 54   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CELL PRESS  

    Although bacterial endotoxin, such as lipopolysaccharide (LPS), plays a key role in the pathogenesis of nonalcoholic steatohepatitis (NASH), detailed mechanisms of this pathogenesis remain unclear. Here, we demonstrate that upregulation of CD14 by leptin-mediated signaling is critical to hyperreactivity against endotoxin during NASH progression. Upregulation of CD14 in Kupffer cells and hyperreactivity against low-dose LPS were observed in high-fat diet (HFD)-induced steatosis mice, but not chow-fed-control mice. Hyperresponsivity against low-dose LPS led to accelerated NASH progression, including liver inflammation and fibrosis. Administering leptin in chow-fed mice caused increased hepatic expression of CD14 via STAT3 signaling, resulting in hyperreactivity against low-dose LPS without steatosis. In contrast, a marked decrease in hepatic CD14 expression was observed in leptin-deficient ob/ob mice, despite severe steatosis. Our results indicate that obesity-induced leptin plays a crucial role in NASH progression via enhanced responsivity to endotoxin, and we propose a mechanism of bacteria-mediated progression of NASH.

    DOI: 10.1016/j.cmet.2012.05.012

    Web of Science

    PubMed

    researchmap

  • Capsule endoscopy with flexible spectral imaging color enhancement reduces the bile pigment effect and improves the detectability of small bowel lesions 査読

    Eiji Sakai, Hiroki Endo, Shingo Kato, Tetsuya Matsuura, Wataru Tomeno, Leo Taniguchi, Takashi Uchiyama, Yasuo Hata, Eiji Yamada, Hidenori Ohkubo, Takuma Higrashi, Kunihiro Hosono, Hirokazu Takahashi, Atsushi Nakajima

    BMC GASTROENTEROLOGY   12   83   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Capsule endoscopy with flexible spectral imaging color enhancement (CE-FICE) has been reported to improve the visualization and detection of small-bowel lesions, however, its clinical usefulness is still not established. Therefore, we conducted a study to evaluate whether CE-FICE contributes to improve the detectability of small-bowel lesions by CE trainees.
    Methods: Four gastroenterology trainees without prior CE experience were asked to read and interpret 12 CE videos. Each of the videos was read by conventional visualization method and under three different FICE settings. To evaluate whether the lesion recognition ability of the CE trainees could be improved by the FICE technology, the lesion detection rate under each of the three FICE settings was compared with that by conventional CE. CE trainees tend to miss small-bowel lesions in bile-pigment-positive condition, therefore we evaluated whether CE-FICE contributes to reducing the bile-pigment effect. The bile-pigment condition was determined by the color values around the small-bowel lesions according to the results of the receiver-operating-characteristic analysis. Moreover, we also evaluated whether poor bowel preparion might affect the accuracy of lesion recognition by CE-FICE.
    Results: Of a total of 60 angioectasias, CE trainees identified 26 by conventional CE, 40 under FICE setting 1, 38 under FICE setting 2, and 31 under FICE setting 3. Of a total of 82 erosions/ulcerations, CE trainees identified 38 by conventional CE, 62 under FICE setting 1, 60 under FICE setting 2, and 20 under FICE setting 3. Compared with conventional CE, FICE settings 1 and 2 significantly improved the detectability of angioectasia (P = 0.0017 and P = 0.014, respectively) and erosions/ulcerations (P = 0.0012 and P = 0.0094, respectively). Although the detectability of small-bowel lesions by conventional CE (P = 0.020) and under FICE setting 2 (P = 0.0023) was reduced by the presence of bile-pigments, that under FICE setting 1 was not affected (P = 0.59). Our results also revealed that in poor bowel visibility conditions, CE-FICE yielded a high rate of false-positive findings.
    Conclusions: CE-FICE may reduce the bile-pigment effect and improve the detectability of small-bowel lesions by CE trainees; the reliability of CE-FICE may be improved by good bowel preparation.

    DOI: 10.1186/1471-230X-12-83

    Web of Science

    PubMed

    researchmap

  • Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? 査読

    Hiroyuki Kirikoshi, Masato Yoneda, Hironori Mawatari, Koji Fujita, Kento Imajo, Shingo Kato, Kaori Suzuki, Noritoshi Kobayashi, Kensuke Kubota, Shin Maeda, Atsushi Nakajima, Satoru Saito

    WORLD JOURNAL OF GASTROENTEROLOGY   18 ( 16 )   1933 - 1939   2012年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBL GRP CO LTD  

    AIM: To evaluate the effectiveness of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) resistant to transarterial chemoembolization (TACE).
    METHODS: This study was conducted on 42 patients who received HAIC for advanced HCC between 2001 and 2010 at our hospital. 5-fluorouracil (5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir. Intra-arterial cisplatin or subcutaneous interferon was administered in combination with the 5-FU. The patients enrolled in this retrospective study were divided into two groups according to whether or not they fulfilled the criteria for resistance to TACE proposed by the Japan Society of Hepatology in 2010 (written in Japanese); one group of patients who did not fulfill the criteria for TACE resistance (group A, n = 23), and another group who fulfilled the criteria for TACE resistance (group B, n = 19). We compared the outcomes in terms of the response and survival rates between the two groups.
    RESULTS: Both the response rate and tumor suppression rate following HAIC were significantly superior in group A than in group B (response rate: 48% vs 16%, P = 0.028, tumor suppression rate: 87% vs 53%, P = 0.014). Furthermore, both the progression-free survival rate and survival time were significantly superior in group A than in group B (3-, 6-, 12-, and 24-mo = 83%, 70%, 29% and 20% vs 63%, 42%, 16% and 0%, respectively, P = 0.040, and 9.8 nno vs 6.2 mo, P = 0.040). A multivariate analysis (Cox proportional hazards regression model) showed that resistance to TACE was an independent predictor of poor survival (P = 0.007).
    CONCLUSION: HAIC administrating 5-FU was not effective against advanced HCC resistant to TACE. Other tools for treatment, i.e., molecular-targeting agents may be considered for these cases. (C) 2012 Baishideng. All rights reserved.

    DOI: 10.3748/wjg.v18.i16.1933

    Web of Science

    PubMed

    researchmap

  • Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas 査読

    Noritoshi Kobayashi, Kazuya Sugimori, Takeshi Shimamura, Kunihiro Hosono, Seitaro Watanabe, Shingo Kato, Michio Ueda, Itaru Endo, Yoshiaki Inayama, Shin Maeda, Atsushi Nakajima, Kensuke Kubota

    PANCREATOLOGY   12 ( 2 )   141 - 145   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Background: The preoperative diagnosis of branch duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas can be very difficult, since low-risk and high-risk lesions can be difficult to differentiate even after cytological analysis. The purpose of this study was to evaluate the preoperative diagnostic value of endoscopic ultrasonography (EUS) in differentiating low-risk and high-risk IPMNs.
    Methods: We retrospectively identified 36 patients who underwent preoperative EUS for branch duct IPMNs. The pathological diagnosis after surgical resection was low-grade dysplasia (n = 26), moderate dysplasia = 1), high-grade dysplasia or carcinoma in situ (n = 5), and invasive carcinoma (n = 4). We divided the patients into two groups: low risk (low-grade dysplasia or moderate dysplasia) and high risk (high-grade dysplasia or carcinoma). We focused on the diameter of the cystic dilated branch duct, the main pancreatic duct, and the mural nodule as measured using the EUS findings.
    Results: The cystic dilated branch duct diameter (31.5 mm vs. 41.9 mm, P = 0.0225) was significantly correlated with low-risk and high-risk IPMNs, but the main pancreatic duct diameter (5.37 mm vs. 5.44 mm, P = 0.9418) was not significantly correlated with the low-risk and high-risk IPMNs. The mural nodule diameter of the papillary protrusions (4.3 mm vs. 16.4 mm, P &lt; 0.0001) and the width diameter of the mural nodule (5.7 mm vs. 23.2 mm, P &lt; 0.0001) were significantly correlated with low-risk and high-risk IPMNs.
    Conclusions: The mural nodule of papillary protrusions diameter and width diameter observed using EUS was a reliable preoperative diagnostic finding capable of distinguishing low-risk and high-risk IPMNs. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.

    DOI: 10.1016/j.pan.2011.12.008

    Web of Science

    PubMed

    researchmap

  • Early effects of oral administration of omeprazole and roxatidine on intragastric pH 査読

    Hiroshi Iida, Shingo Kato, Yusuke Sekino, Eiji Sakai, Takashi Uchiyama, Hiroki Endo, Kunihiro Hosono, Yasunari Sakamoto, Koji Fujita, Masato Yoneda, Tomoko Koide, Hirokazu Takahashi, Chikako Tokoro, Ayumu Goto, Yasunobu Abe, Noritoshi Kobayashi, Kensuke Kubota, Eiji Gotoh, Shin Maeda, Atsushi Nakajima, Masahiko Inamori

    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B   13 ( 1 )   29 - 34   2012年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ZHEJIANG UNIV  

    Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress-related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H-2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacterpylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral administration of omeprazole 20 mg and roxatidine 75 mg. Each administration was separated by a 7-d washout period. Results: During the 6-h study period, the average pH after administration of roxatidine was higher than that after administration of omeprazole (median: 4.45 vs. 2.65; P=0.0367). Also during the 6-h study period, a longer duration of maintenance at pH above 2, 5, and 6 was observed after administration of roxatidine 75 mg than after administration of omeprazole 20 mg (median: 90.6% vs. 55.2%, P=0.0284; 43.7% vs. 10.6%, P=0.0125; 40.3% vs. 3.3%, P=0.0125; respectively). Conclusions: In Helicobacter pylori-negative healthy male subjects, oral administration of roxatidine 75 mg increased the intragastric pH more rapidly than that of omeprazole 20 mg.

    DOI: 10.1631/jzus.B1100078

    Web of Science

    PubMed

    researchmap

  • Imaging Findings of Pancreatic Cystic Lesions in von Hippel-Lindau Disease 査読

    Noritoshi Kobayashi, Takamitsu Sato, Shingo Kato, Seitaro Watanabe, Kunihiro Hosono, Takeshi Shimamura, Hiroshi Iida, Hiroki Endo, Tomoko Koide, Hirokazu Takahashi, Masato Yoneda, Wataru Shibata, Yasunobu Abe, Masahiko Inamori, Hiroyuki Kirikoshi, Satoru Saito, Shin Maeda, Atsushi Nakajima, Kensuke Kubota

    INTERNAL MEDICINE   51 ( 11 )   1301 - 1307   2012年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    Objectives The aim of this study was to characterize the pancreatic cystic lesions in von Hippel-Lindau (VHL) disease and to document the changes that occur in the pancreas.
    Methods We retrospectively analyzed the medical records and the computed tomography (CT) and magnetic resonance imaging (MRI) findings of 20 VHL patients who were diagnosed between 1996 and 2010 at our hospital. The clinical findings, family history and type of tumors and/or cysts were reviewed for each patient. We also analyzed the imaging findings for the pancreas in detail.
    Results Pancreatic involvement was noted in 16 of the 20 patients (80%). Eleven patients had multiple cysts diffusely distributed in the pancreas, and one patient had a single cyst in the pancreas head. Two patients had serous cystic neoplasms (SCNs) with multiple cysts, and another two patients had neuroendocrine tumors (NETs) which were conventional radiological findings. The largest cysts of four patients (26.7%) increased in size and that of three patients (20%) decreased in size during the follow-up period. We performed surgical resections for the pancreatic tumors (one NET and one SCN) and also performed endoscopic treatment for a pancreatic cyst in one VHL patient with obstructive jaundice. None of the patients died as a result of pancreatic disease.
    Conclusion The most common type of pancreatic lesions was multiple cysts. SCNs were present in only 10% of the VHL patients. Pancreatic cysts showed positive and/or negative growth according to the CT and MRI findings. The pancreatic cystic lesions did not influence the outcome of the VHL patients.

    DOI: 10.2169/internalmedicine.51.7194

    Web of Science

    PubMed

    researchmap

  • Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer 査読

    Shingo Kato, Kensuke Kubota, Takeshi Shimamura, Yoshiyasu Shinohara, Noritoshi Kobayashi, Seitaro Watanabe, Masato Yoneda, Masahiko Inamori, Fumio Nakamura, Hitoshi Ishiguro, Noboru Nakaigawa, Yoji Nagashima, Masataka Taguri, Yoshinobu Kubota, Yoshio Goshima, Satoshi Morita, Itaru Endo, Shin Maeda, Atsushi Nakajima, Hitoshi Nakagama

    CANCER SCIENCE   102 ( 11 )   2029 - 2037   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor, for which the development of new biomarkers and therapeutic targets has become critical. The main cause of poor prognosis in PDAC patients is the high invasive and metastatic potential of the cancer. In the present study, we report a new signaling pathway that was found to mediate the enhanced tumor cell motility in pancreatic cancer. Semaphorin 4D (Sema4D) is a ligand known to be expressed on different cell types, and has been reported to be involved in the regulation of immune functions, epithelial morphogenesis, and tumor growth and metastasis. In this study, we revealed for the first time that the cancer tissue cells expressing Sema4D in PDAC are tumor-infiltrating lymphocytes. The overexpression of Sema4D and of its receptor, plexinB1, was found to be significantly correlated with clinical factors, such as lymph node metastasis, distant metastasis, and poor prognosis in patients with PDAC. Through in vitro analysis, we demonstrated that Sema4D can potentiate the invasiveness of pancreatic cancer cells and we identified the downstream molecules. The binding of Sema4D to plexinB1 induced small GTPase Ras homolog gene family, member A activation and resulted in the phosphorylation of MAPK and Akt. In addition, in terms of potential therapeutic application, we clearly demonstrated that the enhanced-cell invasiveness induced by Sema4D could be inhibited by knockdown of plexinB1, suggesting that blockade of plexinB1 might diminish the invasive potential of pancreatic cancer cells. Our findings provide new insight into possible prognostic biomarkers and therapeutic targets in PDAC patients. (Cancer Sci 2011; 102: 2029-2037)

    DOI: 10.1111/j.1349-7006.2011.02053.x

    Web of Science

    PubMed

    researchmap

  • Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm 査読

    Eiji Sakai, Hirokazu Takahashi, Shingo Kato, Takashi Uchiyama, Kunihiro Hosono, Hiroki Endo, Shin Maeda, Masato Yoneda, Masataka Taguri, Atsushi Nakajima

    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION   20 ( 9 )   1918 - 1924   2011年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Background: Aberrant crypt foci (ACF) are considered to be useful as surrogate biomarker for colorectal cancer (CRC), but the biological significance of ACF remains controversial. We attempted to investigate the relationship between the presence of ACF and human colorectal carcinogenesis using a relatively large sample size.
    Methods: We carried out high-magnification chromoscopic colonoscopy to identify ACFs in 861 subjects undergoing a diagnostic endoscopy at the Yokohama City University Hospital. The present study compared the prevalence and number of ACFs in three subject groups (normal subjects, adenoma cases, and CRC cases). The correlations between the demographic and behavioral characteristics of the subjects and the prevalence of ACFs were also assessed.
    Results: The prevalence of ACF was 64%, 88%, and 95%, and the mean number of ACF was 3.6, 6.2, and 10.1, in normal subjects, adenoma cases, and CRC cases, respectively. When differences in the prevalence and number of ACFs among age- and sex-stratified subject groups were examined, significant stepwise increments from normal subjects to adenoma cases to CRC cases were apparent (P &lt; 0.001). Moreover, an age-and sex-adjusted multiple logistic regression analysis revealed that smoking and alcohol habits had a synergistic effect, increasing the prevalence of ACFs as well as the risk of CRC (P &lt; 0.001).
    Conclusions: These results suggested that ACF may serve as a reliable surrogate biomarker for human colorectal carcinogenesis.
    Impact: The use of ACF as an endpoint may enable the size, duration, and cost of CRC chemoprevention studies to be reduced. Cancer Epidemiol Biomarkers Prev; 20(9); 1918-24. (C)2011 AACR.

    DOI: 10.1158/1055-9965.EPI-11-0104

    Web of Science

    PubMed

    researchmap

  • Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids 査読

    Kensuke Kubota, Seitaro Watanabe, Takashi Uchiyama, Shingo Kato, Yusuke Sekino, Kaori Suzuki, Hironori Mawatari, Hiroshi Iida, Hiroki Endo, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Kazuya Sugimori, Kantaro Hisatomi, Nobuyuki Matsuhashi, Hirotaka Sato, Emiko Tanida, Takashi Sakaguchi, Nobutaka Fujisawa, Atsushi Nakajima

    JOURNAL OF GASTROENTEROLOGY   46 ( 6 )   834 - 842   2011年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Background Relapse and spontaneous remission (SR) are characteristic features of autoimmune pancreatitis (AIP).
    Aim and methods We conducted a study to determine if the predictive factors might be potentially related to the relapse in 70 consecutive AIP patients. Regarding SR, we studied the data of patients without corticosteroid treatment (CST).
    Results CST was administered to 60% (42/70) of the patients; however, relapse was noted in 45.2% (19/42) of these patients. In 95% (18/19) of the AIP patients developing relapse, the relapse occurred within 3 years. The relapse rate was 80% (12/15) in the AIP patients administered CST for less than 12 months and 25.9% (7/27) in those administered CST for over 12 months (p &lt; 0.01). The results of univariate analysis revealed significant association of relapse with the presence of jaundice, IgG4 seropositivity, presence of diffuse pancreas swelling, duodenal papillitis (DP), history of initial CST, and history of supportive treatment (p &lt; 0.05), whereas multivariate analysis revealed that IgG4 seropositivity (OR 10.506, p = 0.0422) and the presence of jaundice (OR 6.945, p = 0.0174) are significant independent factors predictive of relapse in AIP patients. SR was recognized in 65.0% (13/20) of AIP patients without CST. The results of univariate analysis revealed that SR was associated with IgG4 seropositivity (p &lt; 0.05), and multivariate analysis identified IgG4 seropositivity (OR 0.032, p = 0.0092) as a significant independent factor predictive of SR in these cases.
    Conclusion AIP patients with IgG4 seropositivity and jaundice are at a higher risk of relapse and they could therefore be candidates for over 3 years of maintenance CST. AIP patients with IgG4 seronegativity have a high likelihood of SR.

    DOI: 10.1007/s00535-011-0393-y

    Web of Science

    PubMed

    researchmap

  • Usefulness of endoscopic biopsy using FOXP3(+) Treg up-regulation in the duodenal papilla in the differential diagnosis between autoimmune pancreatitis and pancreatic cancer 査読

    Kensuke Kubota, Shingo Kato, Seitaro Watanabe, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Masahiko Inamori, Takeshi Shimamura, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Kantaro Hisatomi, Nobuyuki Matsuhashi, Atsushi Nakajima

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   18 ( 3 )   414 - 421   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Expression of the forkhead/winged helix family of transcription factor P3+ regulatory T cells (FOXP3(+) Treg), a master gene of regulatory T cells (Treg) is observed in patients with autoimmune pancreatitis (AIP). We investigated the usefulness of detection of FOXP3(+) Treg in the main duodenal papilla for differential diagnosis between AIP and pancreatic cancer (Pca).
    Firstly, we determined the cut-off value of FOXP3 expression in duodenal papilla taken from the patients with AIP (n = 22) and chronic pancreatitis (n = 21). Data from 32 patients with AIP and 30 patients with Pca who had undergone endoscopic biopsy were then studied. The numbers of FOXP3(+) Treg-positive lymphocytes and IgG4-positive plasma cells per high-power field (HPF) were counted in all the histopathological specimens.
    The areas under the receiver-operating characteristic (AUROC) curves for FOXP3(+) and IgG4 expression were 0.934 and 0.953, respectively. Cut-off values calculated based on AUROC data were 14/HPF in FOXP3 and 10/HPF in IgG4. Seropositivity for IgG4 was observed in 22 out of the 31 patients with AIP (sensitivity 71.0%, specificity 84.6%, accuracy 75.0%). Significant infiltration of the major duodenal papilla by FOXP3(+) lymphocytes (a parts per thousand yen14/HPF) was recognized in 18 of the 32 patients with AIP (sensitivity 56.3%, specificity 100%, accuracy 77.4%). Significant infiltration of the major duodenal papilla by IgG4-positive plasma cells (a parts per thousand yen10/HPF) was recognized in 27 of the 32 patients with AIP (sensitivity 84.4%, specificity 80.0%, accuracy 82.3%).
    Observation of FOXP3(+) cells in the main duodenal papilla may be useful in the differential diagnosis between AIP and Pca.

    DOI: 10.1007/s00534-010-0359-0

    Web of Science

    PubMed

    researchmap

  • Change of Gastric Emptying With Chewing Gum: Evaluation Using a Continuous Real-Time C-13 Breath Test (BreathID System) 査読

    Yasunari Sakamoto, Shingo Kato, Yusuke Sekino, Eiji Sakai, Takashi Uchiyama, Hiroshi Iida, Kunihiro Hosono, Hiroki Endo, Koji Fujita, Tomoko Koide, Hirokazu Takahashi, Masato Yoneda, Chikako Tokoro, Ayumu Goto, Yasunobu Abe, Noritoshi Kobayashi, Kensuke Kubota, Shin Maeda, Atsushi Nakajima, Masahiko Inamori

    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY   17 ( 2 )   174 - 179   2011年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KOREAN SOC NEUROGASTERONTEROL & MOTILITY  

    Background/Aims
    There are few reports on the correlation between chewing gum and the gastrointestinal functions. But previous report showed use of chewing gum to be an effective method for controlling gastrointestinal symptoms. The aim of this study was to determine the correlation between chewing gum and gastric emptying using the continuous real time C-13 breath test (BreathID system).
    Methods
    Ten healthy male volunteers participated in this randomized, 2-way crossover study. The subjects fasted overnight and were randomly assigned to chewing gum (Xylish, 2-3/1 tablet) for an hour following intake of a test meal (200 kcal/200 mL) or intake of the test meal alone. Gastric emptying was monitored for 4 hours after administration of the test meal by the C-13-acetic acid breath test performed continually using the BreathID system.
    Results
    No significant differences in the calculated parameters, namely, T-1/2 (median, 111.82 vs 109.26 minutes; P = 0.575), T-lag (median, 53.28 vs 56.53 minutes; P = 0.333), gastric emptying coefficient (median, 3.58 vs 3.65; P = 0.285), regression-estimated constant beta (median, 1.85 vs 1.80; P = 0.575) and regression-estimated constant kappa (median, 0.61 vs 0.62; P = 0.959) were observed between the test meal alone group and the test meal and chewing gum group.
    Conclusions
    This study showed that chewing gum had no effect on the rate of gastric emptying. Therefore, since chewing gum did not enhance the speed of gastric emptying, it may ameliorate gastrointestinal symptoms through other mechanisms, such as saliva and autonomic nervous system.

    DOI: 10.5056/jnm.2011.17.2.174

    Web of Science

    PubMed

    researchmap

  • Complications of the treatment of endoscopic biliary strictures developing after liver transplantation 査読

    Noritoshi Kobayashi, Kensuke Kubota, Takeshi Shimamura, Seitaro Watanabe, Shingo Kato, Kaori Suzuki, Takashi Uchiyama, Shin Maeda, Kazuhisa Takeda, Atsushi Nakajima, Itaru Endo

    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES   18 ( 2 )   202 - 210   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Bile duct strictures remain a major source of morbidity after orthotopic liver transplantation (OLT). Endoscopic management by the conventional methods of biliary dilatation and/or stent placement has been successful, but sometimes severe complications occur, necessitating prolonged therapy. The aim of this study is to clarify the complications of the endoscopic approach for endoscopic dilatation and/or stent placement.
    Of 46 patients who underwent living-donor liver transplantation, 10 were diagnosed as having anatomic biliary strictures by endoscopic retrograde cholangiopancreatography (ERCP). Two patients developing biliary strictures after deceased-donor liver transplantation were also enrolled in the study. For the purpose of comparison, 302 patients with a total of 550 consecutive ERCP cases (including 115 patients with 250 malignant bile duct strictures) were recruited in this study. Success rate, number of endoscopy sessions, the median procedure time for ERCP, and incidence of complications including post-ERCP pancreatitis were compared in the OLT cases and other cases.
    The following results were obtained in the OLT cases, malignant stricture cases, and all cases, respectively: mean number of endoscopy sessions was 3.62, 2.17, and 1.94 (P = 0.0216, P &lt; 0.0001); post-ERCP pancreatitis occurred in 5 (12.5%), 10 (4.0%), and 19 cases (3.5%) (P = 0.0327, P = 0.0093); and severe pancreatitis occurred in 2 cases of OLT. In a univariate analysis for post-ERCP pancreatitis, OLT was extracted as the only significant risk factor.
    Endoscopic maneuvering for biliary dilatation and/or stent placement following OLT was associated with a higher risk of post-ERCP pancreatitis than the use of the same technique for the treatment of malignant biliary stricture. Endoscopic treatment after OLT was a significant risk factor for post-ERCP pancreatitis.

    DOI: 10.1007/s00534-010-0330-0

    Web of Science

    PubMed

    researchmap

  • Effects of Domperidone on Gastric Emptying: A Crossover Study Using a Continuous Real-Time C-13 Breath Test (BreathID System) 査読

    Yasunari Sahamoto, Shingo Kato, Yusuke Sehino, Eiji Sakai, Takashi Uchiyama, Hiroshi Iida, Kunihiro Hosono, Hiroki Endo, Koji Fujita, Tomoho Koide, Hirokazu Takahashi, Masato Yoneda, Chikako Tokoro, Ayumu Goto, Yasunobu Abe, Noritoshi Kobayashi, Kensuhe Kubota, Shin Maeda, Atsushi Nakajima, Masahiko Inamori

    HEPATO-GASTROENTEROLOGY   58 ( 106 )   637 - 641   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: To determine the correlation between domperidone and gastric emptying using the continuous real time C-13 breath-test (BreathID system), a novel non-invasive technique for measuring gastric emptying.
    Methodology: Six healthy male volunteers participated in this randomized, two-way crossover study. Subjects fasted overnight and were randomly assigned to receive a test meal (400kcal per 400mL) 30 minutes after intake of domperidone (10mg) with 50mL of water or intake of 50mL of water alone. Gastric emptying was monitored for 4h after administration of the test meal by C-13-acetic acid breath test continually performed using the BreathID system. The time taken for emptying of 50% of the labeled meals (T1/2), the analog to the scintigraphy lag time for 10% emptying of the labeled meal (T lag), the gastric emptying coefficient (GEC), and the regression-estimated constants (6 and K) were calculated. Differences in the parameters measured at two time-points were analyzed using the Wilcoxon&apos;s signed-rank test.
    Results: No significant differences in calculated parameters (T lag, T1/2, GEC, beta or kappa) were observed between the treated and non-treated groups.
    Conclusions: This study showed that domperidone had no effect on gastric emptying. The drug ameliorates nausea and vomiting via its antagonic activity against dopamine receptor. Therefore, domperidone probably ameliorates nausea through other mechanisms.

    Web of Science

    PubMed

    researchmap

  • DISCRIMINATION BETWEEN SCLEROSING CHOLANGITIS-ASSOCIATED AUTOIMMUNE PANCREATITIS AND PRIMARY SCLEROSING CHOLANGITIS, CANCER USING INTRADUCTAL ULTRASONOGRAPHY 査読

    Kensuke Kubota, Shingo Kato, Takashi Uchiyama, Seitaro Watanabe, Yuich Nozaki, Koji Fujita, Masato Yoneda, Masahiko Inamori, Takeshi Shimamura, Yasunobu Abe, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima

    DIGESTIVE ENDOSCOPY   23 ( 1 )   10 - 16   2011年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL PUBLISHING, INC  

    Background and Aim:
    Differentiation of sclerosing cholangitis-associated autoimmune pancreatitis (SC-AIP), primary sclerosing cholangitis (PSC) and cancer of the hilar part of the bile duct (CHB) has been challenging. The aim of the present study was to evaluate characteristic intraductal ultrasonography (IDUS) features that could be used to discriminate SC-AIP from PSC and CHB.
    Methods:
    Six patients with SC-AIP, 10 patients with PSC and 12 patients with CHB were identified. We reviewed the following bile duct features observed using IDUS to determine their usefulness for differentiating SC-AIP from PSC and CHB: presence of symmetrical wall thickness, wall thickness, presence of homogeneous internal foci and presence of lateral mucosal lesions continuous to the hilar.
    Results:
    IDUS results (SC-AIP, PSC, CHB) were as follows: wall thickness (mm), 3.7 +/- 0.9, 2.6 +/- 0.9, 2.8 +/- 0.0.6; presence of symmetrical wall thickness, 100% (6/6), 20% (2/10), 8.3% (1/12); presence of homogeneous internal foci, 100% (6/6), 10% (1/10), 8.3% (1/12); and presence of lateral mucosal lesions continuous to the hilar, 83.3% (5/6), 40%(4/10), 25% (3/12). Symmetrical wall thickness of the bile duct, homogeneous internal foci and lateral mucosal lesions continuous to the hilar were detected significantly more often among the patients with SC-PSC than among the patients with PSC or CHB (P &lt; 0.05).
    Conclusions:
    IDUS findings, such as symmetrical wall thickness, presence of homogeneous internal foci and presence of lateral mucosal lesions continuous to the hilar can facilitate the differential diagnosis of SC-AIP from PSC and CHB.

    DOI: 10.1111/j.1443-1661.2010.01039.x

    Web of Science

    PubMed

    researchmap

  • Capsule Endoscopic Evaluation of Eosinophilic Enteritis before and after Treatment 査読

    Hiroki Endo, Kunihiro Hosono, Masahiko Inamori, Shingo Kato, Takashi Uchiyama, Hiroshi Iida, Yasunari Sakamoto, Koji Fujita, Hirokazu Takahashi, Tomoko Koide, Masato Yoneda, Chikako Tokoro, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Kiyotaka Nagahama, Yoshiaki Inayama, Atsushi Nakajima

    DIGESTION   83 ( 1-2 )   134 - 135   2011年

     詳細を見る

    記述言語:英語   出版者・発行元:KARGER  

    DOI: 10.1159/000308654

    Web of Science

    PubMed

    researchmap

  • 下部胆管に skip lesion を有した早期十二指腸乳頭部癌の1例

    加藤 真吾, 渡邉 誠太郎, 遠藤 格, 中山 崇, 稲山 嘉明, 窪田 賢輔

    胆道 = Journal of Japan Biliary Association   24 ( 4 )   617 - 623   2010年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    <b>要旨:</b>十二指腸乳頭部癌は,膵頭部領域癌としては切除率が高く,比較的予後良好な癌である.局所進展形式は,一般に連続した浸潤形式を来し,不連続進展(skip lesion)を認めた報告は認められない.<br> 今回,我々は結節型病変が下部胆管にskipした早期十二指腸乳頭部癌の1例を経験した.画像診断として,腫瘍全体像の描出に超音波内視鏡(Endoscopic ultrasonography;EUS)が有用であったが,前医で胆道処置が施行されており,深達度の診断は腔内超音波検査(Intraductal ultrasonography;IDUS)でも困難であった.<br> 切除標本では,腫瘍間に約1cmの正常粘膜を介し,腫瘍の連続性は認められなかった.2つの腫瘍は組織型,悪性度,p53 indexが一致しており,重複癌ではなく,skip lesionであると診断した.先行した癌は腫瘍のlocation,多寡より,十二指腸乳頭部癌と考えられた.<br>

    DOI: 10.11210/tando.24.617

    CiNii Books

    researchmap

  • Nonalcoholic Fatty Liver Disease: US-based Acoustic Radiation Force Impulse Elastography 査読

    Masato Yoneda, Kaori Suzuki, Shingo Kato, Koji Fujita, Yuichi Nozaki, Kunihiro Hosono, Satoru Saito, Atsushi Nakajima

    RADIOLOGY   256 ( 2 )   640 - 647   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:RADIOLOGICAL SOC NORTH AMERICA  

    Purpose: To investigate the clinical usefulness of ultrasonography-based acoustic radiation force impulse (ARFI) elastography (ie, ARFI sonoelastography) in patients with a diagnosis of nonalcoholic fatty liver disease (NAFLD) and compare ARFI sonoelastography results with transient sonoelastography and serum fibrosis marker test results.
    Materials and Methods: Written informed consent was obtained from all subjects, and the local ethics committee approved the study. Fifty-four patients with a liver biopsy-confirmed diagnosis of NAFLD (mean age, 50.6 years +/- 13.7) were examined. All patients with NAFLD and healthy volunteers underwent ARFI sonoelastography, transient sonoelastography, and serum liver fibrosis marker testing (hyaluronic acids, type IV collagen 7 S domain). Ten healthy volunteers underwent ARFI sonoelastography. ARFI sonoelastography results were compared with liver biopsy findings, the reference standard. ARFI sonoelastography findings were compared with liver biopsy, transient sonoelastography, and serum fibrosis marker test results. Student t testing was used for univariate comparisons; Kruskal-Wallis testing, for assessments involving more than two independent groups; and areas under the receiver operating characteristic curve (A(z)), to assess the sensitivity and specificity of ARFI sonoelastography for detection of stage 3 and stage 4 fibrosis.
    Results: Median velocities in the patients with NAFLD were 1.040 m/sec for those with stage 0 fibrosis, 1.120 m/sec for those with stage 1, 1.130 m/sec for those with stage 2, 1.780 m/sec for those with stage 3, and 2.180 m/sec for those with stage 4. The A(z) for the diagnosis of hepatic fibrosis stages 3 or higher was 0.973 (optimal cutoff value, 1.77 m/sec; sensitivity, 100%; specificity, 91%), while that for the diagnosis of stage 4 fibrosis was 0.976 (optimal cutoff value, 1.90 m/sec; sensitivity, 100%; specificity, 96%). Significant correlations between median velocity measured by using ARFI sonoelastography and the following parameters were observed: liver stiffness measured with transient sonoelastography (r = 0.75, P &lt; .0001), serum level of hyaluronic acid (r = 0.459, P = .0009), and serum level of type IV collagen 7 S domain (r = 0.445, P = .0015).
    Conclusion: There is a significant positive correlation between median velocity measured by using ARFI sonoelastography and severity of liver fibrosis in patients with NAFLD. The results of ARFI sonoelastography were similar to those of transient sonoelastography. (C) RSNA, 2010

    DOI: 10.1148/radiol.10091662

    Web of Science

    PubMed

    researchmap

  • RISKY ENDOSCOPIC ULTRASONOGRAPHY-GUIDED FINE-NEEDLE ASPIRATION FOR ASYMPTOMATIC RETROPERITONEAL TUMORS 査読

    Kensuke Kubota, Shingo Kato, Hironori Mawatari, Hiroshi Iida, Tomoyuki Akiyama, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Masahiko Inamori, Yasunobu Abe, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima

    DIGESTIVE ENDOSCOPY   22 ( 2 )   144 - 146   2010年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL PUBLISHING, INC  

    Paraganglioma, a sporadically occurring rare tumor should be included in the differential diagnosis of retroperitoneal tumors, such as malignant lymphomas, gastrointestinal stromal tumors, sarcoma and carcinoma of unknown primary site. A 58-year-old Japanese woman presented with a large retroperitoneal tumor detected by ultrasonography (US). She had no medical history of hypertension. Computed tomography showed a mass, 7 cm in diameter, located between the pancreas and the inferior vena cava. It was unclear whether the mass originated from the duodenum or the mesentery. Endoscopic ultrasonography (EUS) demonstrated a large solid paraduodenal mass. Doppler US revealed sparse vascularity in the tumor. With the differential diagnosis of retroperitoneal tumor, we carried out EUS-FNA. At the time of the third needle puncture, transient severe hypertension was noted, with a blood pressure measurement of 269/130 mmHg. Data obtained from urine and blood examinations after EUS-fine-needle aspiration indicated a diagnosis of paraganglioma.

    DOI: 10.1111/j.1443-1661.2010.00939.x

    Web of Science

    PubMed

    researchmap

  • Highly Active State of Autoimmune Pancreatitis With Mikulicz Disease 査読

    Kensuke Kubota, Tomoko Wada, Shingo Kato, Yuichi Mozaki, Masato Yoneda, Koji Fujita, Hirokazu Takahashi, Masahiko Inamori, Yasunobu Abe, Noritoshi Kobayashi, Hiroyuki Kirikoshi, Satoru Saito, Yoshiaki Inayama, Atsushi Nakajima

    PANCREAS   39 ( 1 )   E6 - E10   2010年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Objective: Patients with autoimmune pancreatitis (AIP) sometimes present with Mikulicz disease (MD); however, the clinical features regarding these AIP patients with MD have not yet been fully elucidated. Our aim is to study the clinical differences between AIP with and without MD.
    Methods: Twenty-eight AIP patients were divided into 2 groups, one with MD and one without it. The following factors having a possible association with the presence or absence of MD were investigated: sex; serum IgG and IgG4 levels; the presence or absence of antinuclear auto-antibodies, jaundice, diabetes mellitus, swollen duodenal papilla, diffuse pancreatic swelling, spontaneous remission, and relapse.
    Results: The MD and non-MD groups consisted of 5 AIP and 23 AIP patients, respectively. The results of univariate analysis revealed that AIP patients presenting with MD were significantly associated with a younger onset, female predominance, high serum IgG4 titer, and diffuse pancreatic swelling (P &lt; 0.05). In 4 of the MD patients, onset preceded pancreatitis.
    Conclusions: Autoimmune pancreatitis patients presenting with MD tended to have different clinical features from the non-MD AIP patients, such as having an earlier onset, female tendency, and diffuse pancreatic swelling with a high titer of serum IgG4. Autoimmune pancreatitis with MD tended to precede gastroenterological events.

    DOI: 10.1097/MPA.0b013e3181bc119d

    Web of Science

    PubMed

    researchmap

  • FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas 査読

    Noritoshi Kobayashi, Kensuke Kubota, Shingo Kato, Seitaro Watanabe, Takeshi Shimamura, Hiroyuki Kirikoshi, Satoru Saito, Michio Ueda, Itaru Endo, Yoshiaki Inayama, Shin Maeda, Atsushi Nakajima

    PANCREATOLOGY   10 ( 5 )   631 - 640   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Background and Aims: FOXP3+ regulatory T cells (Tregs) play a central role in self-tolerance and suppress the effective antitumor immune response. A recent study revealed that indoleamine 2,3-dioxygenase (IDO)-mediated tryptophan depletion was able to affect local tumor-infiltrating lymphocytes. The aim of this study was to investigate the clinical significance of the tumor-infiltrating Tregs and tumoral IDO expression during the progression of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Methods: We investigated the prevalence and localization of FOXP3+ Tregs, CD8+ lymphocytes, and IDO expression in IPMNs by immunohistochemistry. We recruited 39 cases with IPMNs (IPMA: adenoma, n = 11; IPMB: borderline malignancy, n = 9; IPMC: noninvasive carcinoma, n = 7; I-IPMC: invasive IPMC, n = 12). Results: The prevalence of Tregs increased step by step during the carcinogenesis of IPMNs (Kruskal-Wallis test: p &lt; 0.0001). IDO expression in the tumor was observed in 5 cases with IPMNs (IPMC, n = 1; I-IPMC, n = 4). IDO expression in the tumor was positively correlated with the prevalence of Tregs in IPMNs. Conclusions: FOXP3+ Tregs play a role in controlling the immune surveillance against IPMNs at the premalignant stage. IDO expression in the tumor is one of the late-stage phenomena of multistage carcinogenesis of IPMNs. Copyright (C) 2010 S. Karger AG, Basel and IAP

    DOI: 10.1159/000308966

    Web of Science

    PubMed

    researchmap

  • Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease 査読

    Masato Yoneda, Kikuko Hotta, Yuichi Nozaki, Hiroki Endo, Takashi Uchiyama, Hironori Mawatari, Hiroshi Iida, Shingo Kato, Koji Fujita, Hirokazu Takahashi, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Masahiko Inamori, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Shiro Maeyama, Koichiro Wada, Atsushi Nakajima

    LIVER INTERNATIONAL   29 ( 7 )   1078 - 1085   2009年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL PUBLISHING, INC  

    Background
    Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver injury in many countries. Genetic factors are important for the development of NAFLD, as well as environmental factors. Recently an angiotensin II type 1 receptor (AGTR1) has been recognized as important in the aetiology of fibrosis in the liver.
    Objective
    In this study we investigated the association between angiotensin II type 1 receptor gene polymorphism (ATGR1) and NAFLD.
    Methods
    One hundred and sixty-seven NAFLD patients [106 with nonalcoholic steatohepatitis (NASH) and 61 with simple steatosis] with a positive diagnosis by liver biopsy and 435 healthy control subjects were recruited in this study.
    Results:
    We investigated 12 single nucleotide polymorphisms (SNPs) of the ATGR1 gene, among which rs3772622 showed the lowest P-value of allele frequency model (P=0.0000012) with an odds ratio (95% confidence interval) of 1.95 (1.49-2.55). Five SNPs (rs3772622, rs3772633, rs2276736, rs3772630 and rs3772627) were significantly associated with NAFLD, even when the most conservative Bonferroni&apos;s correction was applied. Linkage disequilibrium analysis revealed that SNP rs3772622 and another four SNPs (rs3772633, rs2276736, rs3772630 and rs3772627) were in the same block. We investigated the association between rs3772622 genotypes and the fibrosis index. The results of the analysis revealed an additive increase of the fibrosis index in the patients with the A allele of rs3772622.
    Conclusions
    This is the first report to demonstrate the genetic variations in ATGR1 that may influence the risk of NAFLD and liver fibrosis in NAFLD.

    DOI: 10.1111/j.1478-3231.2009.01988.x

    Web of Science

    PubMed

    researchmap

  • Identification of Cystatin SN as a novel tumor marker for colorectal cancer 査読

    Kyoko Yoneda, Hiroshi Iida, Hiroki Endo, Kunihiro Hosono, Tomoyuki Akiyama, Hirokazu Takahashi, Masahiko Inamori, Yasunobu Abe, Masato Yoneda, Koji Fujita, Shingo Kato, Yuichi Nozaki, Yasushi Ichikawa, Hiroshi Uozaki, Masashi Fukayama, Takahiro Shimamura, Tatsuhiko Kodama, Hiroyuki Aburatani, Chihiro Miyazawa, Keisuke Ishii, Naoki Hosomi, Mina Sagara, Masazumi Takahashi, Hideyuki Ike, Hiroaki Saito, Akihiko Kusakabe, Atsushi Nakajima

    INTERNATIONAL JOURNAL OF ONCOLOGY   35 ( 1 )   33 - 40   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    The goal of this study was to investigate Cystatin SN, a cysteine protease inhibitor, as a novel tumor marker for colorectal cancer (CRC). Gene expression profiles of mRNA from normal tissues and cancer cell lines were performed. Twenty-eight monoclonal antibodies for Cystatin SN were generated and serum Cystatin SN was quantified using ELISA in sera from 159 patients with CRC and 40 healthy controls. Cystatin SN was highly expressed in colon cancer cells. Employing a receiver-operating characteristic curve, we obtained an area under the curve of 0.708 for Cystatin SN, 0.819 for carcinoembryonic antigen (CEA) and 0.703 for carbohydrate antigen 19-9 (CA19-9). The combination assay of Cystatin SN, CEA and CA19-9 showed 62.9% sensitivity and 90.0% specificity. Especially, the sensitivity of the combination assay in stages I and IT detection, in which stages curative operation would be possible, was improved over that of the assay testing only for CEA and CA 19-9 (from 37.5 to 42.5% in stage I, from 49.0 to 60.8% in stage II). Furthermore, Western blot analysis revealed that Cystatin SN was increased in the urine from patients with CRC. Our results suggest the possibility of utilizing this novel tumor marker that can be tested in urine samples. These observations suggest that Cystatin SN in combination with CEA and CA19-9 is a useful tumor marker for detecting early stage CRC and that it is a unique urinary excretory protein, suggesting that Cystatin SN might be a novel candidate for use in mass screening for CRC.

    DOI: 10.3892/ijo_00000310

    Web of Science

    PubMed

    researchmap

  • A PROPOSAL FOR DIFFERENTIATION BETWEEN EARLY- AND ADVANCED-STAGE AUTOIMMUNE PANCREATITIS BY ENDOSCOPIC ULTRASONOGRAPHY 査読

    Kensuke Kubota, Shingo Kato, Tomoyuki Akiyama, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Masami Ogawa, Masahiko Inamori, Yasunobu Abe, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Kantaro Hisatomi, Nobuyuki Matsuhashi, Atsushi Nakajima

    DIGESTIVE ENDOSCOPY   21 ( 3 )   162 - 169   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL PUBLISHING, INC  

    Aim:
    We evaluated the characteristic endoscopic ultrasonography (EUS) findings of early autoimmune pancreatitis (AIP).
    Methods:
    Nineteen patients with AIP were identified from our database. We reviewed the following features of EUS as being potentially characteristic of early AIP: hyperechoic foci, hyperechoic strands, lobularity, hyperechoic pancreatic duct margins and reduced echogenicity. According to the Cambridge classification for chronic pancreatitis, we classified AIP into early AIP (Grades 0-2) and advanced AIP (Grades 3-5) and examined the histopathological findings in each stage of AIP.
    Results:
    There were nine cases of early AIP and 10 cases of advanced AIP. Five of the nine early cases of AIP showed spontaneous remission without corticosteroid therapy (P &lt; 0.05). The EUS findings were as follows (early vs advanced): hyperechoic foci, 100% (9/9) vs 100% (10/10); hyperechoic strands, 66.7% (6/9) vs 70% (7/10); lobularity, 77.8% (7/9) vs 20% (2/10); hyperechoic pancreatic duct margin, 88.9% (8/9) vs 30% (3/10); reduced echogenicity, 88.9% (8/9) vs 90% (9/10). Lobularity and hyperechoic pancreatic duct margin were detected at a significantly higher frequency in early AIP than in the advanced AIP patients (P &lt; 0.05). Regarding the histopathological findings, acinar cells were better preserved in the cases of early AIP, whereas acinar cells were reduced in number and replaced by massive fibrosis in the patients with advanced AIP.
    Conclusions:
    Lobularity and hyperechoic pancreatic duct margin are characteristic EUS features of early AIP, which has a more favorable prognosis, and shows a higher frequency of spontaneous remission and preservation of acinar cells, than advanced AIP.

    DOI: 10.1111/j.1443-1661.2009.00879.x

    Web of Science

    PubMed

    researchmap

  • Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway 査読

    Michiko Sugiyama, Hirokazu Takahashi, Kunihiro Hosono, Hiroki Endo, Shingo Kato, Kyoko Yoneda, Yuichi Nozaki, Koji Fujita, Masato Yoneda, Koichiro Wada, Hitoshi Nakagama, Atsushi Nakajima

    INTERNATIONAL JOURNAL OF ONCOLOGY   34 ( 2 )   339 - 344   2009年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Adiponectin is a peptide hormone secreted by adipose tissue. It is a key hormone responsible for insulin sensitization, and its circulating level is inversely associated with abdominal obesity. Recent studies have shown that a reduced plasma adiponectin level is significantly correlated with the risk of various cancers. However, there are few studies regarding the association of adiponectin and colorectal cancer. To address this issue, we investigated the effect of adiponectin on colorectal cancer cells. Three colorectal cancer cell lines express both AdipoR1 and AdipoR2 receptors. MTT assay revealed that adiponectin inhibited human colorectal cancer cell growth. Furthermore, Western blot analysis revealed that adiponectin activated adenosine monophosphate-activated protein kinase (AMPK) and suppressed mammalian target of rapamycin (mTOR) pathways. Selective AMPK inhibitor compound C abrogated the inhibitory effect of adiponectin on cell growth. Our results clearly demonstrate the novel findings that adiponectin inhibits colorectal cancer cell growth via activation of AMPK, thereby down-regulating the mTOR pathway.

    DOI: 10.3892/ijo_00000156

    Web of Science

    PubMed

    researchmap

  • Incidence of Small Bowel Injury Induced by Low-Dose Aspirin: A Crossover Study Using Capsule Endoscopy in Healthy Volunteers 査読

    Hiroki Endo, Kunihiro Hosono, Masahiko Inamori, Shingo Kato, Yuichi Nozaki, Kyoko Yoneda, Tomoyuki Akiyama, Koji Fujita, Hirokazu Takahashi, Masato Yoneda, Yasunobu Abe, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Kensuke Kubota, Satoru Saito, Nobuyuki Matsuhashi, Atsushi Nakajima

    DIGESTION   79 ( 1 )   44 - 51   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KARGER  

    Background and Aims: Small intestinal toxicity of low-dose aspirin remains unclear. The purpose of this capsule endoscopy study was to assess the incidence of small bowel injury in healthy volunteers treated with short-term low-dose aspirin. Methods: Healthy subjects were randomly assigned to receive low-dose aspirin for 14 days (Aspirin group) or no drugs for 14 days (Control group). The two treatment occasions were separated by a washout period of at least 4 weeks. All subjects underwent capsule endoscopy at the end of each treatment period. Results: After 2 weeks of treatment, the percentages of subjects with small bowel pathology were 80% in the Aspirin group compared with 20% in the Control group (p = 0.023). The incidence of small bowel mucosal breaks in the Aspirin group was higher than that in the Control group, although the difference was not significant (30 vs. 0%; p = 0.210). Conclusions: This is the first pilot study using capsule endoscopy to report on the relation between small bowel injury and low-dose aspirin. Among the healthy subjects, the short-term administration of low-dose aspirin was associated with a mild mucosal inflammation of the small bowel. Copyright (c) 2009 S. Karger AG, Basel

    DOI: 10.1159/000204465

    Web of Science

    PubMed

    researchmap

  • Differentiating sclerosing cholangitis caused by autoimmune pancreatitis and primary sclerosing cholangitis according to endoscopic duodenal papillary features 査読

    Kensuke Kubota, Shingo Kato, Tomoyuki Akiyama, Masato Yoneda, Koji Fujita, Masami Ogawa, Masahiko Inamori, Noritoshi Kobayashi, Satoru Saito, Yukio Kakuta, Hisashi Ohshiro, Atsushi Nakajima

    GASTROINTESTINAL ENDOSCOPY   68 ( 6 )   1204 - 1208   2008年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MOSBY-ELSEVIER  

    Background: Differentiating primary sclerosing cholangitis (PSC) and sclerosing cholangids caused by autoimmune pancreatitis (SC-AIP) is often challenging. Recently, endoscopic findings of the duodenal papilla in cases with AIP or PSC were reported by Unno and Parlak, although the endoscopic differentiation of these 2 conditions has not yet been fully clarified.
    Objective: Our purpose was to clarify, the endoscopic findings of the duodenal papilla in patients with SC-AIP and those with PSC and to determine criteria for the differentiation of these conditions.
    Design: Case series.
    Setting: Restrospective.
    Patients: Twenty-seven,en patients With SC-AIP and 12 patients with PSC who had undergone ERCP were identified from out database. We reviewed these records to determine whether the duodenal papillary findings (swollen papilla/normal papilla/small papilla) might be potentially useful for differentiating SC-AIP and PSC. Immunohistopathological findings for the duodenal papilla were also examined by using immunoglobulin G4 (IgG4) among the infiltrating plasma cells.
    Interventions: ERCP, biopsy specimen taken from duodenal papilla.
    Main Outcome Measurements: The presence of a swollen duodenal papilla with IgG4-positive plasma cells was useful for discriminating SC-AIP from with PSC.
    Results: A swollen duodenal papilla was observed in 63% (17/27) of the patients with SC-AIP, whereas there was no swelling of the duodenal papilla of the patients with PSC. A small papilla was recognized in 50% (6/12) of the patients with PSC. IgG4-positive plasma cells in the duodenal papilla were significantly detected in the patients with SC-AIP but not in the patients with PSC.
    Limitation: Single-center study.
    Conclusions: Characteristic duodenal endoscopic papillary features in patients with SC-AIP, such as a swollen duodenal papilla and positive immunostaining for IgG4, might be helpful for discriminating this condition from PSC.

    DOI: 10.1016/j.gie.2008.08.013

    Web of Science

    PubMed

    researchmap

  • Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH) 査読

    Masato Yoneda, Takashi Uchiyama, Shingo Kato, Hiroki Endo, Koji Fujita, Kyoko Yoneda, Hironori Mawatari, Hiroshi Iida, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Noritoshi Kobayashi, Kensuke Kubota, Satoru Saito, Shiro Maeyama, Mina Sagara, Hiroyuki Aburatani, Tatsuhiko Kodama, Atsushi Nakajima

    BMC GASTROENTEROLOGY   8   53   2008年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: The changes in the liver in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However it has remained difficult to differentiate between NASH and non-progressive NAFLD on the basis of the clinical findings alone.
    Aims: In this study we investigated the clinical usefulness of plasma Pentraxin3 (PTX3) levels to predict NASH. Plasma PTX3 was measured in 70 patients with histologically verified NAFLD (28 with non-NASH and 42 with NASH) and 10 healthy control subjects.
    Results: The plasma PTX3 level was significantly higher in the NASH cases than in the non-NASH cases (p = 0.0021) and control subjects (p = 0.045). And the plasma PTX3 level was significantly higher in the stages 3-4 NAFLD cases than in the stages 0-2 NAFLD cases (p&lt;0.0001). The PTX3 values were closely correlated with the stages of liver fibrosis (p&lt;0.0001, Kruskal-Wallis test). To detect NASH compared with non-NASH, the area under the curve for plasma PTX3 were 0.755, and to detect stages 3-4 NAFLD compared with stages 0-2 NAFLD, the area under the curve for plasma PTX3 were 0.850.
    Conclusion: This is the first study to demonstrate consistent and profound elevation of plasma PTX3 levels in NASH in comparison with non-NASH. The results suggest that plasma PTX3 levels may not only be laboratory values that differentiate NASH from non-NASH, but marker of the severity of hepatic fibrosis in NASH.

    DOI: 10.1186/1471-230X-8-53

    Web of Science

    PubMed

    researchmap

  • Association between PPARGCIA polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD) 査読

    Masato Yoneda, Kikuko Hotta, Yuichi Nozaki, Hiroki Endo, Takashi Uchiyama, Hironori Mawatari, Hiroshi Iida, Shingo Kato, Kunihiro Hosono, Koji Fujita, Kyoko Yoneda, Hirokazu Takahashi, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Masahiko Inamori, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Shiro Maeyama, Koichiro Wada, Atsushi Nakajima

    BMC GASTROENTEROLOGY   8   27   2008年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Genetic factors as well as environmental factors are important in the development of NAFLD and in this study we investigated associations between polymorphisms of peroxisome proliferators-activated receptor gamma coactivator 1 alpha polymorphism (PPARGC1A) and NAFLD.
    Aims: We recruited 115 patients with biopsy-proven NAFLD, 65 with NASH and 50 with simple steatosis, and 441 healthy control subjects and investigated 15 SNPs of PPARGC1A.
    Results: SNP rs2290602 had the lowest p value in the dominant mode (p = 0.00095), and the odds ratio for NAFLD (95% CI) was 2.73 (1.48-5.06). rs2290602 was significantly associated with NAFLD even when the most conservative Bonferroni&apos;s correction was applied (p = 0.0143). The frequency of the T allele of rs2290602 was significantly higher in the NASH patients than in the control subjects (p = 0.00093, allele frequency mode), and its frequency in the NASH patients tended to be higher than in the simple steatosis patients (p = 0.09). The results of the real-time RT-PCR study showed that intrahepatic mRNA expression of PPARGC1A was lower in the TT group than in the GG or GT group at SNP rs2290602 (p = 0.0454).
    Conclusion: This is the first study to demonstrate a significant association between genetic variations in PPARGC1A and NAFLD. This finding suggested that PPARGC1A polymorphism and lower expression of PPARGC1A mRNA in the liver are an important genetic contribution to etiology of NAFLD.

    DOI: 10.1186/1471-230X-8-27

    Web of Science

    PubMed

    researchmap

  • High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH 査読

    Masato Yoneda, Hironori Mawatari, Koji Fujita, Hiroshi Iida, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima

    JOURNAL OF GASTROENTEROLOGY   42 ( 7 )   573 - 582   2007年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Background. The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH. Methods. Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6. Results. The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228). Conclusions. This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.

    DOI: 10.1007/s00535-007-2060-x

    Web of Science

    PubMed

    researchmap

  • Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage 査読

    Masato Yoneda, Hironori Mawatari, Koji Fujita, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima

    JOURNAL OF GASTROENTEROLOGY   42 ( 5 )   375 - 381   2007年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Background. The changes in nonalcoholic fatty liver disease range over a wide spectrum, extending, from simple steatosis to nonalcoholic steatohepatitis (NASH). We investigated the clinical usefulness of the type IV collagen 7s domain and hyaluronic acid for predicting the severity of fibrosis before progression to the cirrhotic stage in NASH patients. Methods. The type IV collagen 7s domain and hyaluronic acid were measured in 72 patients with histologically verified NASH. Results. In a univariate analysis, marked elevation of hyaluronic acid and the type IV collagen 7s domain was observed in the NASH patients with advanced fibrosis compared with those with mild fibrosis (P = 0.0028, P = 0.0006, respectively). For detection of NASH with advanced fibrosis, the area under the receiver-operating characteristic curves for type IV collagen 7s domain and hyaluronic acid were 0.767 and 0.754, respectively. However, multiple regression analysis revealed that the type IV collagen 7s domain, but not hyaluronic acid, was significantly elevated in patients with advanced fibrosis even after adjustment for age, sex, platelet count, prothrombin time, aspartate aminotransferase/alanine aminotransferase ratio, body mass index, and presence of underlying type 2 diabetes mellitus, all of which have previously been reported as useful predictors of advanced fibrosis in patients with NASH (P = 0.0127, P = 0.2804, respectively). Conclusions. This is the first report to demonstrate a consistent and profound elevation of the type IV collagen 7s domain in NASH patients with advanced fibrosis (before progression to the stage of cirrhosis) compared with those with mild fibrosis.

    DOI: 10.1007/s00535-007-2014-3

    Web of Science

    PubMed

    researchmap

  • Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma 査読

    N Nakaigawa, M Yao, M Baba, S Kato, T Kishida, K Hattori, Y Nagashima, Y Kubota

    CANCER RESEARCH   66 ( 7 )   3699 - 3705   2006年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    It is well known that, inactivation of von Hippel-Lindau (VHL) gene predisposes for human clear cell renal carcinoma (CCRC). However, details about critical roles of VHL inactivation during tumorigenesis are still unknown. MET protein is a tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), which regulates cell growth, cell morphology, and cell motility. We showed that MET protein overexpressed in CCRC cells was phosphorylated without HGF/SF. This constitutive phosphorylation of MET protein in CCRC cells wits inhibited by the rescue of exogenous wild-type VHL gene without. a decrease in expression level of MET protein. Interestingly, wild-type VHL gene suppressed the phosphorylation of MET protein only tinder high cell density conditions. Additionally, MET protein activated by the inactivation of VHL, gene modified cell adherence, including N-cadherin and beta-catenin. When activation of MET protein in CCRC cells was inhibited by the MET inhibitor K252a, the growth of CCRC cells in vitro and the tumorigenesis induced by CCRC cells in nude mice were suppressed. Front these results, we concluded that inactivation of VHL gene induced constitutive phosphorylation of MET protein and modified intercellular adherence structure to trigger the cell growth released front contact inhibition, finally resulting in tumorigenesis. This is one of the mechanisms of CCRC oncogenesis, and MET protein has potential its a molecular target for novel CCRC therapies.

    DOI: 10.1158/0008-5472.CAN-05-0617

    Web of Science

    PubMed

    researchmap

  • Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. 査読 国際誌

    Hiroji Uemura, Hitoshi Ishiguro, Yoji Nagashima, Takeshi Sasaki, Noboru Nakaigawa, Hisashi Hasumi, Shingo Kato, Yoshinobu Kubota

    Molecular cancer therapeutics   4 ( 11 )   1699 - 709   2005年11月

     詳細を見る

    記述言語:英語  

    We showed previously that angiotensin II activated the proliferation of prostate cancer cells and that angiotensin II receptor blockers (ARB) could inhibit it. Here, we investigated whether angiotensin II exerts mitogenic effects on the cross-talk between stromal and cancer cells and whether an ARB can inhibit tumor growth through actions on stromal cells. Cell proliferation and interleukin-6 secretion of prostate stromal PrSC cells stimulated with angiotensin II, tumor necrosis factor-alpha, or epidermal growth factor were examined in the absence and presence of ARB. We examined the effect of ARB on mitogen-activated protein kinase (MAPK) phosphorylation of PrSC and PC-3 cells treated with conditioned medium of PrSC cells and determined the effect of ARB on tumor growth induced by paracrine factors from PrSC cells. Angiotensin II activated the cell proliferation and interleukin-6 secretion of PrSC cells, and ARB inhibited it. Angiotensin II, tumor necrosis factor-alpha, or epidermal growth factor induced MAPK phosphorylation in PrSC cells, and this phosphorylation was inhibited by ARB. Conditioned medium of PrSC cells with angiotensin II activated MAPK phosphorylation in PC-3 cells, and ARB-treated conditioned medium of PrSC cells inhibited it. The tumor growth and angiogenesis of a mixture of PC-3 with PrSC were inhibited by ARB administration, whereas those of PC-3 xenografts were not inhibited. ARB exerted an antiproliferative effect on prostate cancer through paracrine factors from stromal cells. Because prostate stromal cells are thought to be involved in the initiation and development of prostate cancer, the present data suggest the possibility that ARBs are a novel therapeutic class of agents for prostate cancer.

    DOI: 10.1158/1535-7163.MCT-04-0295

    PubMed

    researchmap

▼全件表示

MISC

  • EFFICACY AND SAFETY OF LUBIPROSTONE TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE WITH ADVANCED FIBROSIS: A POST-HOC ANALYSIS OF THE LUBIPRONE RANDOMIZED TRIAL.

    Takaomi Kessoku, Takashi Kobayashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Yasushi Honda, Yuji Ogawa, Kento Imajo, Shingo Kato, Takuma Higurashi, Masato Yoneda, Kazumi Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

    HEPATOLOGY   72   1017 - 1017   2020年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • 抗腫瘍製剤スクリーニングのための膵癌患者モデルの開発

    加藤 真吾, 鈴木 章浩, 松浦 哲也, 筆宝 義隆, 中島 淳

    日本癌学会総会記事   79回   OE2 - 3   2020年10月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 神経内分泌腫瘍に対する病理学的ソマトスタチン受容体発現からみたオクトレオスキャンの有用性

    長谷川 翔, 小林 規俊, 鈴木 洸, 春日 範樹, 佐藤 高光, 加藤 真吾, 細野 邦広, 窪田 賢輔, 市川 靖史, 中島 淳

    日本消化器病学会雑誌   116 ( 臨増大会 )   A861 - A861   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, double-blind, randomized, placebo-controlled, phase II study

    Takaomi Kessoku, Kento Imajo, Yuji Ogawa, Takashi Kobayashi, Yasushi Honda, Takayuki Kato, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazumi Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

    JOURNAL OF HEPATOLOGY   70 ( 1 )   E1 - E1   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ELSEVIER  

    DOI: 10.1016/S0618-8278(19)30001-5

    Web of Science

    researchmap

  • Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis

    Takaomi Kessoku, Takashi Kobayashi, Kento Imajo, Yasushi Honda, Yuji Ogawa, Takuma Higurashi, Shingo Kato, Masato Yoneda, Yousuke Oikawa, Yoshiki Tanaka, Shunji Nakajima, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

    JOURNAL OF HEPATOLOGY   70 ( 1 )   E534 - E534   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ELSEVIER  

    DOI: 10.1016/S0618-8278(19)31055-2

    Web of Science

    researchmap

  • in vitroモデルが明らかにするマウス膵管発がんにおける微小環境の重要性

    松浦 哲也, 加藤 真吾, 落合 雅子, 今井 俊夫, 中島 淳, 筆宝 義隆

    日本癌学会総会記事   76回   P - 2280   2017年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • 胆道疾患に対する超音波内視鏡下胆道ドレナージ術の検討

    佐藤 高光, 栗田 裕介, 岩崎 暁人, 加藤 真吾, 香川 幸二, 細野 邦広, 中島 淳, 窪田 賢輔

    胆道   30 ( 3 )   514 - 514   2016年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    researchmap

  • 臨床経過からみた内視鏡的胃十二指腸ステント留置術の位置づけ

    佐藤 高光, 栗田 裕介, 長谷川 翔, 岩崎 暁人, 藤田 祐司, 加藤 真吾, 細野 邦広, 小林 規俊, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   58 ( Suppl.1 )   682 - 682   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 低用量NSAID静注は高リスク群においてPEP発症率を軽減できる

    藤田 祐司, 長谷川 翔, 岩崎 暁人, 佐藤 高光, 加藤 真吾, 細野 邦広, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   58 ( Suppl.1 )   716 - 716   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 【AIPの概念・診断・治療】 自己免疫性膵胆道疾患における治療法別の長期予後

    窪田 賢輔, 加藤 由理, 石井 研, 佐藤 高光, 加藤 真吾, 藤田 祐司, 渡辺 誠太郎, 関野 雄典, 細野 邦広, 谷田 恵美子, 香川 浩司, 藤澤 聡郎, 藤澤 信隆, 松橋 信行, 中島 淳

    消化器内科   59 ( 5 )   488 - 494   2014年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 【ドレナージ大全】 胆道ドレナージ術 悪性中下部胆道閉塞 Potential resectable pancreatic head cancer(PRPHC)に対する術前内視鏡的治療戦略

    窪田 賢輔, 藤田 祐司, 関野 雄典, 細野 邦広, 小林 規俊, 佐藤 高光, 加藤 真吾, 渡辺 誠太郎, 山中 正二, 中島 淳, 遠藤 格

    胆と膵   34 ( 臨増特大 )   809 - 815   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    膵癌の予後改善のために有効な治療は、R0手術の達成である。Borderline resectableもしくはlocally advancedの膵頭部癌の診療において、術前抗癌剤放射線療法(NACRT)導入により、根治治療の可能性が高まってきている。閉塞性黄疸、胆管炎で発症した膵頭部癌のNACRT期間を安定、確実に遂行するため、partial cover metaric stent(PCMS)の早期導入が肝要である。MDCT診断に立脚したNCCNガイドライン2012をもとに、診断を行い、およそ3ヵ月の治療期間を中断なく行うことで、R0達成率を高められる可能性がある。さらにPCMSはcost面からも、今後の術前内視鏡的内瘻術の、第一選択となる可能性がある。(著者抄録)

    researchmap

  • Primary leiomyoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration

    Takamitsu Sato, Shingo Kato, Seitaro Watanabe, Kunihiro Hosono, Noritoshi Kobayashi, Atsushi Nakajima, Kensuke Kubota

    Digestive Endoscopy   24 ( 5 )   380 - 380   2012年9月

     詳細を見る

  • 膵癌の治療前診断におけるEUS-FNAの有用性

    佐藤 高光, 加藤 真吾, 渡邉 誠太郎, 細野 邦広, 小林 規俊, 前田 愼, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   54 ( Suppl.2 )   2811 - 2811   2012年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Soluble CD14 are a Useful Hallmark of Liver Inflammation and Predictor for Progression of Fibrosis in NASH 査読

    Ogawa Yuji, Imajo Kento, Yoneda Masato, Shinohara Yoshiyasu, Kato Shingo, Mawatari Hironori, Nozaki Yuichi, Fujita Koji, Shibata Wataru, Kirikoshi Hiroyuki, Wada Koichiro, Nakajima Atsushi

    GASTROENTEROLOGY   142 ( 5 )   S1019   2012年5月

  • MDCTと腫瘍マーカーを使用した新しい膵癌の動脈浸潤スコアの提案

    渡邉 誠太郎, 小林 規俊, 佐藤 高光, 藤井 徹朗, 加藤 真吾, 細野 邦広, 嶌村 健, 前田 愼, 中島 淳, 遠藤 格, 窪田 賢輔

    膵臓   27 ( 3 )   398 - 398   2012年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本膵臓学会  

    researchmap

  • Relationship Between the Plasma Concentrations of Free Choline and Parameters of Adiposity and Histological Findings in Patients With Nonalcoholic Fatty Liver Disease. a Multicenter Study in Japan 査読

    Imajo Kento, Yoneda Masato, Fujita Koji, Nozaki Yuichi, Ogawa Yuji, Shinohara Yoshiyasu, Kato Shingo, Mawatari Hironori, Shibata Wataru, Kirikoshi Hiroyuki, Wada Koichiro, Saito Satoru, Nakajima Atsushi

    GASTROENTEROLOGY   142 ( 5 )   S1016   2012年5月

  • 当院における内視鏡的胃十二指腸ステント留置術の現状

    小林 規俊, 佐藤 高光, 加藤 真吾, 渡邉 誠太郎, 細野 邦広, 稲森 正彦, 前田 愼, 中島 淳, 遠藤 格, 窪田 賢輔

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1095 - 1095   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 薬剤性重症膵炎後の感染性膵壊死に、内視鏡的debridementを施行した6歳小児の一例

    佐藤 高光, 加藤 真吾, 渡辺 誠太郎, 細野 邦弘, 小林 規俊, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1347 - 1347   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 当院における超音波内視鏡ガイド下針生検術による上部消化管粘膜下腫瘍診断の遷移

    佐藤 高光, 加藤 真吾, 渡邉 誠太郎, 細野 邦広, 小林 規俊, 前田 愼, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1249 - 1249   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • IPMN診断における、IDUSとPOPSの役割について

    小林 規俊, 窪田 賢輔, 中島 淳, 佐藤 高光, 加藤 真吾, 渡邉 誠太郎, 細野 邦広, 前田 愼

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1267 - 1267   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • シタグリプチンによる胃排出能に及ぼす影響に関する検討

    野中 敬, 藤井 徹朗, 加藤 真吾, 山田 英司, 酒井 英嗣, 大久保 秀則, 日暮 琢磨, 関野 雄典, 渡邉 誠太郎, 飯田 洋, 細野 邦広, 遠藤 宏樹, 米田 正人, 古出 智子, 高橋 宏和, 阿部 泰伸, 後藤 英司, 前田 愼, 中島 淳, 稲森 正彦

    日本消化器病学会雑誌   109 ( 臨増総会 )   A280 - A280   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • von Hippel-Lindau病における膵病変に関する検討

    小林 規俊, 佐藤 高光, 加藤 真吾, 渡邉 誠太郎, 細野 邦広, 嶌村 健, 前田 愼, 中島 淳, 窪田 賢輔

    日本消化器病学会雑誌   109 ( 臨増総会 )   A297 - A297   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 消化器癌の免疫学的解析と治療 膵癌腫瘍微小環境におけるSemaphorin4Dシグナルの解析

    加藤 真吾, 窪田 賢輔, 中島 淳

    日本消化器病学会雑誌   109 ( 臨増総会 )   A174 - A174   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 酸分泌抑制薬による胃機能への影響に関する検討

    野中 敬, 藤井 徹朗, 加藤 真吾, 山田 英司, 酒井 英嗣, 大久保 秀則, 日暮 琢磨, 関野 雄典, 渡邉 誠太郎, 飯田 洋, 細野 邦広, 遠藤 宏樹, 米田 正人, 古出 智子, 高橋 宏和, 阿部 泰伸, 前田 愼, 中島 淳, 後藤 英司, 稲森 正彦

    神奈川医学会雑誌   39 ( 1 )   79 - 79   2012年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:神奈川県医師会  

    researchmap

  • 胆管ステント閉塞を契機に発症した、胆石イレウスの一例

    尾崎 優美, 小林 規俊, 佐藤 高光, 渡邊 誠太郎, 細野 邦広, 加藤 真吾, 前田 愼, 中島 淳, 遠藤 格, 窪田 賢輔

    Progress of Digestive Endoscopy   80 ( 1 )   106 - 106   2011年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • Effective treatment for duodenal variceal bleeding using endoscopic ligation 査読

    Yutaka Kawakami, Hirokazu Takahashi, Shingo Kato, Takashi Uchiyama, Hironori Mawatari, Hiroshi Iida, Masahiko Inamori, Yasunobu Abe, Atsushi Nakajima

    Hepato-Gastroenterology   58 ( 112 )   2024 - 2025   2011年11月

     詳細を見る

    記述言語:英語  

    Duodenal variceal rupture is rare, and there is little agreement on the best therapeutic option. A 72-year-old man treated for liver cirrhosis with HCV visited the emergency room complaining of dizziness and tarry stool. Fiberscope images showed varices (F2CbRC+) with white plaques at the horizontal region of the duodenum. The patient was treated using endoscopic variceal ligation (EVL), and no more bleeding has been detected. © H.G.E. Update Medical Publishing S.A.

    DOI: 10.5754/hge09470

    Scopus

    PubMed

    researchmap

  • TACE不応の進行肝細胞がんに対して、5-FU使用の肝動注化学療法は有効か?

    桐越 博之, 米田 正人, 馬渡 弘典, 藤田 浩司, 今城 健人, 加藤 真吾, 鈴木 香峰理, 前田 愼, 中島 淳, 斉藤 聡

    日本消化器病学会雑誌   108 ( 臨増大会 )   A944 - A944   2011年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院における粘液産生胆道腫瘍9例の検討

    渡邉 誠太郎, 加藤 真吾, 細野 邦広, 嶌村 健, 小林 規俊, 前田 慎, 中島 淳, 遠藤 格, 稲山 嘉三, 窪田 賢輔

    胆道   25 ( 3 )   458 - 458   2011年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    researchmap

  • Rectal carcinoma with metachronous metastasis to the extrahepatic bile duct without liver tumor 査読

    Noritoshi Kobayashi, Ryu Kobayashi, Shingo Kato, Seitaro Watanabe, Takashi Uchiyama, Takeshi Shimamura, Kensuke Kubota, Shin Maeda, Atsushi Nakajima, Yasushi Ichikawa, Hisashi Oshiro, Itaru Endo

    Clinical Journal of Gastroenterology   4 ( 4 )   278 - 282   2011年8月

     詳細を見る

    記述言語:英語  

    In July 2003, a 63-year-old man received a low anterior resection for rectal cancer. In February 2006, he underwent a right hepatectomy for a solitary metastatic liver tumor
    the liver tumor had not invaded the bile duct, and a curative resection was performed. In August 2008, an enhanced computed tomography examination revealed a massive focal lesion at the point of the common bile duct. Endoscopic ultrasonography clearly revealed a hyperechoic polypoid lesion that had spread laterally on the surface of the slightly dilated bile duct and had a smooth outer hyperechoic layer. No lymph nodes were present in this region. Endoscopic retrograde cholangiopancreatography revealed an irregular stricture, and a biopsy was performed through the scope. Microscopic examination revealed a tumor characterized as a moderately differentiated adenocarcinoma resembling the liver tumor. We diagnosed the intrabiliary tumor as a metachronous metastatic bile duct tumor from rectal cancer without involvement of the liver parenchyma. This is a very rare case, with recurrence only in an extrahepatic bile duct after the complete resection of a metastatic liver tumor. This is the first clinical, pathological, and radiological description of this rare condition. © Springer 2011.

    DOI: 10.1007/s12328-011-0240-y

    Scopus

    PubMed

    researchmap

  • 【胆道・膵疾患の画像診断】 膵疾患 自己免疫性膵炎 膵癌との鑑別

    窪田 賢輔, 佐藤 高光, 加藤 真吾, 渡辺 誠太郎, 細野 邦弘, 島村 健, 小林 規俊, 遠藤 格, 中島 淳

    消化器外科   34 ( 8 )   1247 - 1255   2011年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)へるす出版  

    researchmap

  • 胆膵疾患に対する内視鏡的ドレナージ 術後良性胆管狭窄の傾向と内視鏡的治療戦略

    小林 規俊, 加藤 真吾, 渡邊 誠太郎, 細野 邦広, 島村 健, 前田 愼, 中島 淳, 窪田 賢輔

    Progress of Digestive Endoscopy   79 ( 1 )   58 - 58   2011年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 内視鏡的に摘出したスプーン誤飲の1例

    池川 健, 高橋 宏和, 遠藤 宏樹, 古出 智子, 所 知加子, 稲森 正彦, 阿部 泰伸, 加藤 真吾, 渡邉 誠太郎, 馬渡 弘典, 米田 正人, 後藤 歩, 嶌村 健, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 川名 一朗, 前田 愼, 中島 淳

    Progress of Digestive Endoscopy   79 ( 1 )   103 - 103   2011年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 進行膵癌による十二指腸狭窄に対して、Niti-Sステント留置が有効であった2例

    桑原 大輔, 小林 規俊, 窪田 賢輔, 島村 健, 渡邊 誠太郎, 加藤 真吾, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 藤田 浩司, 米田 正人, 高橋 宏和, 古出 智子, 所 知加子, 稲森 正彦, 阿部 泰伸, 桐越 博之, 斎藤 聡, 中島 淳, 前田 愼

    Progress of Digestive Endoscopy   79 ( 1 )   104 - 104   2011年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 【経過を追えた小膵癌 この所見に気をつけろ!】 【症例呈示】 IgG4関連硬化性胆管炎(IgG4-SC)における膵癌併発例の検討

    窪田 賢輔, 渡辺 誠太郎, 細野 邦弘, 加藤 真吾, 島村 健, 小林 規俊, 中島 淳

    肝胆膵画像   13 ( 3 )   299 - 306   2011年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医学書院  

    IgG4関連硬化性胆管炎(IgG4-SC)の膵癌併発の2例を提示した.[症例1]は72歳,男性.68歳時に肝門部胆管癌を疑われ,左葉切除術を施行された.その2年後,閉塞性黄疸が再発した.切除標本の検討からIgG4-SCと診断された.ステロイド維持療法中に膵頭部癌を併発したが,既に進行癌であった.[症例2]は61歳時に黄疸で発症し,維持療法(5mg/day)を2年間行った.66歳時に黄疸が再発し,ステロイド治療で寛解したが,その1年後,肝転移を伴う進行膵尾部癌が発見された.AIPに併発する膵癌は同時性,異時性で認められる.前者はby chanceであるが,後者ではAIPの急性,慢性炎症,ステロイド投与などが発癌に関与している可能性もある.AIPにおける膵癌併発は報告例をみると,ステロイド治療による寛解後,3〜5年の経過に膵体尾部に比較的多く発症していた.(著者抄録)

    DOI: 10.11477/mf.1428100397

    researchmap

  • C型慢性肝炎における肝線維化とCETP活性の関係

    馬渡 弘典, 米田 正人, 藤田 浩司, 加藤 真吾, 篠原 義康, 今城 健人, 鈴木 香峰理, 桐越 博之, 前田 愼, 中島 淳, 斉藤 聡

    肝臓   52 ( Suppl.1 )   A203 - A203   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科における非B非C型肝細胞癌の臨床的特徴・内科的治療成績とHBc抗体の意義

    桐越 博之, 米田 正人, 馬渡 弘典, 藤田 浩司, 加藤 真吾, 今城 健人, 鈴木 香峰理, 前田 愼, 中島 淳, 斉藤 聡

    肝臓   52 ( Suppl.1 )   A339 - A339   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 非切除膵癌に対する内視鏡的金属ステントの早期閉塞に関わる因子の検討

    渡邉 誠太郎, 加藤 真吾, 嶌村 健, 小林 規俊, 前田 愼, 中島 淳, 窪田 賢輔

    Gastroenterological Endoscopy   53 ( Suppl.1 )   822 - 822   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • EUSによる分枝型IPMNの良悪性の鑑別について

    小林 規俊, 窪田 賢輔, 島村 健, 渡邊 誠太郎, 加藤 真吾, 坂本 康成, 遠藤 宏樹, 藤田 浩司, 古出 智子, 米田 正人, 高橋 宏和, 所 知加子, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斎藤 聡, 川名 一朗, 中島 淳, 前田 愼, 遠藤 格

    日本消化器病学会雑誌   108 ( 臨増総会 )   A300 - A300   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵・胆道がんを克服する新たな道はあるか? 基礎と臨床の双方から具体的解決方法の模索を 膵癌における腫瘍間質治療標的としてのSemaphorin 4D signal pathwayの検討

    加藤 真吾, 窪田 賢輔, 中島 淳

    日本消化器病学会雑誌   108 ( 臨増総会 )   A116 - A116   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵尾部癌に対する経胃的EUS-FNA後に播種が疑われた一例

    渡邉 誠太郎, 窪田 賢輔, 加藤 真吾, 嶌村 健, 小林 規俊, 谷口 浩一, 遠藤 格, 前田 愼, 中島 淳

    日本消化器病学会雑誌   108 ( 臨増総会 )   A183 - A183   2011年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Liver abscess caused by periodontal bacterial infection with Fusobacterium necrophorum 査読

    Masato Yoneda, Shingo Kato, Hironori Mawatari, Hiroyuki Kirikoshi, Kento Imajo, Koji Fujita, Hiroki Endo, Hirokazu Takahashi, Masahiko Inamori, Noritoshi Kobayashi, Kensuke Kubota, Satoru Saito, Iwai Tohnai, Kei Watanuki, Koichiro Wada, Shin Maeda, Atsushi Nakajima

    Hepatology Research   41 ( 2 )   194 - 196   2011年2月

     詳細を見る

    記述言語:英語  

    Liver abscess is recognized as a life-threatening disease. However, even in recent years, approximately 50% of liver abscess cases are considered to be cryptogenic. Here, we report a case of liver abscess associated with periodontal bacterial infection by Fusobacterium necrophorum, which is commonly found in the oropharyngeal flora. A 36-year-old man presented with fever and contrast-enhanced abdominal computed tomography revealed multiple liver abscesses. F.necrophorum was isolated from oral smears, liver aspirates and blood samples. Liver abscesses caused by periodontal bacterial infection are rare, however, the incidence is expected to increase in the future, as periodontitis is extremely common and is on the rise as one of the most common chronic infections in the world. A systemic survey including periodontitis may be required for the exact diagnosis of the source of infection. © 2011 The Japan Society of Hepatology.

    DOI: 10.1111/j.1872-034X.2010.00748.x

    Scopus

    researchmap

  • 経鼻内視鏡 スクリーニング検査での有用性及び応用法の現状(ESD、イレウス管挿入、PEG、ERCPなど) 経鼻内視鏡を用いた内視鏡的胃瘻造設術は合併症を軽減させたか?

    古出 智子, 稲森 正彦, 加藤 真吾, 酒井 英嗣, 関野 雄典, 内山 崇, 渡辺 誠太郎, 飯田 洋, 細野 邦弘, 遠藤 宏樹, 坂本 康成, 高橋 宏和, 所 知加子, 後藤 歩, 阿部 泰伸, 小林 規俊, 窪田 賢輔, 中島 淳, 前田 愼, 日下部 明彦

    Progress of Digestive Endoscopy   78 ( 1 )   62 - 62   2010年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 当院におけるInterventional EUSの評価

    渡邉 誠太郎, 窪田 賢輔, 加藤 真吾, 嶌村 健, 小林 規俊, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.2 )   2552 - 2552   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 低分化腺癌と浸潤性微小乳頭癌成分を有した巨大胆管のう胞腺癌の1例

    本多 靖, 米田 正人, 藤田 浩司, 加藤 真吾, 馬渡 弘典, 内山 崇, 今城 健人, 留野 渉, 小林 規俊, 窪田 賢輔, 桐越 博之, 高橋 宏和, 稲森 正彦, 細野 邦弘, 遠藤 宏樹, 大城 久, 山中 正二, 稲山 嘉明, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増大会 )   A892 - A892   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵癌においてSemaphorin 4Dは腫瘍間質に発現し運動能を制御する

    加藤 真吾, 島村 健, 渡邉 誠太郎, 小林 規俊, 中島 淳, 窪田 賢輔

    日本消化器病学会雑誌   107 ( 臨増大会 )   A944 - A944   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢者のC型慢性肝炎(1型・高ウイルス量)に対するPeg-IFN+RBV療法のSVR予測における肝生検とASTの有用性

    馬渡 弘典, 米田 正人, 藤田 浩司, 野崎 雄一, 加藤 真吾, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 島村 健, 小林 規俊, 窪田 賢輔, 桐越 博之, 中島 淳, 斉藤 聡

    肝臓   51 ( Suppl.2 )   A594 - A594   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Acoustic Radiation Force Impulse imaging(ARFI)とフィブロスキャンを用いたNAFLD患者での肝脂肪化、炎症、線維化の比較検討

    米田 正人, 今城 健人, 鈴木 香峰理, 野崎 雄一, 藤田 浩司, 細野 邦広, 遠藤 宏樹, 前田 慎, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増大会 )   A911 - A911   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • EUS-FNA後腫瘍の急速な増大を認めた悪性リンパ腫の一例

    宮腰 藍衣, 渡邉 誠太郎, 加藤 真吾, 嶌村 健, 小林 規俊, 中島 淳, 窪田 賢輔

    日本消化器病学会雑誌   107 ( 臨増大会 )   A928 - A928   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 慢性偽性腸閉塞症 内科的診断・治療の現状

    坂本 康成, 稲森 正彦, 加藤 真吾, 内山 崇, 飯田 洋, 関野 雄典, 酒井 英嗣, 細野 邦広, 遠藤 宏樹, 藤田 浩司, 米田 正人, 高橋 宏和, 古出 智子, 所 知加子, 後藤 歩, 阿部 泰伸, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増大会 )   A823 - A823   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • NASHにおける繊維化発症のメカニズムについて IL-13/TGF-βの役割

    島村 健, 藤澤 俊夫, 加藤 真吾, 渡辺 誠太郎, 藤田 浩司, 米田 正人, 高橋 宏和, 安崎 弘晃, 後藤 歩, 稲森 正彦, 阿部 泰伸, 桐越 博之, 小林 規俊, 川名 一郎, 窪田 賢輔, 斎藤 聡, 市川 靖史, 前田 愼, 中島 淳, Puri R

    日本消化器病学会雑誌   107 ( 臨増大会 )   A909 - A909   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • EUSによるearly-and advanced-stageの自己免疫性膵炎診断の提言

    窪田 賢輔, 加藤 真吾, 秋山 智之, 藤田 浩司, 米田 正人, 高橋 宏和, 稲森 正彦, 阿部 泰伸, 桐越 博之, 小林 規俊, 斉藤 聡, 久富 勘太郎, 松橋 信行, 中島 淳

    Gastroenterological Endoscopy   52 ( 9 )   2745 - 2754   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    ERCP、超音波内視鏡(EUS)を行った自己免疫膵炎(AIP)19例を対象とし、Cambridge Gradeにより早期(Grade 1・2)と進行期(Grade 3・4・5)に分類してEUS所見を検討した。治療として、血性IgG4値が135mg/dl以上の陽性例にはステロイド治療を行い、全例治療に良好に反応した。一方、ステロイド非投与の5例は、膵酵素阻害剤や抗生物質投与で4例が改善し、1例は自然緩解した。また、EUS所見により早期と診断した9例では5例がステロイド治療を行うことなく緩解したが、進行期例では自然緩解例はなかった。再燃は全体で21.2%に認め、1例は早期、3例は進行期で、ステロイド治療施行例であった。早期9例、進行期10例のEUS所見についてみたところ、年齢、性別、血清において両群で有意差は認めなかった。病期との関連が考えられる所見をみると、lobularityとhyperechoic duct marginは早期群で有意に高頻度に認めた。AIPの病理所見に対応したEUS所見についてみたところ、早期例では線維化は小葉内と小葉間に認め、膵腺房の小葉構造は保たれていた。進行期例では膵腺房の小葉構造は脱落し、著明な線維化に置き換わっていた。

    researchmap

  • PPIとH2RAの単回経口投与における胃内pHの立ち上がりに関する検討

    飯田 洋, 稲森 正彦, 加藤 真吾, 内山 崇, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 坂本 康成, 藤田 浩司, 古出 智子, 高橋 宏和, 米田 正人, 所 知加子, 後藤 歩, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増大会 )   A805 - A805   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 急性腹症で発症した異物性胃潰瘍の1例

    梅沢 翔太郎, 高橋 宏和, 内山 崇, 飯田 洋, 坂本 康成, 細野 邦広, 遠藤 宏樹, 古出 智子, 所 知加子, 阿部 泰伸, 稲森 正彦, 加藤 真吾, 渡辺 誠太郎, 藤田 浩司, 米田 正人, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.2 )   2415 - 2415   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 非切除膵癌に対する内視鏡的金属ステントの早期閉塞に関わる因子の検討

    渡邉 誠太郎, 加藤 真吾, 嶌村 健, 小林 規俊, 中島 淳, 窪田 賢輔

    胆道   24 ( 3 )   440 - 440   2010年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    researchmap

  • 【膵基礎研究の新しい潮流 Bench to Bedをめざして】 自己免疫性膵炎と膵癌との鑑別診断における十二指腸乳頭部のFOXP3発現の有用性

    窪田 賢輔, 加藤 真吾, 渡辺 誠太郎, 島村 健, 小林 規俊, 久富 勘太郎, 松橋 信行, 中島 淳

    胆と膵   31 ( 6 )   597 - 603   2010年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    自己免疫性膵炎(AIP)の病因としてTh2優位の免疫応答が指摘されており、それと関連して制御性T細胞(Treg)の局所でのup-regulationが指摘されている。Tregは、免疫組織化学により、そのMaster geneであるFOXP3を染色することで検討が可能である。自己免疫性膵炎(AIP)と膵癌(Pca)の鑑別は、腫瘤を形成する点でしばしば困難である。十二指腸乳頭部生検組織を用い、IgG4と合わせてFOXP3の免疫組織化学的検討を行うことが、AIPのより深い病態の理解と、Pcaとの鑑別診断に有用である可能性が示唆された。(著者抄録)

    researchmap

  • HDL-free cholesterolとC型慢性肝炎(genotype1・高ウイルス量)に対する治療抵抗性との関係

    馬渡 弘典, 斉藤 聡, 篠原 義康, 米田 正人, 藤田 浩司, 野崎 雄一, 桐越 博之, 加藤 真吾, 遠藤 宏樹, 細野 邦広, 坂本 康成, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 小林 規俊, 窪田 賢輔, 中島 淳

    肝臓   51 ( Suppl.1 )   A298 - A298   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科における内視鏡的十二指腸乳頭部腫瘍切除術の検討

    渡邉 誠太郎, 窪田 賢輔, 加藤 真吾, 小林 規俊, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.1 )   1014 - 1014   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 分枝型IPMN診断におけるEUSの役割について

    小林 規俊, 窪田 賢輔, 島村 健, 渡邊 誠太郎, 加藤 真吾, 鈴木 香峰里, 内山 崇, 飯田 洋, 馬渡 弘典, 坂本 康成, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.1 )   1075 - 1075   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 内視鏡的治療からみた悪性胆管狭窄と良性胆管狭窄の違い 肝移植後胆管狭窄症例を中心に

    小林 規俊, 窪田 賢輔, 島村 健, 渡邊 誠太郎, 加藤 真吾, 内山 崇, 鈴木 香峰理, 飯田 洋, 馬渡 弘典, 細野 邦広, 坂本 康成, 遠藤 宏樹, 野崎 雄一, 藤田 浩司, 米田 正人, 稲森 正彦, 桐越 博之, 斉藤 聡, 武田 和永, 遠藤 格, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.1 )   971 - 971   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 特異な画像を呈し、診断が困難であった肝内胆管癌の一例

    加藤 真吾, 窪田 賢輔, 小林 規俊, 渡邉 誠太郎, 中島 淳

    Gastroenterological Endoscopy   52 ( Suppl.1 )   971 - 971   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 大腸憩室症の存在部位と内臓脂肪との関連性についての検討

    渡邉 誠太郎, 稲森 正彦, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 鈴木 香峰理, 細野 邦広, 遠藤 宏樹, 坂本 康成, 古出 智子, 高橋 宏和, 所 知加子, 阿部 泰伸, 桐越 博之, 小林 規俊, 嶌村 健, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A208 - A208   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 内視鏡的胃ろう造設術後の出血に関する検討

    古出 智子, 稲森 正彦, 日下部 明彦, 加藤 真吾, 内山 崇, 飯田 洋, 細野 邦広, 遠藤 宏樹, 坂本 康成, 藤田 浩司, 高橋 宏和, 米田 正人, 所 知加子, 後藤 歩, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A250 - A250   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝腫瘍、膵腫瘍の予後因子としてのFOXP3+制御性T細胞について

    小林 規俊, 平岡 伸介, 窪田 賢輔, 渡邊 誠太郎, 加藤 真吾, 島村 健, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A233 - A233   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院における分枝型IPMNの切除例および経過観察例の検討

    小林 規俊, 窪田 賢輔, 渡邊 誠太郎, 加藤 真吾, 島村 健, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 遠藤 格, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A234 - A234   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • NASH患者に対するエゼチミブの有用性 6ヵ月投与による肝組織改善効果のパイロットスタディー

    米田 正人, 藤田 浩司, 野崎 雄一, 遠藤 宏樹, 加藤 真吾, 細野 邦広, 高橋 宏和, 鈴木 香峰理, 内山 崇, 坂本 康成, 飯田 洋, 馬渡 弘典, 小林 規俊, 島村 健, 阿部 泰伸, 稲森 正彦, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A227 - A227   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵癌におけるSema4D-PlexinB1 signal pathwayの機能解析

    加藤 真吾, 窪田 賢輔, 小林 規俊, 島村 健, 渡邉 誠太郎, 馬渡 弘典, 野崎 雄一, 藤田 浩司, 米田 正人, 桐越 博之, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   107 ( 臨増総会 )   A232 - A232   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically 査読

    K. Yoneda, H. Takahashi, Y. Abe, M. Inamori, S. Kato, T. Uchiyama, H. Iida, H. Mawatari, K. Hosono, H. Endo, Y. Nozaki, T. Akiyama, K. Fujita, M. Yoneda, N. Kobayashi, H. Kirikoshi, K. Kubota, S. Saito, A. Nakajima

    Endoscopy   42 ( 2 )   E175   2010年

     詳細を見る

  • Duodenal Gastrointestinal stromal tumor resembling a pancreatic neuroendocrine tumor in a patient with neurofibromatosis type I (von Recklinghausen's disease): A case report 査読

    Shinji Ohtake, Noritoshi Kobayashi, Shingo Kato, Kensuke Kubota, Itaru Endo, Yoshiaki Inayama, Atsushi Nakajima

    Journal of Medical Case Reports   4 ( 1 )   302   2010年

     詳細を見る

    記述言語:英語   出版者・発行元:BioMed Central Ltd.  

    Introduction: Gastrointestinal stromal tumor is the most frequent nonepithelial tumor found in the gastrointestinal tract. One important clinical problem is that gastrointestinal stromal tumors, especially the extramural growth type, can be difficult to distinguish from other organ tumors. The case of a patient with an extramural gastrointestinal stromal tumor of the duodenum that mimicked a pancreatic head tumor has previously been reported. Here, we report a rare case of a patient with a duodenal gastrointestinal stromal tumor with extramural growth that mimicked a pancreatic neuroendocrine tumor. In this case, the gastrointestinal stromal tumor was also associated with neurofibromatosis type 1 (also known as von Recklinghausen's disease). To the best of our knowledge, this is the first report to describe the case of a patient with a duodenal gastrointestinal stromal tumor with neurofibromatosis type 1 in which the radiological findings resembled those of a pancreatic neuroendocrine tumor. Case presentation: A 60-year-old Japanese woman with a history of neurofibromatosis type 1 was admitted to our hospital for the treatment of a tumor of her pancreas. She had no symptoms, but an abdominal ultrasonography screening examination had revealed a hypoechoic mass in the head of her pancreas. Laboratory data, including tumor markers, were within the normal ranges, and her insulin and glucagon levels were also within the normal ranges. However, her plasma gastrin level was elevated at 580 pg/mL (30 to 150 pg/mL). A computed tomography examination revealed a hypervascular tumor measuring 14 mm in diameter in the head of her pancreas. We diagnosed the patient as having a pancreatic neuroendocrine tumor and performed a tumor resection with a duodenal wedge resection. Microscopic analysis revealed spindle cell tumors in a trabecular pattern. The patient was finally diagnosed as having a duodenal gastrointestinal stromal tumor of the uncommitted type. Conclusion: Extramural growth-type gastrointestinal stromal tumors can be difficult to distinguish from other organ tumors. In our case, a duodenal gastrointestinal stromal tumor was difficult to distinguish from a pancreatic neuroendocrine tumor based on radiological findings. When patients are identified as having hypervascular lesions that have adhered to the gastrointestinal tract, the possibility of an extramural growth-type gastrointestinal stromal tumor as a differential diagnosis should be considered in patients with neurofibromatosis type 1.

    DOI: 10.1186/1752-1947-4-302

    Scopus

    PubMed

    researchmap

  • Metastatic tumor in the colon from renal cell carcinoma 査読

    Yuichi Nozaki, Masahiko Inamori, Koji Fujita, Masato Yoneda, Shingo Kato, Takashi Uchiyama, Kaori Suzuki, Seitaro Watanabe, Hironori Mawatari, Hiroshi Iida, Kunihiro Hosono, Hiroki Endo, Yasunari Sakamoto, Kyoko Yoneda, Hirokazu Takahashi, Tomoko Koide, Chikako Tokoro, Noritoshi Kobayashi, Hiroyuki Kirikoshi, Takeshi Shimamura, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Hisashi Oshiro, Yoshiaki Inayama, Atsushi Nakajima

    Internal Medicine   49 ( 7 )   709   2010年

     詳細を見る

    記述言語:英語   出版者・発行元:Japanese Society of Internal Medicine  

    DOI: 10.2169/internalmedicine.49.3233

    Scopus

    PubMed

    researchmap

  • Esophagomediastinal and esophagobronchial fistulas associated with invasive aspergillosis 査読

    S. Kato, S. Inoue, M. Inamori, N. Miyazawa, T. Sato, N. Kobayashi, K. Mishina, M. Sasaki, Y. Ishigatsubo, A. Nakajima

    Endoscopy   42 ( 2 )   E48 - E49   2010年

     詳細を見る

  • A duodenal mucosal lesion coming from pancreatic arteriovenous malformation 査読

    Shingo Kato, Noritoshi Kobayashi, Kensuke Kubota, Hiroyuki Kirikoshi, Seitaro Watanabe, Masami Ogawa, Masahiko Inamori, Takeshi Shimamura, Wataru Tomeno, Atsushi Nakajima, Kazuhisa Takeda, Itaru Endo, Yoji Nagashima, Ichiro Aoki

    Gastrointestinal Endoscopy   71 ( 7 )   1299 - 1300   2010年

     詳細を見る

    記述言語:英語   出版者・発行元:Mosby Inc.  

    DOI: 10.1016/j.gie.2010.01.033

    Web of Science

    Scopus

    PubMed

    researchmap

  • 消化器内視鏡偶発症に対するトラブルシューティング 胃瘻損傷時の胃壁固定を用いたリカバリー

    古出 智子, 稲森 正彦, 加藤 真吾, 内山 崇, 渡邊 誠太郎, 飯田 洋, 遠藤 宏樹, 細野 邦広, 藤田 浩司, 米田 正人, 高橋 宏和, 所 知加子, 後藤 歩, 阿部 泰伸, 嶌村 健, 小林 規俊, 窪田 賢輔, 佐藤 晶子, 日下部 明彦, 中島 淳

    Progress of Digestive Endoscopy   76 ( 1 )   81 - 81   2009年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 超音波内視鏡的胆道ドレナージが有用であった膵頭部腫瘍の一例

    藤原 祐, 窪田 賢輔, 加藤 真吾, 小川 真実, 小林 規俊, 中島 淳

    Progress of Digestive Endoscopy   76 ( 1 )   125 - 125   2009年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 【自己免疫性膵炎の最前線】 自己免疫性膵炎の診断 膵癌との鑑別を中心に ERCP・IDUS

    窪田 賢輔, 内山 崇, 加藤 真吾, 渡辺 誠太郎, 小川 真実, 小林 規俊, 久富 勘太郎, 松橋 信行, 中島 淳

    肝胆膵画像   11 ( 6 )   639 - 645   2009年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医学書院  

    自己免疫性膵炎(AIP)の内視鏡,ERCP,IDUS所見について解説した.AIPでは十二指腸乳頭部の浮腫状の腫大を呈し,はちまき襞との境界が不鮮明となる.同部位からの生検でIgG4陽性の形質細胞浸潤がみられる.これらはおおよそAIPの40〜70%の症例で認められ,AIPの補助診断,膵癌との鑑別に有用である.ERCPでは主膵管の狭細像を呈し,時にスキップする.狭細像とは正常膵管より細く不整形を呈し,膵癌と異なり5mm以上の尾側膵管の拡張を伴わないことが多い.ERCPより引き続き行われるIDUSでは,胆道粘膜の浮腫状の変化を反映する均一な壁肥厚,壁内の点状高エコーを認め,直接胆道造影では異常を認めない部位での壁肥厚所見をみる.(著者抄録)

    DOI: 10.11477/mf.1428100209

    researchmap

  • 【自己免疫関連性胆管炎をめぐって】 IgG4関連硬化性胆管炎(SC-AIP)の再燃に関する危険因子の検討

    窪田 賢輔, 内山 崇, 加藤 真吾, 渡辺 誠太郎, 小川 真実, 小林 規俊, 久富 勘太郎, 松橋 信行, 中島 淳, 遠藤 格

    胆と膵   30 ( 10 )   1311 - 1315   2009年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    自己免疫関連性胆管炎(SC-AIP)の再燃因子について解説した。SC-AIPの臨床的特徴はステロイド反応性、自然寛解例の存在、再燃のriskである。再燃はステロイド非投与例、投与例でもhigh risk群に認められ、前者では最長10年近く経って再燃する場合もある。後者では初回治療後、通常2〜3年以内に認められ、再燃を防ぐためのステロイド維持療法が推奨されている。再燃は臨床データで予測可能である。従来から言われている黄疸の存在、血清IgG4高値と、膵のdiffuseな腫大、膵外病変の合併、さらに十二指腸乳頭部の腫大所見は再燃のhigh riskであり、2〜3年のステロイドの維持療法が肝要である。一方、膵病変がfocalな場合、十二指腸乳頭部の腫大所見を認めない場合は、自然寛解を認めることがある。しかし、focalな病変では無論、膵癌との鑑別が重要で、FNA、場合によっては開腹膵生検も考慮すべきである。(著者抄録)

    researchmap

  • 開腹生検によっても膵癌の確定診断に至らなかった症例の検討

    小林 規俊, 窪田 賢輔, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 米田 恭子, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 遠藤 格, 稲山 嘉明, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A931 - A931   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 大腸ポリープ、大腸癌の診断に血清レプチン値は有用か

    内山 崇, 高橋 宏和, 飯田 洋, 遠藤 宏樹, 細野 邦弘, 秋山 智之, 阿部 泰伸, 稲森 正彦, 加藤 真吾, 渡辺 誠太郎, 馬渡 弘典, 米田 恭子, 野崎 雄一, 藤田 浩司, 米田 正人, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A853 - A853   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院で経験した無症候性に診断された日本住血吸虫症の3例

    竹前 久美, 米田 正人, 野崎 雄一, 留野 渉, 藤田 浩司, 内山 崇, 遠藤 宏樹, 飯田 洋, 馬渡 弘典, 細野 邦彦, 高橋 宏和, 加藤 真吾, 秋山 智之, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A094 - A094   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 十二指腸静脈瘤破裂に対し3度のEVLが必要であった1例

    高橋 宏和, 阿部 泰伸, 稲森 正彦, 留野 渉, 渡辺 誠太郎, 加藤 真吾, 内山 崇, 藤田 浩司, 米田 正人, 島村 健, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 上野 規男, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A793 - A793   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 生活習慣病からみた大腸癌の新たな化学発癌予防 抗糖尿病薬メトホルミンを用いた検討

    細野 邦広, 高橋 宏和, 加藤 真吾, 内山 嵩, 鈴木 香峰理, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 坂本 康成, 米田 恭子, 藤田 浩司, 米田 正人, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A839 - A839   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 満腹感と膨満感を日本人は区別しているのか?(第2報)

    坂本 康成, 稲森 正彦, 飯田 洋, 加藤 真吾, 内山 崇, 細野 邦広, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 後藤 歩, 廣川 智, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A779 - A779   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • IPMNの多段階発がんにおけるFOXP3+制御性T細胞の変化についての検討

    小林 規俊, 窪田 賢輔, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 米田 恭子, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 上田 倫夫, 遠藤 格, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A922 - A922   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • metallic stent逸脱に対し、内視鏡的抜去が可能であった膵癌の2例

    加藤 真吾, 窪田 賢輔, 小林 規俊, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 稲森 正彦, 阿部 泰伸, 桐越 博之, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.2 )   2272 - 2272   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 十二指腸球部に穿破をきたした胆嚢がんの一例

    石戸 岳仁, 小林 規俊, 窪田 賢輔, 加藤 真吾, 山本 晴美, 内山 崇, 飯田 洋, 馬渡 弘典, 米田 恭子, 遠藤 宏樹, 野崎 雄一, 藤田 浩司, 米田 正人, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 遠藤 格, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.2 )   2294 - 2294   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 急激に進行した食道静脈瘤破裂に対する内視鏡治療後に脳梗塞を起した1例

    竹中 麻起, 内山 崇, 高橋 宏和, 阿部 泰伸, 加藤 真吾, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 細野 邦広, 秋山 智之, 米田 恭子, 藤田 浩司, 米田 正人, 稲森 正彦, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.2 )   2208 - 2208   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 6歳小児の感染性膵仮性嚢胞に対し、direct endoscopic drainageを施行した一例

    加藤 真吾, 窪田 賢輔, 小林 規俊, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 稲森 正彦, 阿部 泰伸, 桐越 博之, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.2 )   2300 - 2300   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • H2受容体拮抗薬投与初期における胃内pHに関する検討 mint oilの効果について

    飯田 洋, 稲森 正彦, 加藤 真吾, 内山 崇, 細野 邦広, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 坂本 康成, 高橋 宏和, 米田 正人, 後藤 歩, 廣川 智, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増大会 )   A763 - A763   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • HBs抗体陽性でALTが軽度異常を示したB型肝炎の1例

    馬渡 弘典, 斉藤 聡, 桐越 博之, 米田 正人, 藤田 浩司, 野崎 雄一, 飯田 洋, 篠原 義康, 秋山 智之, 内山 崇, 加藤 真吾, 遠藤 宏樹, 米田 恭子, 細野 邦広, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 小林 規俊, 窪田 賢輔, 中島 淳

    肝臓   50 ( Suppl.2 )   A504 - A504   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Telmisartan投与が推奨されるNASH背景病態の検討

    藤田 浩司, 野崎 雄一, 留野 渉, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 坂本 康成, 細野 邦広, 遠藤 宏樹, 米田 正人, 高橋 宏和, 稲森 正彦, 阿部 泰伸, 島村 健, 小林 規俊, 桐越 博之, 窪田 賢輔, 斎藤 聡, 中島 淳

    肝臓   50 ( Suppl.2 )   A553 - A553   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 下部胆管にskip lesionを有した早期十二指腸乳頭部癌の一例

    加藤 真吾, 窪田 賢輔, 小川 真実, 稲森 正彦, 遠藤 格, 稲山 嘉明, 中島 淳

    胆道   23 ( 3 )   531 - 531   2009年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    researchmap

  • 硬化性胆管炎の病態と胆管がんの発生リスク IDUSによる硬化性胆管炎の鑑別診断

    窪田 賢輔, 加藤 真吾, 中島 淳

    胆道   23 ( 3 )   422 - 422   2009年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本胆道学会  

    researchmap

  • 経鼻内視鏡の現状と問題点 経鼻内視鏡の位置づけ 医療者側の評価

    細野 邦広, 稲森 正彦, 内山 崇, 加藤 真吾, 飯田 洋, 遠藤 宏樹, 秋山 智之, 池田 多聞, 米田 恭子, 坂本 康成, 藤田 浩司, 米田 正人, 高橋 宏和, 後藤 歩, 阿部 泰伸, 桐越 博之, 小林 規俊, 窪田 賢輔, 斎藤 聡, 中島 淳

    Progress of Digestive Endoscopy   75 ( 1 )   76 - 76   2009年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 当院におけるEUS下膵仮性嚢胞ドレナージ20例の検討

    加藤 真吾, 窪田 賢輔, 小林 規俊, 中島 淳

    膵臓   24 ( 3 )   450 - 450   2009年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本膵臓学会  

    researchmap

  • 十二指腸静脈瘤破裂に対し2度のEVLが奏功した1例

    加藤 真吾, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 秋山 智之, 米田 恭子, 藤田 浩司, 米田 正人, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 上野 規男, 中島 淳

    Progress of Digestive Endoscopy   75 ( 1 )   81 - 81   2009年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • 肝硬変とIL-13

    加藤 真吾, 島村 健, 藤澤 聡郎, 小林 規俊, 窪田 賢輔, 中島 淳

    臨床免疫・アレルギー科   51 ( 6 )   647 - 653   2009年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • Aberrant crypt fociの自然史に対する解析

    高橋 宏和, 細野 邦広, 遠藤 宏樹, 米田 恭子, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 野崎 雄一, 秋山 智之, 藤田 浩司, 米田 正人, 稲森 正彦, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 上野 規男, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.1 )   832 - 832   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • C型慢性肝炎患者におけるインスリン抵抗性の変化

    斉藤 聡, 馬渡 弘典, 桐越 博之, 米田 正人, 藤田 浩司, 野崎 雄一, 飯田 洋, 内山 崇, 加藤 真吾, 篠原 義康, 遠藤 宏樹, 細野 邦広, 阿部 泰伸, 稲森 正彦, 高橋 宏和, 小林 規俊, 窪田 賢輔, 中島 淳

    肝臓   50 ( Suppl.1 )   A380 - A380   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 糖尿病患者に発症した虚血性胃炎の1症例

    細野 邦広, 稲森 正彦, 加藤 真吾, 遠藤 宏樹, 藤田 浩司, 高橋 宏和, 阿部 泰伸, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.1 )   959 - 959   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 当院におけるB型慢性肝炎と肝癌発癌の検討

    内山 崇, 斉藤 聡, 加藤 真吾, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 細野 邦広, 秋山 智之, 藤田 浩司, 米田 恭子, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 小林 規俊, 窪田 賢輔, 中島 淳

    肝臓   50 ( Suppl.1 )   A311 - A311   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝移植後胆管狭窄に対する内視鏡的治療に関する検討

    小林 規俊, 窪田 賢輔, 加藤 真吾, 小川 真実, 馬渡 弘典, 飯田 洋, 内山 崇, 米田 恭子, 遠藤 宏樹, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 上野 規男, 武田 和永, 遠藤 格, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.1 )   845 - 845   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 膵動静脈奇形の内視鏡所見についての検討

    加藤 真吾, 小林 規俊, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 稲森 正彦, 阿部 泰伸, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   51 ( Suppl.1 )   846 - 846   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • NASH診断、進行度判定における炎症マーカー高感度CRPとPentraxin3の臨床有用性に対する比較検討

    米田 正人, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 藤田 浩司, 高橋 宏和, 留野 渉, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 前山 史朗, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A206 - A206   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Mikulicz病を合併した自己免疫性膵炎症例の臨床病理学的検討

    和田 朋子, 石田 修一, 加藤 真吾, 小林 規俊, 窪田 賢輔, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A492 - A492   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 大量の胸水を契機に発症し、2度のEUS下ドレナージ術が有効であった慢性膵炎の一例

    大森 尚子, 小林 規俊, 窪田 賢輔, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 野崎 雄一, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A496 - A496   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • C型慢性肝炎に対しインターフェロン治療中にShewanella putrefasciensによる敗血症を合併し救命しえた先天性胆道閉鎖症術後の1例

    濱口 冴香, 留野 渉, 小川 祐二, 加藤 真吾, 米田 恭子, 遠藤 宏樹, 野崎 雄一, 飯田 洋, 馬渡 弘典, 内山 崇, 藤田 浩司, 米田 正人, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A413 - A413   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 下血が発見の契機となった高齢発症gastrointestinal stromal tumor(GIST)の1例

    内山 崇, 高橋 宏和, 加藤 真吾, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 細野 邦弘, 秋山 智之, 藤田 浩司, 米田 恭子, 米田 正人, 稲森 正彦, 阿部 泰伸, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 利野 靖, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A457 - A457   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 小腸癌の診断に冠状断CT像が有用であった1例

    飯田 洋, 稲森 正彦, 加藤 真吾, 内山 崇, 馬渡 弘典, 遠藤 宏樹, 細野 邦広, 秋山 智之, 米田 恭子, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 桐越 博之, 窪田 賢輔, 斉藤 聡, 菅野 信洋, 利野 靖, 稲山 嘉明, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A398 - A398   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 健康診断で偶発的に発見された肝血管筋脂肪腫の1例

    小川 祐二, 留野 渉, 谷口 礼央, 加藤 真吾, 内山 崇, 日暮 琢磨, 馬渡 弘典, 飯田 洋, 米田 恭子, 藤田 浩司, 米田 正人, 高橋 宏和, 小林 規俊, 阿部 泰伸, 稲森 正彦, 桐越 博之, 坂口 隆, 窪田 賢輔, 齋藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A370 - A370   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Barrett粘膜の形状・長さと逆流性食道炎の分布の関連性について

    秋山 智之, 稲森 正彦, 野崎 雄一, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦広, 遠藤 宏樹, 米田 恭子, 米田 正人, 高橋 宏和, 後藤 歩, 藤田 浩司, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斎藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A373 - A373   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 内臓脂肪およびアディポサイトカインの大腸発癌に関する解析

    高橋 宏和, 細野 邦広, 中島 淳, 米田 恭子, 遠藤 宏樹, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 野崎 雄一, 秋山 智之, 藤田 浩司, 米田 正人, 稲森 正彦, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 上野 規男

    日本消化器病学会雑誌   106 ( 臨増総会 )   A269 - A269   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • チューインガムはdistention induced accommodationに影響するか? 飲水試験を用いた研究

    坂本 康成, 稲森 正彦, 加藤 真吾, 飯田 洋, 内山 崇, 野崎 雄一, 後藤 歩, 細野 邦広, 遠藤 宏樹, 秋山 智之, 米田 恭子, 藤田 浩司, 米田 正人, 高橋 宏和, 阿部 泰伸, 小林 規俊, 桐越 博之, 窪田 賢輔, 斎藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A336 - A336   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵癌におけるSema4D/PlexinB1/METの発現とその機能解析

    加藤 真吾, 小林 規俊, 内山 崇, 飯田 洋, 馬渡 弘典, 細野 邦弘, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 稲森 正彦, 阿部 泰伸, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A245 - A245   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • IPMNの多段階発がんにおけるFOXP3+制御性T細胞の変化についての検討

    小林 規俊, 窪田 賢輔, 小川 真実, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 米田 恭子, 秋山 智之, 藤田 浩司, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A246 - A246   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝ミクロソームTG輸送蛋白(MTTP)がNAFLD病態進展に与える影響

    藤田 浩司, 野崎 雄一, 加藤 真吾, 内山 崇, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 細野 邦広, 秋山 智之, 米田 恭子, 池田 多聞, 米田 正人, 高橋 宏和, 阿部 泰伸, 稲森 正彦, 小林 規俊, 桐越 博之, 窪田 賢輔, 斎藤 聡, 中島 淳

    日本消化器病学会雑誌   106 ( 臨増総会 )   A205 - A205   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 胃瘻カテーテル迷入後の胃壁固定を用いた加療

    稲森 正彦, 内山 崇, 加藤 真吾, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 細野 邦弘, 秋山 智之, 米田 恭子, 藤田 浩司, 米田 正人, 高橋 宏和, 後藤 歩, 阿部 泰伸, 日下部 明彦, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    神奈川医学会雑誌   36 ( 1 )   65 - 66   2009年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:神奈川県医師会  

    researchmap

  • Asymptomatic hepatic Schistosomiasis detected by ultrasonograpy and confirmed by liver biopsy 査読

    Yuichi Nozaki, Masahiko Inamori, Koji Fujita, Masato Yoneda, Takashi Uchiyama, Shingo Kato, Hironori Mawatari, Hiroshi Iida, Kunihiro Hosono, Hiroki Endo, Tomoyuki Akiyama, Kyoko Yoneda, Hirokazu Takahashi, Ayumu Goto, Noritoshi Kobayashi, Hiroyuki Kirikoshi, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Hanako Kurai, Shoji Yamanaka, Atsushi Nakajima

    Internal Medicine   48 ( 12 )   1109 - 1110   2009年

     詳細を見る

  • 治療の効果判定にVater乳頭部生検が有用であった自己免疫性膵炎の一例

    石田 修一, 窪田 賢輔, 小林 規俊, 加藤 真吾, 稲森 正彦, 阿部 泰伸, 斎藤 聡, 稲山 嘉昭, 山中 正二, 中島 淳

    Progress of Digestive Endoscopy   74 ( 1 )   102 - 102   2008年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会-関東支部  

    researchmap

  • THE COMPARISON OF THE TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) MONOTHERAPY AND THE COMBINED TACE WITH PERCUTANEOUS LOCAL THERAPY FOR HEPATOCELLULAR CARCINOMA (HCC)

    Hiroyuki Kirikoshi, Satoru Saito, Masato Yonedo, Koji Fujita, Hironori Mawatari, Yuichi Nozaki, Takashi Uchiyama, Tamon Ikeda, Kunihiro Hosono, Tomoyuki Akiyama, Hiroki Endo, Kyoko Yoneda, Masahiko Inamori, Hirokazu Takahashi, Hiroshi Iida, Shingo Kato, Yasunobu Abe, Noritoshi Kobayashi, Kensuke Kubota, Atsushi Nakajima

    HEPATOLOGY   48 ( 4 )   967A - 968A   2008年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JOHN WILEY & SONS INC  

    Web of Science

    researchmap

  • 当院におけるB型慢性肝炎に対するlamivudine治療の実際

    内山 崇, 斉藤 聡, 加藤 真吾, 飯田 洋, 馬渡 弘典, 遠藤 宏樹, 野崎 雄一, 細野 邦弘, 秋山 智則, 藤田 浩司, 米田 恭子, 高橋 宏和, 米田 正人, 阿部 泰伸, 稲森 正彦, 桐越 博之, 小林 則俊, 窪田 賢輔, 中島 淳

    肝臓   49 ( Suppl.3 )   A752 - A752   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 門脈血栓による胃静脈瘤破裂に対しヒストアクリル局注法を繰り返し止血を得た1例

    谷口 礼央, 高橋 宏和, 飯田 洋, 阿部 泰伸, 稲森 正彦, 加藤 真吾, 内山 崇, 馬渡 弘典, 藤田 浩司, 米田 正人, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    Gastroenterological Endoscopy   50 ( Suppl.2 )   2322 - 2322   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 血友病Aに発症した門脈血栓症に対しAT3およびダナパロイドナトリウム併用療法が有効であった1例

    留野 渉, 高橋 宏和, 飯田 洋, 阿部 泰伸, 稲森 正彦, 加藤 真吾, 内山 崇, 馬渡 弘典, 藤田 浩司, 米田 正人, 小林 規俊, 桐越 博之, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   105 ( 臨増大会 )   A873 - A873   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • EzetimibeによるNAFLD病態の改善効果に関する検討

    野崎 雄一, 藤田 浩司, 米田 正人, 留野 渉, 加藤 真吾, 馬渡 弘典, 飯田 洋, 遠藤 宏樹, 秋山 智之, 米田 恭子, 高橋 宏和, 後藤 歩, 廣川 智, 阿部 泰伸, 稲森 正彦, 桐越 博之, 小林 規俊, 窪田 賢輔, 斉藤 聡, 中島 淳

    日本消化器病学会雑誌   105 ( 臨増大会 )   A849 - A849   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • NASH診断、線維化進行判定におけるPentraxin3の有効性についての検討

    加藤 真吾, 米田 正人, 内山 崇, 留野 渉, 馬渡 弘典, 飯田 洋, 野崎 雄一, 遠藤 宏樹, 米田 恭子, 藤田 浩司, 高橋 宏和, 小林 規俊, 稲森 正彦, 阿部 泰伸, 桐越 博之, 窪田 賢輔, 斉藤 聡, 上野 規男, 前山 史朗, 中島 淳

    日本消化器病学会雑誌   105 ( 臨増大会 )   A850 - A850   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • NAFLD,NASH発症におけるアンジオテンシンIIタイプ1受容体(AGTR1)の遺伝子多型解析

    米田 正人, 内山 崇, 留野 渉, 加藤 真吾, 馬渡 弘典, 飯田 洋, 野崎 雄一, 遠藤 宏樹, 藤田 浩司, 高橋 宏和, 小林 規俊, 稲森 正彦, 阿部 泰伸, 桐越 博之, 窪田 賢輔, 斉藤 聡, 前山 史朗, 堀田 紀久子, 上野 規男, 中島 淳

    日本消化器病学会雑誌   105 ( 臨増大会 )   A846 - A846   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

▼全件表示

講演・口頭発表等

  • 臨床検査としてのがん遺伝子パネル検査の現状と課題

    加藤真吾, 鈴木章浩, 中島淳

    第106回日本消化器病学会総会  2020年8月 

     詳細を見る

    開催年月日: 2020年8月

    会議種別:シンポジウム・ワークショップ パネル(公募)  

    researchmap

受賞

  • 令和5年理事長・学長表彰(教職協働・職員部門)

    2024年3月   公立大学法人横浜市立大学   「がんゲノム医療拠点病院」及び「がんゲノム医療連携病院」の運営開始

    附属病院, がんゲノム診断科, 医学, 病院企画課, センター病院, がんゲノム診療科, 患者総合サポートセンター, が, 包括センター担当

     詳細を見る

  • 令和5年理事長・学長表彰(教員部門) 優秀賞

    2024年3月   公立大学法人横浜市立大学   がんゲノム医療拠点病院指定への貢献

     詳細を見る

  • 第25回日本がん分子標的治療学会学術集会 優秀演題賞

    2021年5月   日本がん分子標的治療学会   局所免疫反応及び薬物応答の解析が可能な胆のうがん患者モデルマウスの構築

    加藤真吾

     詳細を見る

  • 若手奨励賞

    2019年11月   日本消化器関連学会機構   ヒト膵癌の多段階発癌を模倣するマウス膵癌オルガノイド細胞株セットを用いた 早期診断マーカーの探索

    加藤真吾

     詳細を見る

  • Poster of Distinction

    2019年5月   Digestive Disease Week   DEVELOPMENT OF A NOVEL GALLBLADDER CANCER MOUSE MODEL USING ORGANOID CELL LINES

    加藤 真吾

     詳細を見る

  • 若手奨励賞

    2018年11月   日本消化器関連学会機構   ヒトオルガノイド細胞株を用いたがんクリニカルシークエンス検査における意義不明変異の機能解析

    加藤 真吾

     詳細を見る

  • FARE (Fellows Award for Research Excellence)

    2014年11月   National Institute of Health, USA  

    加藤 真吾

     詳細を見る

  • Federal Technology Transfer award

    2014年4月   National Institute of Health, USA  

    加藤 真吾

     詳細を見る

  • 優秀ポスター賞

    2010年10月   日本消化器関連学会機構  

    加藤 真吾

     詳細を見る

  • 日本胆道学会賞

    2010年5月   日本胆道学会  

    加藤 真吾

     詳細を見る

▼全件表示

共同研究・競争的資金等の研究課題

  • 通常型膵癌に腫瘍浸潤T細胞を増加させる新規免疫療法の開発

    研究課題/領域番号:19K16840  2019年4月 - 2021年3月

    日本学術振興会  科学研究費助成事業 若手研究  若手研究

    加藤 真吾

      詳細を見る

    担当区分:研究代表者 

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

担当経験のある科目(授業)

  • 医学科1年生リメディアル科目「生命のしくみを考える」

    2025年6月

     詳細を見る

  • 医学部3年生 リサーチクラークシップ 肝胆膵消化器病学

    2025年4月 - 2025年7月

     詳細を見る

  • 横浜市立大学全学部混合一年 総合ゼミ

    2025年4月 - 2025年7月

     詳細を見る

  • 医学科1年 医療と社会

    2025年4月

     詳細を見る